US20080118526A1 - Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof - Google Patents
Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof Download PDFInfo
- Publication number
- US20080118526A1 US20080118526A1 US11/602,120 US60212006A US2008118526A1 US 20080118526 A1 US20080118526 A1 US 20080118526A1 US 60212006 A US60212006 A US 60212006A US 2008118526 A1 US2008118526 A1 US 2008118526A1
- Authority
- US
- United States
- Prior art keywords
- protein
- acid sequence
- nucleic acid
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 126
- 230000002188 osteogenic effect Effects 0.000 title claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 title claims description 226
- 102000004169 proteins and genes Human genes 0.000 title claims description 200
- 230000001965 increasing effect Effects 0.000 title claims description 9
- 230000030648 nucleus localization Effects 0.000 title description 6
- 101710121660 PDZ and LIM domain protein 7 Proteins 0.000 claims abstract description 87
- 102100033337 PDZ and LIM domain protein 7 Human genes 0.000 claims abstract description 87
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 80
- 230000014509 gene expression Effects 0.000 claims abstract description 67
- 239000013598 vector Substances 0.000 claims abstract description 56
- 239000002773 nucleotide Substances 0.000 claims abstract description 44
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 44
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 41
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 41
- 238000001727 in vivo Methods 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 239000013612 plasmid Substances 0.000 claims abstract description 23
- 238000002347 injection Methods 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 18
- 241000700605 Viruses Species 0.000 claims abstract description 16
- 238000010361 transduction Methods 0.000 claims abstract description 12
- 230000026683 transduction Effects 0.000 claims abstract description 12
- 108010067390 Viral Proteins Proteins 0.000 claims abstract 11
- 210000004027 cell Anatomy 0.000 claims description 277
- 210000000988 bone and bone Anatomy 0.000 claims description 63
- 239000012634 fragment Substances 0.000 claims description 56
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 238000004519 manufacturing process Methods 0.000 claims description 34
- 210000004962 mammalian cell Anatomy 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 230000011164 ossification Effects 0.000 claims description 28
- 239000013604 expression vector Substances 0.000 claims description 26
- 241000701161 unidentified adenovirus Species 0.000 claims description 25
- 101001134647 Homo sapiens PDZ and LIM domain protein 7 Proteins 0.000 claims description 24
- 238000000338 in vitro Methods 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 239000007943 implant Substances 0.000 claims description 18
- 101710149951 Protein Tat Proteins 0.000 claims description 16
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 15
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 15
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 15
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 12
- 108010043267 Sp7 Transcription Factor Proteins 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 11
- 102100032317 Transcription factor Sp7 Human genes 0.000 claims description 10
- 239000012876 carrier material Substances 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 108010003661 Distal-less homeobox proteins Proteins 0.000 claims description 8
- 102000004648 Distal-less homeobox proteins Human genes 0.000 claims description 8
- 210000001612 chondrocyte Anatomy 0.000 claims description 7
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 6
- 238000003259 recombinant expression Methods 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000000560 biocompatible material Substances 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 7
- 230000002068 genetic effect Effects 0.000 claims 3
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 claims 2
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000000921 morphogenic effect Effects 0.000 claims 2
- 102000000645 Core Binding Factor alpha Subunits Human genes 0.000 claims 1
- 108010002444 Core Binding Factor alpha Subunits Proteins 0.000 claims 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 claims 1
- 102000002624 Sp7 Transcription Factor Human genes 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 25
- 238000001890 transfection Methods 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 206010061246 Intervertebral disc degeneration Diseases 0.000 abstract description 5
- 108091061960 Naked DNA Proteins 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 4
- 230000008733 trauma Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 178
- 239000002299 complementary DNA Substances 0.000 description 92
- 241000700159 Rattus Species 0.000 description 50
- 239000013615 primer Substances 0.000 description 50
- 238000003752 polymerase chain reaction Methods 0.000 description 47
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 32
- 239000000523 sample Substances 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 29
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 29
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 29
- 239000000499 gel Substances 0.000 description 29
- 101000988394 Homo sapiens PDZ and LIM domain protein 5 Proteins 0.000 description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 26
- 239000000872 buffer Substances 0.000 description 26
- 238000001262 western blot Methods 0.000 description 26
- 108020004999 messenger RNA Proteins 0.000 description 25
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 24
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 210000000963 osteoblast Anatomy 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 230000002441 reversible effect Effects 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 239000002609 medium Substances 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 20
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 20
- 239000003862 glucocorticoid Substances 0.000 description 20
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 102000016611 Proteoglycans Human genes 0.000 description 18
- 108010067787 Proteoglycans Proteins 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 230000001086 cytosolic effect Effects 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 18
- 210000004379 membrane Anatomy 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 230000004927 fusion Effects 0.000 description 17
- 102000049444 human PDLIM7 Human genes 0.000 description 17
- 239000011347 resin Substances 0.000 description 17
- 229920005989 resin Polymers 0.000 description 17
- 102100036601 Aggrecan core protein Human genes 0.000 description 16
- 108010067219 Aggrecans Proteins 0.000 description 16
- 238000010561 standard procedure Methods 0.000 description 16
- 229910001868 water Inorganic materials 0.000 description 16
- 102000004067 Osteocalcin Human genes 0.000 description 15
- 108090000573 Osteocalcin Proteins 0.000 description 15
- 239000012506 Sephacryl® Substances 0.000 description 15
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 230000002018 overexpression Effects 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 230000024121 nodulation Effects 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 13
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 13
- 238000001415 gene therapy Methods 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 230000033558 biomineral tissue development Effects 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 239000008188 pellet Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 11
- 210000004940 nucleus Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 238000002372 labelling Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 101150118728 Dlx5 gene Proteins 0.000 description 9
- 101100478063 Mus musculus Sp7 gene Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 101150059149 rob gene Proteins 0.000 description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 102000040945 Transcription factor Human genes 0.000 description 8
- 108091023040 Transcription factor Proteins 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 239000000074 antisense oligonucleotide Substances 0.000 description 8
- 238000012230 antisense oligonucleotides Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000004072 osteoblast differentiation Effects 0.000 description 8
- 201000008968 osteosarcoma Diseases 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 238000001712 DNA sequencing Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 102000007999 Nuclear Proteins Human genes 0.000 description 7
- 108010089610 Nuclear Proteins Proteins 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 206010017076 Fracture Diseases 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 5
- -1 Runx-2 Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000002805 bone matrix Anatomy 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000002138 osteoinductive effect Effects 0.000 description 5
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 101001134645 Rattus norvegicus PDZ and LIM domain protein 7 Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 108010087924 alanylproline Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 4
- 230000018678 bone mineralization Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002270 exclusion chromatography Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 102000045246 noggin Human genes 0.000 description 4
- 108700007229 noggin Proteins 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000010379 pull-down assay Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101000572820 Homo sapiens MICOS complex subunit MIC60 Proteins 0.000 description 3
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 3
- 208000018650 Intervertebral disc disease Diseases 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 238000003314 affinity selection Methods 0.000 description 3
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 102000046079 human IMMT Human genes 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000001582 osteoblastic effect Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 108010053725 prolylvaline Proteins 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- 238000002601 radiography Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 2
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 2
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 2
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 2
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- HULHGJZIZXCPLD-FXQIFTODSA-N Arg-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N HULHGJZIZXCPLD-FXQIFTODSA-N 0.000 description 2
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 2
- NGYHSXDNNOFHNE-AVGNSLFASA-N Arg-Pro-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O NGYHSXDNNOFHNE-AVGNSLFASA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 2
- AYOAHKWVQLNPDM-HJGDQZAQSA-N Asn-Lys-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AYOAHKWVQLNPDM-HJGDQZAQSA-N 0.000 description 2
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 108010038061 Chymotrypsinogen Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 description 2
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 2
- HDNXXTBKOJKWNN-WDSKDSINSA-N Gly-Glu-Asn Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O HDNXXTBKOJKWNN-WDSKDSINSA-N 0.000 description 2
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 2
- 102000012998 LIM-Homeodomain Proteins Human genes 0.000 description 2
- 108010079858 LIM-Homeodomain Proteins Proteins 0.000 description 2
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 2
- FGZVGOAAROXFAB-IXOXFDKPSA-N Leu-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(C)C)N)O FGZVGOAAROXFAB-IXOXFDKPSA-N 0.000 description 2
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- SVSQSPICRKBMSZ-SRVKXCTJSA-N Lys-Pro-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O SVSQSPICRKBMSZ-SRVKXCTJSA-N 0.000 description 2
- BDFHWFUAQLIMJO-KXNHARMFSA-N Lys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N)O BDFHWFUAQLIMJO-KXNHARMFSA-N 0.000 description 2
- TZLYIHDABYBOCJ-FXQIFTODSA-N Met-Asp-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O TZLYIHDABYBOCJ-FXQIFTODSA-N 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 102100026632 Mimecan Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100009733 Mus musculus Dlx5 gene Proteins 0.000 description 2
- 101100476217 Mus musculus Runx2 gene Proteins 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101800002327 Osteoinductive factor Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- GPSMLZQVIIYLDK-ULQDDVLXSA-N Phe-Lys-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O GPSMLZQVIIYLDK-ULQDDVLXSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- XKHCJJPNXFBADI-DCAQKATOSA-N Pro-Asp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O XKHCJJPNXFBADI-DCAQKATOSA-N 0.000 description 2
- DMNANGOFEUVBRV-GJZGRUSLSA-N Pro-Trp-Gly Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)O)C(=O)[C@@H]1CCCN1 DMNANGOFEUVBRV-GJZGRUSLSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- BKZYBLLIBOBOOW-GHCJXIJMSA-N Ser-Ile-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O BKZYBLLIBOBOOW-GHCJXIJMSA-N 0.000 description 2
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- NMOIRIIIUVELLY-WDSOQIARSA-N Trp-Val-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)C(C)C)=CNC2=C1 NMOIRIIIUVELLY-WDSOQIARSA-N 0.000 description 2
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 2
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- 208000037873 arthrodesis Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000012511 carbohydrate analysis Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 2
- 108010054813 diprotin B Proteins 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000035194 endochondral ossification Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 239000012145 high-salt buffer Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 208000005198 spinal stenosis Diseases 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 108010029384 tryptophyl-histidine Proteins 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102100025908 5-oxoprolinase Human genes 0.000 description 1
- 101150117081 51 gene Proteins 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- UCIYCBSJBQGDGM-LPEHRKFASA-N Ala-Arg-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N UCIYCBSJBQGDGM-LPEHRKFASA-N 0.000 description 1
- WYPUMLRSQMKIJU-BPNCWPANSA-N Ala-Arg-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WYPUMLRSQMKIJU-BPNCWPANSA-N 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- MPLOSMWGDNJSEV-WHFBIAKZSA-N Ala-Gly-Asp Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MPLOSMWGDNJSEV-WHFBIAKZSA-N 0.000 description 1
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 1
- IAUSCRHURCZUJP-CIUDSAMLSA-N Ala-Lys-Cys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CS)C(O)=O IAUSCRHURCZUJP-CIUDSAMLSA-N 0.000 description 1
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- SBVJJNJLFWSJOV-UBHSHLNASA-N Arg-Ala-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SBVJJNJLFWSJOV-UBHSHLNASA-N 0.000 description 1
- FBLMOFHNVQBKRR-IHRRRGAJSA-N Arg-Asp-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FBLMOFHNVQBKRR-IHRRRGAJSA-N 0.000 description 1
- UGZUVYDKAYNCII-ULQDDVLXSA-N Arg-Phe-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UGZUVYDKAYNCII-ULQDDVLXSA-N 0.000 description 1
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- NVPHRWNWTKYIST-BPNCWPANSA-N Arg-Tyr-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 NVPHRWNWTKYIST-BPNCWPANSA-N 0.000 description 1
- IZSMEUDYADKZTJ-KJEVXHAQSA-N Arg-Tyr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IZSMEUDYADKZTJ-KJEVXHAQSA-N 0.000 description 1
- GOVUDFOGXOONFT-VEVYYDQMSA-N Asn-Arg-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GOVUDFOGXOONFT-VEVYYDQMSA-N 0.000 description 1
- PCKRJVZAQZWNKM-WHFBIAKZSA-N Asn-Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O PCKRJVZAQZWNKM-WHFBIAKZSA-N 0.000 description 1
- PLVAAIPKSGUXDV-WHFBIAKZSA-N Asn-Gly-Cys Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)C(=O)N PLVAAIPKSGUXDV-WHFBIAKZSA-N 0.000 description 1
- ZUFPUBYQYWCMDB-NUMRIWBASA-N Asn-Thr-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZUFPUBYQYWCMDB-NUMRIWBASA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- BKOIIURTQAJHAT-GUBZILKMSA-N Asp-Pro-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 BKOIIURTQAJHAT-GUBZILKMSA-N 0.000 description 1
- YODBPLSWNJMZOJ-BPUTZDHNSA-N Asp-Trp-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N YODBPLSWNJMZOJ-BPUTZDHNSA-N 0.000 description 1
- 208000030016 Avascular necrosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100257127 Caenorhabditis elegans sma-2 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241001622623 Coeliadinae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- TVYMKYUSZSVOAG-ZLUOBGJFSA-N Cys-Ala-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O TVYMKYUSZSVOAG-ZLUOBGJFSA-N 0.000 description 1
- FMDCYTBSPZMPQE-JBDRJPRFSA-N Cys-Ala-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FMDCYTBSPZMPQE-JBDRJPRFSA-N 0.000 description 1
- IIGHQOPGMGKDMT-SRVKXCTJSA-N Cys-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N IIGHQOPGMGKDMT-SRVKXCTJSA-N 0.000 description 1
- RFHGRMMADHHQSA-KBIXCLLPSA-N Cys-Gln-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RFHGRMMADHHQSA-KBIXCLLPSA-N 0.000 description 1
- AVFGSUXQKHIQJS-QEJZJMRPSA-N Cys-Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CS)N)C(O)=O)=CNC2=C1 AVFGSUXQKHIQJS-QEJZJMRPSA-N 0.000 description 1
- QQOWCDCBFFBRQH-IXOXFDKPSA-N Cys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N)O QQOWCDCBFFBRQH-IXOXFDKPSA-N 0.000 description 1
- YYLBXQJGWOQZOU-IHRRRGAJSA-N Cys-Phe-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N YYLBXQJGWOQZOU-IHRRRGAJSA-N 0.000 description 1
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- ALUBSZXSNSPDQV-WDSKDSINSA-N Gln-Cys-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ALUBSZXSNSPDQV-WDSKDSINSA-N 0.000 description 1
- ZRXBYKAOFHLTDN-GUBZILKMSA-N Gln-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N ZRXBYKAOFHLTDN-GUBZILKMSA-N 0.000 description 1
- VOLVNCMGXWDDQY-LPEHRKFASA-N Gln-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O VOLVNCMGXWDDQY-LPEHRKFASA-N 0.000 description 1
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 1
- NYCVMJGIJYQWDO-CIUDSAMLSA-N Gln-Ser-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NYCVMJGIJYQWDO-CIUDSAMLSA-N 0.000 description 1
- SDSMVVSHLAAOJL-UKJIMTQDSA-N Gln-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N SDSMVVSHLAAOJL-UKJIMTQDSA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 description 1
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 1
- GRHXUHCFENOCOS-ZPFDUUQYSA-N Glu-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)N GRHXUHCFENOCOS-ZPFDUUQYSA-N 0.000 description 1
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FEUPVVCGQLNXNP-IRXDYDNUSA-N Gly-Phe-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FEUPVVCGQLNXNP-IRXDYDNUSA-N 0.000 description 1
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- ZNPRMNDAFQKATM-LKTVYLICSA-N His-Ala-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZNPRMNDAFQKATM-LKTVYLICSA-N 0.000 description 1
- YOSQCYUFZGPIPC-PBCZWWQYSA-N His-Asp-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YOSQCYUFZGPIPC-PBCZWWQYSA-N 0.000 description 1
- LVWIJITYHRZHBO-IXOXFDKPSA-N His-Leu-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LVWIJITYHRZHBO-IXOXFDKPSA-N 0.000 description 1
- PYNPBMCLAKTHJL-SRVKXCTJSA-N His-Pro-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O PYNPBMCLAKTHJL-SRVKXCTJSA-N 0.000 description 1
- PLCAEMGSYOYIPP-GUBZILKMSA-N His-Ser-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 PLCAEMGSYOYIPP-GUBZILKMSA-N 0.000 description 1
- FFYYUUWROYYKFY-IHRRRGAJSA-N His-Val-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O FFYYUUWROYYKFY-IHRRRGAJSA-N 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 101000720962 Homo sapiens 5-oxoprolinase Proteins 0.000 description 1
- 101000734351 Homo sapiens PDZ and LIM domain protein 1 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 1
- 101000742658 Human papillomavirus type 1 Regulatory protein E2 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- BOTVMTSMOUSDRW-GMOBBJLQSA-N Ile-Arg-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O BOTVMTSMOUSDRW-GMOBBJLQSA-N 0.000 description 1
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 1
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 206010055040 Intervertebral disc injury Diseases 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
- BJWKOATWNQJPSK-SRVKXCTJSA-N Leu-Met-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N BJWKOATWNQJPSK-SRVKXCTJSA-N 0.000 description 1
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 1
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 1
- FLCMXEFCTLXBTL-DCAQKATOSA-N Lys-Asp-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N FLCMXEFCTLXBTL-DCAQKATOSA-N 0.000 description 1
- IUWMQCZOTYRXPL-ZPFDUUQYSA-N Lys-Ile-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O IUWMQCZOTYRXPL-ZPFDUUQYSA-N 0.000 description 1
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 1
- SKUOQDYMJFUMOE-ULQDDVLXSA-N Lys-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCCCN)N SKUOQDYMJFUMOE-ULQDDVLXSA-N 0.000 description 1
- YCJCEMKOZOYBEF-OEAJRASXSA-N Lys-Thr-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YCJCEMKOZOYBEF-OEAJRASXSA-N 0.000 description 1
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- HLYIDXAXQIJYIG-CIUDSAMLSA-N Met-Gln-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HLYIDXAXQIJYIG-CIUDSAMLSA-N 0.000 description 1
- VQILILSLEFDECU-GUBZILKMSA-N Met-Pro-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O VQILILSLEFDECU-GUBZILKMSA-N 0.000 description 1
- XLTSAUGGDYRFLS-UMPQAUOISA-N Met-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCSC)N)O XLTSAUGGDYRFLS-UMPQAUOISA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100034819 PDZ and LIM domain protein 1 Human genes 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- CYZBFPYMSJGBRL-DRZSPHRISA-N Phe-Ala-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CYZBFPYMSJGBRL-DRZSPHRISA-N 0.000 description 1
- QMMRHASQEVCJGR-UBHSHLNASA-N Phe-Ala-Pro Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 QMMRHASQEVCJGR-UBHSHLNASA-N 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- ILGCZYGFYQLSDZ-KKUMJFAQSA-N Phe-Ser-His Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O ILGCZYGFYQLSDZ-KKUMJFAQSA-N 0.000 description 1
- MRWOVVNKSXXLRP-IHPCNDPISA-N Phe-Ser-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MRWOVVNKSXXLRP-IHPCNDPISA-N 0.000 description 1
- 101000708422 Podarcis siculus Tissue- and phase-specific nuclear protein Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 1
- VJLJGKQAOQJXJG-CIUDSAMLSA-N Pro-Asp-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJLJGKQAOQJXJG-CIUDSAMLSA-N 0.000 description 1
- FISHYTLIMUYTQY-GUBZILKMSA-N Pro-Gln-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1 FISHYTLIMUYTQY-GUBZILKMSA-N 0.000 description 1
- NFLNBHLMLYALOO-DCAQKATOSA-N Pro-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 NFLNBHLMLYALOO-DCAQKATOSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- CZCCVJUUWBMISW-FXQIFTODSA-N Pro-Ser-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O CZCCVJUUWBMISW-FXQIFTODSA-N 0.000 description 1
- AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
- NBDHWLZEMKSVHH-UVBJJODRSA-N Pro-Trp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3 NBDHWLZEMKSVHH-UVBJJODRSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000002607 Pseudarthrosis Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000983304 Rattus norvegicus Osteocalcin Proteins 0.000 description 1
- 101000988393 Rattus norvegicus PDZ and LIM domain protein 4 Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 description 1
- HVKMTOIAYDOJPL-NRPADANISA-N Ser-Gln-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVKMTOIAYDOJPL-NRPADANISA-N 0.000 description 1
- FYUIFUJFNCLUIX-XVYDVKMFSA-N Ser-His-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O FYUIFUJFNCLUIX-XVYDVKMFSA-N 0.000 description 1
- JAWGSPUJAXYXJA-IHRRRGAJSA-N Ser-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=CC=C1 JAWGSPUJAXYXJA-IHRRRGAJSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- NQQMWWVVGIXUOX-SVSWQMSJSA-N Thr-Ser-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NQQMWWVVGIXUOX-SVSWQMSJSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- KXFYAQUYJKOQMI-QEJZJMRPSA-N Trp-Ser-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 KXFYAQUYJKOQMI-QEJZJMRPSA-N 0.000 description 1
- MOCXXGZHHSPNEJ-AVGNSLFASA-N Tyr-Cys-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O MOCXXGZHHSPNEJ-AVGNSLFASA-N 0.000 description 1
- XDGPTBVOSHKDFT-KKUMJFAQSA-N Tyr-Met-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O XDGPTBVOSHKDFT-KKUMJFAQSA-N 0.000 description 1
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- WKWJJQZZZBBWKV-JYJNAYRXSA-N Val-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WKWJJQZZZBBWKV-JYJNAYRXSA-N 0.000 description 1
- YLHLNFUXDBOAGX-DCAQKATOSA-N Val-Cys-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YLHLNFUXDBOAGX-DCAQKATOSA-N 0.000 description 1
- HIZMLPKDJAXDRG-FXQIFTODSA-N Val-Cys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N HIZMLPKDJAXDRG-FXQIFTODSA-N 0.000 description 1
- CFSSLXZJEMERJY-NRPADANISA-N Val-Gln-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CFSSLXZJEMERJY-NRPADANISA-N 0.000 description 1
- OUUBKKIJQIAPRI-LAEOZQHASA-N Val-Gln-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OUUBKKIJQIAPRI-LAEOZQHASA-N 0.000 description 1
- PWRITNSESKQTPW-NRPADANISA-N Val-Gln-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N PWRITNSESKQTPW-NRPADANISA-N 0.000 description 1
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000008226 craniofacial development Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000032631 intramembranous ossification Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000006517 limb development Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 description 1
- 230000001785 maturational effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004823 osteo-induction effect Effects 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 108010025826 prolyl-leucyl-arginine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010003885 valyl-prolyl-glycyl-glycine Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
- A61L27/3856—Intervertebral discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/38—Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Definitions
- the field of the invention relates generally to methods for expressing LIM mineralization proteins in a host cell. More specifically, the field of the invention relates to expression and purification of intracellular mediators involved in the osteogenic factor signaling cascade during osteoblast differentiation. The field of invention also relates to methods of improving the nuclear localization of osteogenic factors in suitable cells. Finally, the field of invention relates to transfecting host cells such as intervertebral disc cells with a nucleic acid encoding a LIM mineralization protein.
- Osteoblasts are thought to differentiate from pluripotent mesenchymal stem cells. The maturation of an osteoblast results in the secretion of an extracellular matrix which can mineralize and form bone. The regulation of this complex process is not well understood but is thought to involve a group of signaling glycoproteins known as bone morphogenetic proteins (BMPs). These proteins have been shown to be involved with embryonic dorsal-ventral patterning, limb bud development, and fracture repair in adult animals. B. L. Hogan, Genes & Develop., 10, 1580 (1996).
- TGF- ⁇ Transforming growth factor-beta superfamily
- LMPs LIM mineralization proteins
- Runx-2 Runt-Related Transcription Factor
- Dlx Drosophila distalles
- Osx Osterix
- osteoblasts require a complex coordination of all such osteogenic factors including BMPs, other members of the transforming TGF- ⁇ superfamily, LMPs, Dlx, Runx-2, Osx are key osteogenic factors that play critical roles in the BMP pathway.
- This secondary culture system is distinct from primary rat osteoblast cultures which undergo spontaneous differentiation.
- glucocorticoid resulted in a ten-fold induction of BMP-6 mRNA and protein expression which was responsible for the enhancement of osteoblast differentiation. Boden, et al., Endocrinology, 138, 2920 (1997).
- Runx2-deficient mice completely lack bone formation owing to the absence of osteoblasts.
- Runx2 determines the osteoblast lineage from multipotent mesenchymal cells, induces osteoblastic differentiation at the early stage, and inhibits it at the late stage. Further, Runx2 has been shown to induce alkaline phosphatase (ALP) activity, expression of bone matrix protein genes, and mineralization in immature mesenchymal cells and osteoblastic cells in vitro. Chondrocyte differentiation is also disturbed in Runx2 ⁇ / ⁇ mice.
- ALP alkaline phosphatase
- Runx2 Overexpression of Runx2 or the dominant-negative (dn) form of Runx2 (dn-Runx2) in chondrocytes accelerates or decelerates chondrocyte maturation, respectively, indicating that Runx2 is a positive regulatory factor in chondrocyte maturation. Further, introduction of dn-Runx2 inhibited cell condensation in insulin-induced chondrogenesis of ATDC5 cells. Thus, Runx2 plays crucial roles in osteoblast and chondrocyte differentiation.
- Dlx proteins have been implicated to play major role in osteogenesis as well. Ryoo, H. M., et al. (1997) “Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression.” Mol. Endocrinol. 11, 1681-1694. It has been shown that the mammalian homologs of Dlx 5 and 6 are homeobox genes essential for craniofacial and skeletal development. Dlx5 is a target gene for BMPs that regulate osteogenesis and dorsoventral patterning and targeted gene inactivation of Dlx 5 and 6 results in severe skeletal abnormalities leading to prenatal lethality. Sandhu et al. “Evaluation of rhBMP-2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model.” Spine 1995; 20:2669-82.
- Osx is a novel zinc finger containing transcription factor expressed by osteoblasts and required for endochondral and intra membranous bone formation.
- Osterix-null mice have normal cartilage development but fail to develop mineralized skeleton.
- Yasko et al the Healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. J Bone Joint Surg Am, 1992; 74:659-70.
- LIM proteins Another broad class of intracellular regulatory molecules are the LIM proteins, which are so named because they possess a characteristic structural motif known as the LIM domain. Viggeswarapu M, Boden S D et al. (2001) “Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo.” J Bone & Joint Surg Am. 83:364-376.
- the LIM domain is a cysteine-rich structural motif composed of two special zinc fingers that are joined by a 2-amino acid spacer. Some proteins have only LIM domains, while others contain a variety of additional functional domains. LIM proteins form a diverse group, which includes transcription factors and cytoskeletal proteins. The primary role of LIM domains appears to be in mediating protein-protein interactions, through the formation of dimers with identical or different LIM domains, or by binding distinct proteins.
- LIM homeodomain proteins that is, proteins having both LIM domains and a homeodomain sequence
- the LIM domains function as negative regulatory elements.
- LIM homeodomain proteins are involved in the control of cell lineage determination and the regulation of differentiation, although LIM-only proteins may have similar roles.
- LIM-only proteins are also implicated in the control of cell proliferation since several genes encoding such proteins are associated with oncogenic chromosome translocations.
- Gene therapy for bone formation offers a number of potential advantages: (1) lower production costs; (2) greater efficacy, compared to extracellular treatment regimens, due to the ability to achieve prolonged expression of the intracellular signal; (3) it would by-pass the possibility that treatment with extracellular signals might be hampered due to the presence of limiting numbers of receptors for those signals; (4) it permits the delivery of transfected potential osteoprogenitor cells directly to the site where localized bone formation is required; and (5) it would permit systemic bone formation, thereby providing a treatment regimen for osteoporosis and other metabolic bone diseases.
- intervertebral disc degeneration In addition to diseases of the bone, humans and other mammalian species are also subject to intervertebral disc degeneration, which is associated with, among other things, low back pain, disc herniation, and spinal stenosis. Disc degeneration is associated with a progressive loss of proteoglycan matrix. This may cause the disc to be more susceptible to bio-mechanical injury and degeneration. Accordingly, it would be desirable to have a method of stimulating proteoglycan and/or collagen synthesis by the appropriate cells, such as, for example, cells of the nucleus pulpous, cells of the annulus fibrosis, and cells of the intervertebral disc.
- a method of expressing a LIM mineralization protein in a host mammalian cell comprises transfecting the cell with an isolated nucleic acid comprising a nucleotide sequence encoding the LIM mineralization protein operably linked to a promoter.
- the cell can be a cell capable of producing proteoglycan and/or collagen such that the expression of the LIM mineralization protein stimulates proteoglycan and/or collagen synthesis in the cell.
- the isolated nucleic acid according to this aspect of the invention can be a nucleic acid which can hybridize under standard conditions to a nucleic acid molecule complementary to the full length of SEQ.
- the cell can be a stem cell, an intervertebral disc cell, a cell of the annulus fibrosus, or a cell of the nucleus pulposus.
- a mammalian cell comprising an isolated nucleic acid sequence encoding a LIM mineralization protein.
- purified chimeric nucleotides are also prepared that are expected to exhibit a greater degree of expression relative to those of their parental counterparts.
- the cell can be a stem cell, a cell of the nucleus pulposus, a cell of the annulus fibrosus, an intervertebral disc cell or other types of cell capable of such expression.
- chimeric polypeptide sequences are developed for delivery of the bone specific mammalian transcription factors.
- the developed chimeric polypeptide sequences are capable of nuclear localization in a form accessible to interaction with other nuclear proteins.
- a method of treating intervertebral disc injury or disease comprises transfecting an isolated nucleic acid into a mammalian cell capable of producing proteoglycan and/or collagen.
- the isolated nucleic acid comprises a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter.
- the LIM mineralization protein stimulates proteoglycan and/or collagen synthesis in the cell.
- an intervertebral disc implant comprising a carrier material and a plurality of mammalian cells comprising an isolated nucleic acid sequence encoding a LIM mineralization protein optionally with a nuclear localization signal.
- the carrier material comprises a porous matrix of biocompatible material and the mammalian cells are incorporated into the carrier material.
- a system and a method is developed to meet the demands of proteomics for transient transfection-based mammalian expression.
- a method is developed for identifying LMP-1 protein internal sequencing and assessing post-translational glycosylation in a mammalian expression system wherein the method employs carbohydrate analysis of LMP-1 hydrolysates.
- this aspect of the invention introduces a novel purification and detection methods wherein the skilled artisan is now able to purify the recombinant proteins to a level of homogeneity by means of (1) size fractionation of proteins prior to metal affinity chromatography to improve efficiency of affinity resin and (2) identification of tryptic fragments of purified protein.
- composition is prepared that comprises a LIM mineralization protein that is substantially free of any carbohydrate moiety.
- FIG. 1 is a graph showing the production of sulfated glycosaminoglycan (sGAG) after expression of HLMP-1 by rat intervertebral disc cells transfected with different MOIs (SEQ ID NOS 84-86);
- FIG. 2 is a chart showing the dose response of rat intervertebral disc cells six days after infection with different MOI of AdHLMP-1;
- FIG. 3 is a chart showing the expression of Aggrecan and BMP-2 mRNA by AdHLMP-1 transfected rat intervertebral disc cells six days following transfection with an MOI of 250 virions/cell;
- FIG. 4A is a chart showing HLMP-1 mRNA expression 12 hours after infection with Ad-hLMP-1 at different MOIs.
- exogenous LMP-1 expression was induced with different doses (MOI) of the Ad-hLMP-1 virus and quantitated with real-time PCR.
- the data is normalized to HLMP-1 mRNA levels from Ad-LMP-1 MOI 5 for comparison purposes. No HLMP-1 was detected in negative control groups, the no-treatment (“NT”) or Ad-LacZ treatment (“LacZ”). HLMP-1 mRNA levels in a dose dependent fashion to reach a plateau of approximately 8 fold with a MOI of 25 and 50.
- NT no-treatment
- LacZ Ad-LacZ
- FIG. 4B is a chart showing the production of sGAG in medium from 3 to 6 days after infection.
- DMMB assay was used to quantitate total sGAG production between days 3 to 6 after infection.
- the data in FIG. 4B is normalized to the control (i.e., no treatment) group.
- FIG. 4B there was a dose dependent increase in sGAG. with the peak of approximately three fold increase above control reached with a MOI of 25 and 50.
- each result is expressed as mean with SD for three samples.
- FIG. 5 is a chart showing time course changes of the production of sGAG.
- sGAG production increased significantly at a MOI of 25 and 50.
- AdLMP-1 On day 6 there was a dose dependent increase in sGAG production in response to AdLMP-1.
- the plateau level of sGAG increase was achieved at a MOI of 25.
- treatment with AdLacZ (“LacZ”) did not significantly change the sGAG production.
- Each result is expressed as mean with SD for six to nine samples.
- “**” indicates data points for which the P value is ⁇ 0.01 versus the untreated control.
- FIGS. 6A and 6B are charts showing gene response to LMP-1 over-expression in rat annulus fibrosus cells for aggrecan and BMP-2, respectively.
- Quantitative real-time PCR was performed on day 3 after infection with Ad-LMP-1 (“LMP-1”) at a MOI of 25.
- LMP-1 Ad-LMP-1
- the gene expression of aggrecan and BMP-2 increased significantly after infection with Ad-LMP-1 compared to the untreated control (“NT”).
- AdLacZ AdLacZ
- each result is expressed as mean with SD for six samples.
- “**” indicates data points for which the P value is P ⁇ 0.01.
- FIG. 7 is a graph showing the time course of HLMP-1 mRNA levels in rat annulus fibrosus cells after infection with AdLMP-1 at a MOI of 25. The data is expressed as a fold increase above a MOI of 5 of AdLMP-1 after standardization using 18S and replication coefficient of over-expression LMP-1 primer. As can be seen from FIG. 7 , HLMP-1 mRNA was upregulated significantly as early as 12 hours after infection. Further, there was a marked increase of expression levels between day 1 and day 3. Each result in FIG. 7 is expressed as mean with SD for six samples.
- FIG. 8 is a chart showing changes in mRNA levels of BMPs and aggrecan in response to HLMP-1 over-expression.
- the mRNA levels of BMP-2, BMP-4, BMP-6, BMP-7, and aggrecan were determined with real-time-PCR at different time points after infection with Ad-hLMP-1 at a MOI of 25.
- BMP-2 mRNA was upregulated significantly as early as 12 hours after infection with AdLMP-1.
- Aggrecan mRNA was not upregulated until 3 day after infection. Each result is expressed as mean with SD for six samples.
- “**” indicates data points for which the P value is ⁇ 0.01 for infection with AdLMP-1 versus an untreated control.
- FIG. 9 is a graph showing the time course of sGAG production enhancement in response to HLMP-1 expression.
- rat annulus cells were infected with Ad-hLMP-1 at a MOI of 25. The media was changed every three days after infection and assayed for sGAG with the DMMB assay. This data shows that sGAG production reaches a plateau at day 6 and is substantially maintained at day 9.
- FIG. 10 is a chart showing the effect of noggin (a BMP antagonist) on LMP-1 mediated increase in sGAG production.
- noggin a BMP antagonist
- infection of rat annulus cells with Ad-LMP-1 at a MOI of 25 led to a three fold increase in sGAG produced between day 3 and day 6.
- This increase was blocked by the addition of noggin (a BMP antagonist) at concentration of 3200 ng/ml and 800 ng/m.
- noggin did not significantly alter sGAG production in uninfected cells.
- stimulation with rhBMP-2 at 100 ng/ml led to a 3 fold increase in sGAG production between day 3 and day 6 after addition of BMP-2.
- Noggin at 800 ng/ml also blocked this increase.
- FIG. 11 is a chart showing the effect of LMP-1 on sGAG in media after day 6 of culture in monolayer. The data points are represented as fold increase above untreated cells. As shown in FIG. 11 , LMP-1 with the CMV promoter when delivered by the AAV vector is also effective in stimulating glycosaminoglycan synthesis by rat disc cells in monolayer.
- FIG. 12 shows Sephacryl S-300 molecular exclusion chromatographic profile obtained for the crude A549 lysate.
- the clarified lysate was applied to Sephacryl S-300 column (HiPrep 16 ⁇ 60) using the AKTA FPLC/Unicorn 3.1 System in 50 mM phosphate buffer, pH 7.5 and 5 M NaCl. After the void volume eluted from the column, fractions (6 ml) were collected. Fractions containing fusion proteins were detected by western blots with LMP-1-specific antibody and pooled for Ni ++ -affinity enrichment. Inclusion of 5 M NaCl in buffer avoided non-specific aggregation of recombinant proteins on column resin.
- FIG. 13 is a graph showing SDS-PAGE and detection of purified LMP-1.
- Purified protein fractions were concentrated, dialyzed and a 5 ug aliquot of recombinant protein was loaded.
- the purity of pooled fractions from Sephacryl S-300 molecular exclusion chromatography and Ni ++ -affinity chromatography were determined by coomassie staining of gels after SDS-PAGE (10% acrylamide). Each of the fusion-protein was the expected size as determined from molecular weight markers as marked.
- FIG. 14 is a chromatograph showing the tryptic digest (15%) OF LMP-1 purified and concentrated by a Zip Tip (Millipore) column which has Cl 8 resin fixed at its end.
- the column was rinsed in 10 ⁇ l of 0.1% trifluoroacetic acid (TFA) in 50% acetonitrile (ACN). Peptides were eluted in 10 ⁇ l 1:1 ACN-0.1% TFA.
- a 0.5 ⁇ l volume of the concentrated peptide-containing sample was mixed with 0.5 ⁇ l of a saturated solution of alpha-cyano-4-hydroxycinnamic acid. Each sample (0.5 ul) was spotted on the mass spectrometer sample plate for analysis.
- HPLC-purified peptide was subjected to ion generation by post-source decay using the FASTTM method as described in the methods.
- a matrix-assisted laser adsorption ionization-post-source decay (MALDI-PSD) time-of-flight spectrum was recorded using ⁇ -cyano-4-hydroxy cinnamic acid as a matrix; acquisition was at 27.5 kV under continuous extraction conditions; reflector voltage was stepped from 30 to 1.27 kV, and the spectrum was constructed.
- PSD post source decay
- FIG. 16 is a chromatograph of a tryptic peptide mixture (85%) of LMP-1 after digestion was separated by capillary reversed-phase HPLC using the method described before [Hubalek, F., Edmondson].
- the peptide fragments were separated by small bore reverse phase HPLC on a Vydac C 18 column (4.6 ⁇ 250 mm) with a gradient HPLC system (Waters).
- the chromatographic run was performed with an aqueous phase containing 0.1% trifluoroacetic acid and an organic phase containing 0.085% trifluoroacetic acid in acetonitrile with a flow rate of 0.5 ml/min.
- the gradient used for separation was 2-60% of acetonitrile during 40 min; the total run time was 60 min.
- FIG. 17 is a chromatograph showing MALDI-TOF MS analysis of HPLC separated tryptic peptide fractions of LMP-1. A representative data obtained for fractions 33 (A), 35 (B), 48 (C) and 51 (D) is shown. These samples contained an exact match of the expected molecular ions for the corresponding peptide species derived from LMP-1.
- FIG. 18 is a depiction of general strategy for construction and cloning of TAT-cDNA for expression in E. coli .
- FIG. 19 is a Sephacryl S-100 molecular exclusion chromatographic profiles obtained for the bacterial crude lysates for LMP-1.
- the clarified bacterial lysate was applied to Sephacryl S-100 column (HiPrep 16 ⁇ 60) using the AKTA FPLC/Unicorn 3.1 System in 50 mM phosphate buffer, pH 7.5 and 5 M NaCl. After the void volume eluted from the column, fractions (4 ml) were collected. Fractions containing fusion proteins were detected by slot blots and western blots with hemagglutinin-specific antibody and pooled for Ni ++ -affinity enrichment. Inclusion of 5 M NaCl in buffer avoided non-specific aggregation of recombinant proteins on column resin.
- FIG. 20 is a Sephacryl S-100 molecular exclusion chromatographic profiles obtained for the bacterial crude lysates for Dlx5. Same method was employed as for LMP-1 in FIG. 19 .
- FIG. 21 is a Sephacryl S-100 molecular exclusion chromatographic profiles obtained for the bacterial crude lysates for Runx2. Same method was employed as for FIG. 19 .
- FIG. 22 is a Sephacryl S-100 molecular exclusion chromatographic profiles obtained for the bacterial crude lysates for Osx. Same method was employed as for FIG. 19 .
- FIG. 23 is a depiction of SDS-PAGE of purified LMP-1, Dlx5, Runx2 and Osterix. Purified protein fractions were concentrated, dialyzed and a 5 ug aliquot of each recombinant protein was loaded. The purity of each preparation was determined by coomassie staining of gels after SDS-PAGE (12% acrylamide). Each of the fusion-protein was the expected size as determined from molecular weight markers as marked.
- FIG. 24 is a time and Dose-dependent accumulation of FITC labeled TAT-LMP-1 into rabbit buffy coat cells.
- TAT-LMP-1 was labeled with FITC and incubated with rabbit buffy coat cells. Concentrations ranging from 1.0 to 25 nM of FITC-labeled TAT-LMP-1 was incubated for 15, 30 and 60 min at 37° C. with 10 6 cells. After washes the % of total cells containing FITC was determined by flow cytometry.
- FIG. 25 shows that a TAT-fusion protein was detected in both nuclear and cytoplasmic fractions in MSCs. Equal aliquots of protein (10 ug) were loaded in each lane. The cytoplasmic and nuclear lanes contained samples obtained from cells that were treated with 0.3 to 300 nM TAT-LMP-1. The blots were blocked and probed with rabbit HA-specific antibodies. The signal is detected by HRP-labeled anti-rabbit second antibodies and enhanced chemi-luminescence.
- FIG. 26 shows TAT-LMP-1 associates with specific nuclear proteins.
- a Metal affinity tag pull-down assay was performed as described in methods. The bound proteins were eluted with 250 mM imidazole followed by removal of Ni ++ with 50 mM EDTA. Protein samples (5 ug) were resolved by SDS-PAGE, transblotted to nitrocellulose membrane. The blotted proteins were stained with colloidal gold for total protein (Panel A) or probed with HA-specific primary antibody followed by horse radish peroxidase (HRP)-labeled second antibody (Panel B). The signal was developed with enhanced chemi-luminescence as described in methods.
- HRP horse radish peroxidase
- HLMP-1 Human LMP-1, also designated as Human LIMProtein or HLMP;
- LMP-1 LIM mineralization protein-1
- Trm Triamcinolone
- RLMP Rat LIM mineralization protein, also designated as RLMP-1; RLMPU,
- AdHLMP-1 Recombinant Type 5 Adenovirus comprising nucleotide sequence encoding HLMP-1;
- Ni-NTA Nickel-nitrilotriacetic acid
- BSA bovine serum albumin
- MALDI TOF Matrix Assisted Laser Desorption Ionization Time of Flight
- IPTG Isopropyl- ⁇ D-thiogalactopyranoside
- LB Luria
- isolated/and or purified refers to in vitro preparation, isolation, and/or purification of a nucleic acid or protein from its natural cellular environment or from association with other components of the cell, so that it is not associated with in vivo substances.
- the term “recombinant DNA” means any DNA molecule consisting of segments of DNA from different genomes (the entire DNA or cell or virus) which have been joined end-to-end outside of living cells and have the capacity to transfect suitable host cells and be maintained therein.
- the term “recombinant polypeptide, protein or amino acid sequence” means any such molecule that was expressed from a recombinant DNA consisting of segments of DNA that have been joined end-to-end outside of living cells and have the capacity to be transfected into host cells and be maintained therein.
- chimeric means that a vector comprises DNA from at least two different species or comprises DNA from the same species which is linked or associated in a manner which does not occur in the “native,” or “wild type” of the species.
- operably linked means that the nucleic acids are placed in a functional relationship with another nucleic acid sequence.
- Transfection can occur either ex vivo or in vivo by direct injection of virus or naked DNA, such as, for example, a plasmid.
- the virus is a recombinant adenovirus, preferably AdHLMP-1
- the present invention relates to the transfection of non-osseous cells with nucleic acids encoding LIM mineralization proteins.
- the present inventors have discovered that transfection of non-osseous and osseous cells such as intervertebral disc cells with nucleic acids encoding LIM mineralization proteins can result in the increased synthesis of proteoglycan, collagen and other intervertebral disc components and tissue.
- the present invention also provides a method for treating intervertebral disc disease associated with the loss of proteoglycan, collagen, or other intervertebral disc components.
- a LIM gene (10-4/RLMP) has been isolated from stimulated rat calvarial osteoblast cultures (SEQ. ID NO: 1, SEQ. ID NO: 2). See U.S. Pat. No. 6,300,127. This gene has been cloned, sequenced and assayed for its ability to enhance the efficacy of bone mineralization in vitro.
- the protein RLMP has been found to affect the mineralization of bone matrix as well as the differentiation of cells into the osteoblast lineage.
- RLMP is not a secreted protein, but is instead an intracellular signaling molecule. This feature has the advantage of providing intracellular signaling amplification as well as easier assessment of transfected cells. It is also suitable for more efficient and specific in vivo applications. Suitable clinical applications include enhancement of bone repair in fractures, bone defects, bone grafting, and normal homeostasis in patients presenting with osteoporosis.
- the amino acid sequence of a corresponding human protein has also been cloned, sequenced and deduced. (SEQ. ID NO: 10). See U.S. Pat. No. 6,300,127.
- the human protein has been found to demonstrate enhanced efficacy of bone mineralization in vitro and in vivo.
- the sequence of LMP-1 contains a highly conserved N-terminal PDZ domain and three C-terminal LIM domains.
- HLMP-1s a truncated (short) version of HLMP-1, termed HLMP-1s, has been characterized. See U.S. Pat. No. 6,300,127. This short version resulted from a point mutation in one source of a cDNA clone, providing a stop codon which truncates the protein. HLMP-1s has been found to be fully functional when expressed in cell culture and in vivo.
- HLMP-2 and HLMP-3 Two alternative splice variants (referred to as HLMP-2 and HLMP-3) have been identified that differ from HLMP-1 in a region between base pairs 325 and 444 in the nucleotide sequence encoding HLMP-1. See U.S. patent application Ser. No. 09/959,578, filed Apr. 28, 2000, now U.S. Pat. No. 7,045,614.
- the HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region.
- the nucleotide sequence encoding HLMP-3 has no deletions, but it does have the same 17 base pairs as HLMP-2, which are inserted at position 444 in the HLMP-1 sequence.
- LMP is a pluripotent molecule, which regulates or influences a number of biological processes.
- the different splice variants of LMP are expected to have different biological functions in mammals. They may play a role in the growth, differentiation, and/or regeneration of various tissues. For example, some form of LMP is expressed not only in bone, but also in muscle, tendons, ligaments, spinal cord, peripheral nerves, and cartilage.
- the present invention relates to a method of stimulating proteoglycan and/or collagen synthesis in a mammalian cell by providing an isolated nucleic acid comprising a nucleotide sequence encoding LIM mineralization protein operably linked to a promoter; transfecting said isolated nucleic acid sequence into a mammalian cell capable of producing proteoglycan; and expressing said nucleotide sequence encoding LIM mineralization protein, whereby proteoglycan synthesis is stimulated.
- the mammalian cell may be a non-osseous cell, such as an intervertebral disc cell, a cell of the annulus fibrosus, or a cell of the nucleus pulposus.
- Transfection may occur either ex vivo or in vivo by direct injection of virus or naked DNA, such as, for example, a plasmid.
- the virus is a recombinant adenovirus, preferably AdHLMP-1.
- Another embodiment of the invention comprises a non-osseous mammalian cell comprising an isolated nucleic acid sequence encoding a LIM mineralization protein.
- the non-osseous mammalian cell may be a stem cell (e.g., a pluripotent stem cell or a mesenchymal stem cell) or an intervertebral disc cell, preferably a cell of the nucleus pulposus or a cell of the annulus fibrosus.
- the invention is directed to a method of expressing an isolated nucleotide sequence encoding LIM mineralization protein in a non-osseous mammalian cell, comprising: providing an isolated nucleic acid comprising a nucleotide sequence encoding LIM mineralization protein operably linked to a promoter; transfecting said isolated nucleic acid sequence into a non-osseous mammalian cell; and expressing said nucleotide sequence encoding LIM mineralization protein.
- the non-osseous mammalian cell may be a stem cell or an intervertebral disc cell (e.g., a cell of the nucleus pulposus or annulus fibrosus). Transfection may occur either ex vivo or in vivo by direct injection of virus or naked DNA, such as, for example, a plasmid.
- the virus can be a recombinant adenovirus, preferably AdHLMP-1.
- purified chimeric nucleotides are prepared that will exhibit a greater degree of expression relative to those of their parental counterparts.
- bacterially expressed TAT-fusion-cDNAs of osteogenic factors were prepared that have the potential to either replace BMP-2 in inducing bone formation or to serve as enhancers of BMP-2 efficacy.
- chimeric polypeptide sequences are developed for delivery of the bone specific mammalian transcription factors.
- Osteogenic factors containing TAT domain were obtained and purified.
- the developed chimeric polypeptide sequences are capable of nuclear localization in a form accessible to interaction with other nuclear proteins.
- the application is directed to a method of treating intervertebral disc disease by reversing, retarding or slowing disc degeneration, comprising providing an isolated nucleic acid comprising a nucleotide sequence encoding LIM mineralization protein operably linked to a promoter; transfecting said isolated nucleic acid sequence into a mammalian cell capable of producing proteoglycan; and stimulating proteoglycan synthesis in said cell by expressing said nucleotide sequence encoding LIM mineralization protein, whereby disc degeneration is reversed, halted or slowed.
- the disc disease may involve lower back pain, disc herniation, or spinal stenosis.
- the mammalian cell may be a non-osseous cell, such as a stem cell or an intervertebral disc cell (e.g., a cell of the annulus fibrosus, or a cell of the nucleus pulposus).
- Transfection may occur either ex vivo or in vivo by direct injection of virus or naked DNA, such as, for example, a plasmid.
- the virus is a recombinant adenovirus, preferably AdHLMP-1.
- the present invention relates to novel mammalian LIM proteins, herein designated LIM mineralization proteins, or LMPs.
- LIM mineralization proteins or LMPs.
- the invention relates more particularly to human LMP, known as HLMP or HLMP-1, or alternative splice variants of human LMP, which are known as HLMP-2 or HLMP-3.
- HLMP human LMP
- HLMP-1 human LMP
- HLMP-2 or HLMP-3 alternative splice variants of human LMP
- hybrid proteins that are expressed and further accumulated in both cytoplasmic and nuclear compartments.
- the hybrid protein is a TAT-tagged osteogenic factor, more preferably a TAT-tagged-LMP-1. This is the first time that a recombinant TAT-LMP-1 has been shown to interact with nuclear proteins. Accordingly, such TAT-fusion proteins can be used as molecular bait to identify the intracellular interacting proteins.
- ex vivo transfection of bone marrow cells, osteogenic precursor cells, peripheral blood cells, and stem cells e.g., pluripotent stem cells or mesenchymal stem cells
- a LIM mineralization protein e.g., LMP or HLMP
- this method to: augment long bone fracture repair; generate bone in segmental defects; provide a bone graft substitute for fractures; facilitate tumor reconstruction or spine fusion; and provide a local treatment (by injection) for weak or osteoporotic bone, such as in osteoporosis of the hip, vertebrae, or wrist.
- Transfection with LMP or HLMP-encoding nucleic acid is also useful in: the percutaneous injection of transfected marrow cells to accelerate the repair of fractured long bones; treatment of delayed union or non-unions of long bone fractures or pseudoarthrosis of spine fusions; and for inducing new bone formation in avascular necrosis of the hip or knee.
- transfection of a recombinant DNA vector comprising a nucleic acid sequence that encodes LMP or HLMP can be accomplished in vivo.
- an appropriate viral vector for example, an adenovirus vector
- the viral construct can be injected directly into a body site were endochondral bone formation is desired.
- a direct, percutaneous injection to introduce the LMP or HLMP sequence stimulation of bone formation can be accomplished without the need for surgical intervention either to obtain bone marrow cells (to transfect ex vivo) or to reimplant them into the patient at the site where new bone is required.
- Alden, et al., Neurosurgical Focus (1998) have demonstrated the utility of a direct injection method of gene therapy using a cDNA that encodes BMP-2, which was cloned into an adenovirus vector.
- a naked that is, unencapsulated, recombinant plasmid comprising a nucleic acid sequence that encodes HLMP.
- transfection occurs when the naked plasmid DNA is taken up, or internalized, by the appropriate target cells, which have been described.
- direct injection of naked plasmid DNA offers the advantage that little or no surgical intervention is required.
- ex vivo transfection may be accomplished by harvesting cells from an intervertebral disc, transfecting the cells with nucleic acid encoding LMP in vitro, followed by introduction of the cells into an intervertebral disc.
- the cells may be harvested from or introduced back into the intervertebral disc using any means known to those of skill in the art, such as, for example, any surgical techniques appropriate for use on the spine.
- the cells are introduced into the intervertebral disc by injection.
- stem cells e.g., pluripotential stem cells or mesenchymal stem cells
- nucleic acid encoding a LIM Mineralization Protein ex vivo and introduced into the intervertebral disc (e.g., by injection).
- the cells transfected ex vivo can also be combined with a carrier to form an intervertebral disc implant.
- the carrier comprising the transfected cells can then be implanted into the intervertebral disc of a subject.
- Suitable carrier materials are disclosed in Helm, et al., “Bone Graft Substitutes for the Promotion of Spinal Arthrodesis”, Neurosurg Focus, Vol. 10 (4): April 2001.
- the carrier preferably comprises a biocompatible porous matrix such as a demineralized bone matrix (DBM), a biocompatible synthetic polymer matrix or a protein matrix. Suitable proteins include extracellular matrix proteins such as collagen.
- DBM demineralized bone matrix
- Suitable proteins include extracellular matrix proteins such as collagen.
- the cells transfected with the LMP ex vivo can be incorporated into the carrier (i.e., into the pores of the porous matrix) prior to implantation.
- the DNA may be introduced into the intervertebral disc using any suitable method known to those of skill in the art.
- the nucleic acid is directly injected into the intervertebral space.
- transient expression of LMP is achieved. This occurs because adenovirus does not incorporate into the genome of target cells that are transfected. Transient expression of LMP, that is, expression that occurs during the lifetime of the transfected target cells, is sufficient to achieve the objects of the invention. Stable expression of LMP, however, can occur when a vector that incorporates into the genome of the target cell is used as a delivery vehicle. Nishida et al, the teaching of which is incorporated herewith in its entirety, investigated the efficacy of adenovirus-mediate gene transfer to Nucleus Pulposus cells. Neshida et al., Spine, Vol. 23(22): 2437-2442 (15 Nov. 1998).
- Nishida et al successfully demonstrate adenovirus-mediated gene transfer to the intervertebral disc with persistent expression of the marker gene for at least 12 weeks in vivo in high titters.
- the transfected intervertebral discs in Nishida's experiment did not exhibit typical signs of local immune activity. This result indicates that the avascular environment of intervertebral disc limits the access of immunocompetent cells, thereby preventing immune reactivity and prolonging gene expressions. Due to such results the inventors believe that Retrovirus-based vectors, are also suitable for this purpose.
- LMP expression is particularly useful for treating various systemic bone-related disorders, such as osteoporosis and osteogenesis imperfecta.
- LMP expression in addition to using a vector that integrates into the genome of the target cell to deliver an LMP-encoding nucleotide sequence into target cells, LMP expression can be placed under the control of a regulatable promoter.
- a promoter that is turned on by exposure to an exogenous inducing agent, such as tetracycline is suitable.
- HLMP-specific antibodies are particularly suitable for use in methods for assaying the osteoinductive, that is, bone-forming, potential of patient cells. In this way one can identify patients at risk for slow or poor healing of bone repair. Also, HLMP-specific antibodies are suitable for use in marker assays to identify risk factors in bone degenerative diseases, such as, for example, osteoporosis.
- the genes of the present invention are prepared by ligation of nucleic acid segments that encode LMP to other nucleic acid sequences, such as cloning and/or expression vectors. Methods needed to construct and analyze these recombinant vectors, for example, restriction endonuclease digests, cloning protocols, mutagenesis, organic synthesis of oligonucleotides and DNA sequencing, have been described. For DNA sequencing DNA, the dioxyterminator method is the preferred.
- Primer-directed amplification of DNA or cDNA is a common step in the expression of the genes of this invention. It is typically performed by the polymerase chain reaction (PCR). PCR is described in U.S. Pat. No. 4,800,159 to Mullis, et al. and other published sources. The basic principle of PCR is the exponential replication of a DNA sequence by successive cycles of primer extension. The extension products of one primer, when hybridized to another primer, becomes a template for the synthesis of another nucleic acid molecule. The primer-template complexes act as substrate for DNA polymerase, which in performing its replication function, extends the primers.
- the conventional enzyme for PCR applications is the thermostable DNA polymerase isolated from Thermus aquaticus , or Taq DNA polymerase.
- RNA is extracted and reverse transcribed under standard and well known procedures.
- the resulting cDNA is then analyzed for the appropriate mRNA sequence by PCR.
- the gene encoding the LIM mineralization protein is expressed in an expression vector in a recombinant expression system.
- the constructed sequence need not be the same as the original, or its complimentary sequence, but instead may be any sequence determined by the degeneracy of the DNA code that nonetheless expresses an LMP having bone forming activity.
- Conservative amino acid substitutions, or other modifications, such as the occurrence of an amino-terminal methionine residue, may also be employed.
- a ribosome binding site active in the host expression system of choice is ligated to the 5′ end of the chimeric LMP coding sequence, forming a synthetic gene.
- the synthetic gene can be inserted into any one of a large variety of vectors for expression by ligating to an appropriately linearized plasmid.
- a regulatable promoter for example, the E. coli lac promoter, is also suitable for the expression of the chimeric coding sequences.
- Other suitable regulatable promoters include trp, tac, recA, T7 and lambda promoters.
- DNA encoding LMP is transfected into recipient cells by one of several standard published procedures, for example, calcium phosphate precipitation, DEAE-Dextran, electroporation or protoplast fusion, to form stable transformants.
- Calcium phosphate precipitation is preferred, particularly when performed as follows.
- DNAs are co precipitated with calcium phosphate according to the method of Graham and Van Der, Virology, 52, 456 (1973), before transfer into cells.
- the DNA is mixed with 0.5 ml of 2 ⁇ Hepes solution (280 mM NaCl, 50 mM Hepes and 1.5 mM Na 2 HPO 4 , pH 7.0), to which an equal volume of 2 ⁇ CaCl 2 (250 mM CaCl 2 and 10 mM Hepes, pH 7.0) is added.
- the medium is removed and the cells shocked with 15% glycerol in PBS for 3 minutes. After removing the glycerol, the cells are fed with Dulbecco's Minimal Essential Medium (DMEM) containing 10% fetal bovine serum.
- DMEM Dulbecco's Minimal Essential Medium
- DNA can also be transfected using: the DEAE-Dextran methods of Kimura, et al., Virology, 49:394 (1972) and Sompayrac et al., Proc. Natl. Acad. Sci. USA, 78, 7575 (1981); the electroporation method of Potter, Proc. Natl. Acad. Sci. USA, 81, 7161 (1984); and the protoplast fusion method of Sandri-Goddin et al., Molec. Cell. Biol., 1, 743 (1981).
- Phosphoramidite chemistry in solid phase is the preferred method for the organic synthesis of oligodeoxynucleotides and polydeoxynucleotides.
- many other organic synthesis methods are available. Those methods are readily adapted by those skilled in the art to the particular sequences of the invention.
- the present invention also includes nucleic acid molecules that hybridize under standard conditions to any of the nucleic acid sequences encoding the LIM mineralization proteins of the invention.
- Standard hybridization conditions will vary with the size of the probe, the background and the concentration of the nucleic acid reagents, as well as the type of hybridization, for example, in situ, Southern blot, or hybrization of DNA-RNA hybrids (Northern blot).
- standard hybridization conditions is within the level of skill in the art. For example, see U.S. Pat. No. 5,580,775 to Fremeau, et al., herein incorporated by reference for this purpose. See also, Southern, J. Mol.
- One preferred set of standard hybrization conditions involves a blot that is prehybridized at 42° C. for 2 hours in 50% formamide, 5 ⁇ SSPE (150 nM NaCl, 10 mM Na H 2 PO 4 [pH 7.4], 1 mM EDTA [pH 8.0]) l 5 ⁇ Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water), 10% dextran sulphate, 1% SDS and 100 ⁇ g/ml salmon sperm DNA. A 32 P-labeled cDNA probe is added, and hybridization is continued for 14 hours.
- 5 ⁇ SSPE 150 nM NaCl, 10 mM Na H 2 PO 4 [pH 7.4], 1 mM EDTA [pH 8.0]
- 5 ⁇ Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water
- the blot is washed twice with 2 ⁇ SSPE, 0.1% SDS for 20 minutes at 22° C., followed by a 1 hour wash at 65° C. in 0.1 ⁇ SSPE, 0.1% SDS.
- the blot is then dried and exposed to x-ray film for 5 days in the presence of an intensifying screen.
- a probe Under “highly stringent conditions,” a probe will hybridize to its target sequence if those two sequences are substantially identical. As in the case of standard hybridization conditions, one of skill in the art can, given the level of skill in the art and the nature of the particular experiment, determine the conditions under which only susbstantially identical sequences will hybridize.
- an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a LIM mineralization protein.
- the nucleic acid molecule according to the invention can be a molecule which hybridizes under standard conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 25 and/or which hybridizes under highly stringent conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 26. More specifically, the isolated nucleic acid molecule according to the invention can encode HLMP-1, HLMP-1s, RLMP, HLMP-2, or HLMP-3.
- the invention relates to the identification of such proteins based on anti-LMP antibodies.
- protein samples are prepared for Western blot analysis by lysing cells and separating the proteins by SDS-PAGE.
- the proteins are transferred to nitrocellulose by electrobloffing as described by Ausubel, et al., Current Protocols in Molecular Biology, John Wiley and Sons (1987).
- anti-LMP antibody is added to the filter and incubated for 1 hour at room temperature.
- the filter is washed thoroughly with phosphate buffered saline (PBS) and incubated with horseradish peroxidase (HRPO)-antibody conjugate for 1 hour at room temperature.
- HRPO horseradish peroxidase
- the filter is again washed thoroughly with PBS and the antigen bands are identified by adding diaminobenzidine (DAB).
- DAB diaminobenzidine
- Monospecific antibodies are the reagent of choice in the present invention, and are specifically used to analyze patient cells for specific characteristics associated with the expression of LMP.
- “Monospecific antibody” as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for LMP.
- “Homogeneous binding” as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with LMP, as described above.
- Monospecific antibodies to LMP are purified from mammalian antisera containing antibodies reactive against LMP or are prepared as monoclonal antibodies reactive with LMP using the technique of Kohler and Milstein. Kohler et al., Nature, 256, 495-497 (1975). The LMP specific antibodies are raised by immunizing animals such as, for example, mice, rats, guinea pigs, rabbits, goats or horses, with an appropriate concentration of LMP either with or without an immune adjuvant.
- pre-immune serum is collected prior to the first immunization.
- Each animal receives between about 0.1 mg and about 1.0 mg of LMP associated with an acceptable immune adjuvant, if desired.
- acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA adjuvants.
- the initial immunization consists of LMP in, preferably, Freund's complete adjuvant injected at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer.
- the animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are generally given an equal amount of the antigen in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about ⁇ 20° C.
- Monoclonal antibodies (mAb) reactive with LMP are prepared by immunizing inbred mice, preferably Balb/c mice, with LMP.
- the mice are immunized by the IP or SC route with about 0.1 mg to about 1.0 mg, preferably about 1.0 mg, of LMP in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred.
- the mice receive an initial immunization on day 0 and are rested for about 3-30 weeks. Immunized mice are given one or more booster immunizations of about 0.1 to about 10 mg of LMP in a buffer solution such as phosphate buffered saline by the intravenous (IV) route.
- IV intravenous
- Lymphocytes from antibody-positive mice are obtained by removing the spleens from immunized mice by standard procedures known in the art.
- Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred.
- the antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1,000 mol. wt., at concentrations from about 30% to about 50%.
- Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin in supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art.
- DMEM Dulbecco's Modified Eagles Medium
- Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21, and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using LMP as the antigen.
- SPIRA solid phase immunoradioassay
- the culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb.
- Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, “Soft Agar Techniques Tissue Culture Methods and Applications”, Kruse and Paterson (eds.), Academic Press (1973). See, also, Harlow, et al., Antibodies: A Laboratory Manual, Cold Spring Laboratory (1988).
- Monoclonal antibodies may also be produced in vivo by injection of pristane-primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 ⁇ 10 6 to about 6 ⁇ 10 6 hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.
- In vitro production in anti-LMP mAb is carried out by growing the hydridoma cell line in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb.
- the mAb are purified by techniques known in the art.
- Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays, which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of the LMP in body fluids or tissue and cell extracts.
- serological or immunological assays include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of the LMP in body fluids or tissue and cell extracts.
- the invention is directed to alternative splice variants of HLMP-1.
- PCR analysis of human heart cDNA revealed mRNA for two HLMP alternative splice variants, named HLMP-2 and HLMP-3, that differ from HLMP-1 in a region between base pairs 325 and 444 in the HLMP-1 sequence.
- the HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. These changes preserve the reading frame, resulting in a 423 amino acid protein, which compared to HLMP-1, has a net loss of 34 amino acids (40 amino acids deleted plus 6 inserted amino acids).
- HLMP-2 contains the c-terminal LIM domains that are present in HLMP-1.
- HLMP-3 Compared to HLMP-1, HLMP-3 has no deletions, but it does have the same 17 base pair insertion at position 444. This insertion shifts the reading frame, causing a stop codon at base pairs 459-461. As a result, HLMP-3 encodes a protein of 153 amino acids. This protein lacks the c-terminal LIM domains that are present in HLMP-1 and HLMP-2. The predicted size of the proteins encoded by HLMP-2 and HLMP-3 was confirmed by western blot analysis.
- HLMP-1 is apparently the predominant form expressed in leukocytes, spleen, lung, placenta, and fetal liver.
- HLMP-2 appears to be the predominant isoform in skeletal muscle, bone marrow, and heart tissue.
- HLMP-3 was not the predominant isoform in any tissue examined.
- HLMP-3 Over-expression of HLMP-3 in secondary rat osteoblast cultures induced bone nodule formation (287 ⁇ 56) similar to the effect seen for glucicorticoid (272 ⁇ 7) and HLMP-1 (232 ⁇ 200). Since HLMP-3 lacks the C-terminal LIM domains, there regions are not required for osteoinductive activity.
- HLMP-2 did not induce nodule formation (11 ⁇ 3).
- amino acids encoded by the deleted 119 base pairs are necessary for osteoinduction.
- the data also suggest that the distribution of HLMP splice variants may be important for tissue-specific function.
- HLMP-2 inhibits steroid-induced osteoblast formation in secondary rat osteoblast cultures. Therefore, HLMP-2 may have therapeutic utility in clinical situations where bone formation is not desirable.
- a sample of 10-4/RLMP in a vector designated pCMV2/RLMP (which is vector pRc/CMV2 with insert 10-4 clone/RLMP) was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852. The culture accession number for that deposit is 209153.
- ATCC American Type Culture Collection
- a sample of the vector pHis-A with insert HLPM-1s was deposited at the American Type Culture Collection (“ATCC”). The culture accession number for that deposit is 209698.
- ATCC American Type Culture Collection
- inventors have enhance the bioavailability of osteogenic factors within a cell.
- Work by Becker-Hapak et al. has shown that the TAT protein of HIV-1 can enter a wide variety of cells efficiently when added exogenously.
- Becker-Hapak, M., et al. (2001) TAT-mediated protein transduction into mammalian cells. Methods. 24, 247-256.
- TAT protein added to medium at concentrations of 1 nM can induce biological responses in the nucleus of the target cell, although the mechanisms by which the molecule is taken up and distributed within the cell are unknown.
- the inventors have developed an efficient systems for delivery of osteogenic factors into the cells. Accordingly, a purified recombinant protein cargo delivered by the TAT-peptide tag was delivered for nuclear localization in such form accessible to interaction with other nuclear proteins.
- the inventors applied techniques to deliver signaling molecules as bait to eventually identify and characterize their interacting partners to determine the mode of action of each of these factors.
- Transcription factors in general, are expressed in response to specific extra and/or intracellular signals. These proteins are transiently expressed in low amounts in cells. For extensive studies on their interacting proteins in vitro, it is necessary to isolate them in large quantities. At least one objective of the present embodiment was to engineer, express and purify such factors in large quantities that can be used to develop further tools (antibodies, protein-interaction pull-down assays, protein delivery vehicles etc.) to facilitate our understanding of their mode of action in vivo.
- Labeling of the purified fusion-proteins with FITC allowed us to monitor their entry into cells in a time and concentration dependent manner. Incubation of TAT-proteins for 30 min attained maximum cellular entry when doses of 25 nM and above were added. The inventors have also the first to demonstrate that the presence of the cationic peptide allows the TAT-tagged protein to accumulate both in the cytoplasmic and nuclear fractions in a dose dependent fashion.
- this aspect of the invention provides a quick purification protocol for the purification of HIV derived TAT-domain fused signaling molecules. Accordingly, the purified proteins were able to enter cells in a time and dose-dependent manner.
- inventors confirmed the presence of newly accumulated TAT-protein in cytoplasmic and nuclear compartments.
- One of ordinary skill in the art in possession of this aspect of the invention can determine the down stream interacting proteins by pull-down assays and binding assays in vitro using conventional methods in the art.
- Another aspect of the invention includes the proteins encoded by the nucleic acid sequences.
- purified recombinant protein cargo of bone-specific mammalian transcription factors are prepared for delivery into the nucleus.
- protein cargos comprise osteogenic proteins which are delivered by the TAT-peptide tag capable of nuclear localization.
- this invention is directed to cell expression systems and methods of use thereof to meet the demands of proteomics for large scale production of LMP proteins.
- a method is developed to remedy the main drawback of the expression of heterologous proteins in non-mammalian hosts (e.g. bacteria, yeast, baculovirus).
- Inventors are thus the first to introduce a method for purifying and manufacturing LMP-1 protein by identifying LMP-1 protein internal sequencing and assessing post-translational glycosylation.
- heterologous proteins in non-mammalian hosts e.g. bacteria, yeast, baculovirus
- High-level mammalian recombinant protein production mostly relies on the establishment of stably expressing cell lines. Such procedures are not only labor-intensive and time consuming, but also precludes the expression of proteins whose biological activities interfere with cell growth.
- the inventors show that LMP-1 protein is expressed upon plasmid-mediated transformation of mammalian cells by purifying and characterizing the identity of the protein.
- the inventors have purified the recombinant proteins to a suitable level of homogeneity using a novel purification and detection methods with following features: (1) size fractionation of proteins prior to metal affinity chromatography to improve efficiency of affinity resin and (2) identification of tryptic fragments of purified protein.
- inventors determined whether the expressed protein undergoes any post-translational modification. According to this aspect of the invention inventors assess the presence of carbohydrate on LMP-1 polypeptide in any suitable cell expression system which includes prokaryotic (e.g bacteria, blue green algae) and non-mammalian eukaryotic cells (e.g. insect cells, plant cells) as well as mammalian cells (e.g. A-549 cells). The inventions have further characterized the structural and functional role of the carbohydrate moiety in LMP-1 purified in normal human cells.
- prokaryotic e.g bacteria, blue green algae
- non-mammalian eukaryotic cells e.g. insect cells, plant cells
- mammalian cells e.g. A-549 cells
- A549 cells derived from a human lung adenocarcinoma, are not fully representative of normal human respiratory epithelium but have been a quick and useful in vitro model for protein expression studies. Allen and White, Am. J. Physiol., 274 (Lung Cell. Mol. Physiol. 18): L159-L164, (1998). Kazzaz et al, J. Biol. Chem., 271:15182-15186 (1996). Wong et al. J. Clin. Invest., 99: 2423-2428 (1997).
- the A-549 cell system has all the eukaryotic protein processing capabilities.
- A-549 cells can fold, modify, traffic and assemble newly synthesized polypeptides to produce highly authentic, soluble end products.
- the present invention provides that a full length LMP-1 is indeed expressed in A549 cells and milligram quantities of protein can be obtained from mammalian cell cultures.
- the inventors were able to determine that the protein did not contain carbohydrate as chemical analysis showed little or no N-acetyl glucosamine or N-acetyl galactosamine.
- prokaryotic cell systems e.g. bacteria
- non-mammalian eukaryotic cells e.g. insect and plant cells
- compositions of matter comprising LIM mineralization protein that are substantially free of carbohydrate moieties and are manufactured in accord to the instantly described method.
- Such compositions can further contain physiologically acceptable carrier system for in vivo administration.
- enzyme assays, protein purification, and other conventional biochemical methods are employed.
- DNA and RNA are analyzed by Southern blotting and Northern blotting techniques, respectively.
- the samples analyzed are size fractionated by gel electrophoresis.
- the DNA or RNA in the gels are then transferred to nitrocellulose or nylon membranes.
- the blots which are replicas of sample patterns in the gels, were then hybridized with probes.
- the probes are radio-labeled, preferably with 32 P, although one could label the probes with other signal-generating molecules known to those in the art. Specific bands of interest can then be visualized by detection systems, such as autoradiography.
- Rat calvarial cells also known as rat osteoblasts (“ROB”)
- ROB rat osteoblasts
- Primary cultures were grown to confluence (7 days), trypsinized, and passed into 6-well plates (1 ⁇ 10 5 cells/35 mm well) as first subculture cells.
- the subculture cells which were confluent at day 0, were grown for an additional 7 days. Beginning on day 0, media were changed and treatments (Trm and/or BMPs) were applied, under a laminar flow hood, every 3 or 4 days.
- the standard culture protocol was as follows: days 1-7, MEM, 10% FBS, 50 ⁇ g/ml ascorbic acid, ⁇ stimulus; days 8-14, BGJb medium, 10% FBS, 5 mM ⁇ GlyP (as a source of inorganic phosphate to permit mineralization). Endpoint analysis of bone nodule formation and osteocalcin secretion was performed at day 14.
- the dose of BMP was chosen as 50 ng/ml based on pilot experiments in this system that demonstrated a mid-range effect on the dose-response curve for all BMPs studied.
- oligonucleotide concentration 22 ⁇ g was incubated in MEM for 45 minutes at room temperature. Following that incubation, either more MEM or pre-incubated lipofectamine/MEM (7% v/v; incubated 45 minutes at room temperature) was added to achieve an oligonucleotide concentration of 0.2 ⁇ M. The resulting mixture was incubated for 15 minutes at room temperature. Oligonucleotide mixtures were then mixed with the appropriate medium, that is, MEM/Ascorbate/ ⁇ Trm, to achieve a final oligonucleotide concentration of 0.1 ⁇ M.
- LMP-1 antisense oligonucleotide inhibited mineralized nodule formation and osteocalcin secretion in a dose-dependent manner, similar to the effect of BMP-6 oligonucleotide.
- the LMP-1 antisense block in osteoblast differentiation could not be rescued by addition of exogenous BMP-6, while the BMP-6 antisense oligonucleotide inhibition was reversed with addition of BMP-6.
- This experiment further confirmed the upstream position of LMP-1 relative to BMP-6 in the osteoblast differentiation pathway.
- LMP-1 antisense oligonucleotide also inhibited spontaneous osteoblast differentiation in primary rat osteoblast cultures.
- Tubes containing 200 gl of assay buffer (0.02 M sodium phosphate, 1 mM EDTA, 0.001% thimerosal, 0.025% BSA) received media taken from cell cultures or osteocalcin standards (0-12,000 fmole) at 100 gl/tube in assay buffer.
- the Pab (1:40,000; 100 ⁇ l) was then added, followed by the iodinated peptide (12,000 cpm; 100 ⁇ l). Samples tested for non-specific binding were prepared similarly but contained no antibody.
- Bound and free PAbs were separated by the addition of 700 ⁇ l goat antirabbit IgG, followed by incubation for 18 hours at 4° C. After samples were centrifuged at 1200 rpm for 45 minutes, the supernatants were decanted and the precipitates counted in a gamma counter. Osteocalcin values were reported in fmole/100 ⁇ l, which was then converted to pmole/ml medium (3-day production) by dividing those values by 100. Values were expressed as the mean ⁇ S.E.M. of triplicate determinations for 5-6 wells for each condition. Each experiment was confirmed at least two times using cells from different calvarial preparations.
- RNA from duplicate wells of ROBs was harvested using 4M guanidine isothiocyanate (GIT) solution to yield statistical triplicates. Briefly, culture supernatant was aspirated from the wells, which were then overlayed with 0.6 ml of GIT solution per duplicate well harvest. After adding the GIT solution, the plates were swirled for 5-10 seconds (being as consistent as possible). Samples were saved at ⁇ 70° C. for up to 7 days before further processing.
- GIT guanidine isothiocyanate
- RNA concentrations were calculated from optical densities that were determined with a spectrophotometer.
- Heated total RNA (5 ⁇ g in 10.5 ⁇ l total volume DEPC-H 2 O at 65° C. for 5 minutes) was added to tubes containing 4 ⁇ l 5 ⁇ MMLV-RT buffer, 2 ⁇ l dNTPs, 2 ⁇ l dT17 primer (10 pmol/ml), 0.5 ⁇ l RNAsin (40 U/ml) and 1 ⁇ l MMLV-RT (200 units/ ⁇ l).
- the samples were incubated at 37° C. for 1 hour, then at 95° C. for 5 minutes to inactivate the MMLV-RT.
- the samples were diluted by addition of 80 ⁇ l of water.
- Reverse-transcribed samples (5 ⁇ ) were subjected to polymerase-chain reaction using standard methodologies (50 ⁇ l total volume). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer, 25 mM MgCl 2 , dNTPs, forward and reverse primers for glyceraldehyde 3-phosphate dehydrogenase (GAP, a housekeeping gene) and/or BMP-6, 32 P-dCTP, and Taq polymerase. Unless otherwise noted, primers were standardized to run consistently at 22 cycles (94° C., 30′′; 58° C., 30′′; 72° C., 20′′).
- GAP glyceraldehyde 3-phosphate dehydrogenase
- RT-PCR products received 5 ⁇ l/tube loading dye, were mixed, heated at 65° C. for 10 min and centrifuged. Ten ⁇ l of each reaction was subjected to PAGE (12% polyacrylamide:bis; 15 V/well; constant current) under standard conditions. Gels were then incubated in gel preserving buffer (10% v/v glycerol, 7% v/v acetic acid, 40% v/v methanol, 43% deionized water) for 30 minutes, dried (80° C.) in vacuo for 1-2 hours and developed with an electronically-enhanced phosphoresence imaging system for 6-24 hours. Visualized bands were analyzed. Counts per band were plotted graphically.
- Radio-labeled PCR products were fractionated by gel electrophoresis on a DNA sequencing gel. After electrophoresis, the resulting gels were dried in vacuo and autoradiographs were exposed overnight. Bands representing differentially-expressed cDNAs were excised from the gel and reamplified by PCR using the method of Conner. et al., Proc. Natl. Acad. Sci. USA, 88, 278 (1983). The products of PCR reamplification were cloned into the vector PCR-11 (TA cloning kit; InVitrogen, Carlsbad, Calif.).
- a UMR 106 library (2.5 ⁇ 1010 pfu/ml) was plated at 5 ⁇ 104 pfu/ml onto agar plates (LB bottom agar) and the plates were incubated overnight at 37° C. Filter membranes were overlaid onto plates for two minutes. Once removed, the filters were denatured, rinsed, dried and UV cross-linked. The filters were then incubated in pre-hybridization buffer (2 ⁇ PIPES [pH 6.5], 5% formamide, 1% SDS and 100 ⁇ g/ml denatured salmon sperm DNA) for 2 h at 42° C.
- pre-hybridization buffer (2 ⁇ PIPES [pH 6.5], 5% formamide, 1% SDS and 100 ⁇ g/ml denatured salmon sperm DNA
- cDNA inserts were sequenced by standard methods. Ausubel, et al., Current Protocols in Molecular Biology, Wiley Interscience (1988). Briefly, appropriate concentrations of termination mixture, template and reaction mixture were subjected to an appropriate cycling protocol (95° C., 30 sec; 68° C., 30 sec; 72° C., 60 sec; x25). Stop mixture was added to terminate the sequencing reactions. After heating at 92° C. for 3 minutes, the samples were loaded onto a denaturing 6% polyacrylamide sequencing gel (29:1 acrylamide:bisacrylamide). Samples were electrophoresed for about 4 hours at 60 volts, constant current. After electrophoresis, the gels were dried in vacuo and autoradiographed.
- the autoradiographs were analyzed manually.
- the resulting sequences were screened against the databases maintained by the National Center for Biotechnology Information (NIH, Bethesda, Md.; hftp://www.ncbi.nlm.nih.gov-/) using the BLASTN program set with default parameters. Based on the sequence data, new sequencing primers were prepared and the process was repeated until the entire gene had been sequenced. All sequences were confirmed a minimum of three times in both orientations.
- Nucleotide and amino acid sequences were also analyzed using the PCGENE software package (version 16.0). Percent homology values for nucleotide sequences were calculated by the program NALIGN, using the following parameters: weight of non-matching nucleotides, 10; weight of non-matching gaps, 10; maximum number of nucleotides considered, 50; and minimum number of nucleotides considered, 50.
- percent homology values were calculated using PALIGN. A value of 10 was selected for both the open gap cost and the unit gap cost.
- the differential display PCR amplification products described in Example 9 contained a major band of approximately 260 base pairs. This sequence was used to screen a rat osteosarcoma (UMR 106) cDNA library. Positive clones were subjected to nested primer analysis to obtain the primer sequences necessary for amplifying the full length cDNA. (SEQ. ID NOs: 11, 12, 29, 30 and 31). One of those positive clones selected for further study was designated clone 10-4.
- Clone 10-4 (1696 base pairs; SEQ ID NO: 2) contains an open reading frame of 1371 base pairs encoding a protein having 457 amino acids (SEQ. ID NO: 1).
- the termination codon, TGA occurs at nucleotides 1444-1446.
- RLMP also designated 10-4
- RLMP has 78.5% amino acid homology to the human enigma protein (see U.S. Pat. No. 5,504,192), but only 24.5% and 22.7% amino acid homology to its closest rat homologs, CLP-36 and RIT-18, respectively.
- RNA from ROBs prepared according to Examples 1 and 2 was size fractionated by formaldehyde gel electrophoresis in 1% agarose flatbed gels and osmotically transblotted to nylon membranes. The blot was probed with a 600 base pair EcoRI fragment of full-length 10-4 cDNA labeled with 32 P-dCTP by random priming.
- HeLa cells were transfected with pCMV2/RLMP. Protein was harvested from the transfected cells according to the method of Hair, et al., Leukemia Research, 20, 1 (1996). Western Blot Analysis of native RLMP was performed as described by Towbin, et al., Proc. Natl. Acad. Sci. USA, 76:4350 (1979).
- forward and reverse PCR primers (SEQ. ID NOS: 15 and 16) were synthesized and a unique 223 base-pair sequence was PCR amplified from the rat LMP-1 cDNA.
- a similar PCR product was isolated from human MG63 osteosarcoma cell cDNA with the same PCR primers.
- the 0.6 ml samples received 60 ⁇ l 2.0 M sodium acetate (pH 4.0), 550 ⁇ l water saturated phenol and 150 ⁇ l chloroform:isoamyl alcohol (49:1). After addition of those reagents, the samples were vortexed, centrifuged (10000 ⁇ g; 20 min; 4 C) and the aqueous phase transferred to a fresh tube. Isopropanol (600, ⁇ l) was added and the RNA was precipitated overnight at ⁇ 20° C. The samples were centrifuged (10000 ⁇ g; 20 minutes) and the supernatant was aspirated gently.
- the pellets were resuspended in 400 ⁇ l of DEPC-treated water, extracted once with phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and precipitated overnight at ⁇ 20° C. in 40 ⁇ l sodium acetate (3.0 M; pH 5.2) and 1.0 ml absolute ethanol. After precipitation, the samples were centrifuged (10000 ⁇ g; 20 min), washed once with 70% ethanol, air dried for 5-10 minutes and resuspended in 20 ⁇ l of DEPC-treated water. RNA concentrations were derived from optical densities.
- RNA 5 ⁇ g in 10.5 ⁇ l total volume in DEPC-H 2 O was heated at 65° C. for 5 minutes, and then added to tubes containing 4 ⁇ l 5 ⁇ MMLV-RT buffer, 2 ⁇ l dNTPS, 2 ⁇ l dT17 primer (10 ⁇ mol/ml), 0.5 ⁇ l RNA sin (40 U/ml) and 1 ⁇ l MMLV-RT (200 units/ ⁇ l). The reactions were incubated at 37° C. for 1 hour. Afterward, the MMLV-RT was inactivated by heating at 95° C. for 5 minutes. The samples were diluted by addition of 80 ⁇ l water.
- LMP-1 is expressed at different levels by several different tissues, including human heart muscle.
- a human heart cDNA library was therefore examined.
- the library was plated at 5 ⁇ 10 4 pfu/ml onto agar plates (LB bottom agar) and plates were grown overnight at 37° C. Filter membranes were overlaid onto the plates for two minutes. Afterward, the filters were denatured, rinsed, dried, UV cross-linked and incubated in pre-hybridization buffer (2 ⁇ PIPES [pH 6.5]; 5% formamide, 1% SDS, 100 g/ml denatured salmon sperm DNA) for 2 h at 42° C.
- pre-hybridization buffer 2 ⁇ PIPES [pH 6.5]; 5% formamide, 1% SDS, 100 g/ml denatured salmon sperm DNA
- a radio-labeled, LMP-unique, 223 base-pair probe ( 32 P, random primer labeling; SEQ ID NO: 6) was added and hybridized for 18 h at 42° C. Following hybridization, the membranes were washed once at room temperature (10 min, 1 ⁇ SSC, 0.1% SDS) and three times at 55° C. (15 min, 0.1 ⁇ SSC, 0.1% SDS). Double-positive plaque-purified heart library clones, identified by autoradiography, were rescued as lambda phagemids according to the manufacturers' protocols (Stratagene, La Jolla, Calif.).
- Clone 7 (Partial Human LMP-1 cDNA from a heart library; SEQ. ID NO: 8) contained a sequence that was more than 87% homologous to the rat LMP cDNA sequence in the translated region.
- Overlapping regions of the MG63 human osteosarcoma cell cDNA sequence and the human heart cDNA clone 7 sequence were used to align those two sequences and derive a complete human cDNA sequence of 1644 base-pairs.
- NALIGN a program in the PCGENE software package, was used to align the two sequences.
- the overlapping regions of the two sequences constituted approximately 360 base-pairs having complete homology except for a single nucleotide substitution at nucleotide 672 in the MG63 cDNA (SEQ. ID NO: 7) with clone 7 having an “A” instead of a “G” at the corresponding nucleotide 516 (SEQ. ID NO: 8).
- the two aligned sequences were joined using SEQIN, another subprogram of PCGENE, using the “G” substitution of the MG63 osteosarcoma cDNA clone.
- the resulting sequence is shown in SEQ. ID NO: 9.
- Alignment of the novel human-derived sequence with the rat LMP-1 cDNA was accomplished with NALIGN.
- the full-length human LMP-1 cDNA sequence (SEQ. ID NO: 9) is 87.3% homologous to the translated portion of rat LMP-1 cDNA sequence.
- the putative amino acid sequence of human LMP-1 was determined with the PCGENE subprogram TRANSL.
- the open reading frame in SEQ. ID NO: 9 encodes a protein comprising 457 amino acids (SEQ. ID NO: 10).
- the human LMP-1 amino acid sequence was found to be 94.1% homologous to the rat LMP-1 amino acid sequence.
- MG63 5′ cDNA was amplified by nested RT-PCR of MG63 total RNA using a 5′ rapid amplification of cDNA ends (5′ RACE) protocol.
- This method included first strand cDNA synthesis using a lock-docking oligo (dT) primer with two degenerate nucleotide positions at the 3′ end (Chenchik. et al., CLONTECHniques, X:5 (1995); Borson, et al., PC Methods Applic., 2, 144 (1993)).
- Second-strand synthesis is performed according to the method of Gubler, et al., Gene, 2, 263 (1983), with a cocktail of Escherichia coli DNA polymerase 1, RNase H, and E. coli DNA ligase.
- double-stranded cDNA was ligated to the fragment (5′-CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGT-3′) (SEQ. ID NO: 19).
- the adaptor-ligated cDNA was diluted to a concentration suitable for Marathon RACE reactions (1:50). Adaptor-ligated double-stranded cDNA was then ready to be specifically cloned.
- First-round PCR was performed with the adaptor-specific oligonucleotide, 5′-CCATCCTAATACGACTCACTATAGGGC-3′ (AP1) (SEQ. ID NO: 20) as sense primer and a Gene Specific Primer (GSP) from the unique region described in Example 16 (HLMPU).
- the second round of PCR was performed using a nested primers GSP1-HLMPU (antisense/reverse primer) (SEQ. ID NO: 23) and GSP2-HLMPUF (SEQ. ID NO: 24) (see Example 16; sense/forward primer).
- PCR was performed using a commercial kit (Advantage cDNA PCR core kit; CloneTech Laboratories Inc., Palo Alto, Calif.) that utilizes an antibody-mediated, but otherwise standard, hot-start protocol.
- PCR conditions for MG63 cDNA included an initial hot-start denaturation (94° C., 60 sec) followed by: 94° C., 30 sec; 60° C., 30 sec; 68° C., 4 min; 30 cycles.
- the firstround PCR product was approximately 750 base-pairs in length whereas the nested PCR product was approximately 230 base-pairs.
- the first-round PCR product was cloned into linearized pCR 2.1 vector (3.9 Kb). The inserts were sequenced in both directions using M13 Forward and Reverse primers (SEQ. ID NO: 11; SEQ. ID NO: 12).
- Overlapping MG63 human osteosarcoma cell cDNA 5′-UTR sequence (SEQ. ID NO: 21), MG63 717 base-pair sequence (Example 17; SEQ. ID NO: 8) and human heart cDNA clone 7 sequence (Example 18) were aligned to derive a novel human cDNA sequence of 1704 base-pairs (SEQ. ID NO: 22).
- the alignment was accomplished with NALIGN, (both PCGENE and Omiga 1.0; Intelligenetics).
- Over-lapping sequences constituted nearly the entire 717 base-pair region (Example 17) with 100% homology. Joining of the aligned sequences was accomplished with SEQIN.
- pHIS-5ATG LMP-1s expression vector was carried out with the sequences described in Examples 17 and 18.
- the 717 base-pair clone (Example 17; SEQ. ID NO: 7) was digested with ClaI and EcoRV. A small fragment ( ⁇ 250 base-pairs) was gel purified.
- Clone 7 (Example 18; SEQ. ID NO: 8) was digested with ClaI and XbaI and a 1400 base-pair fragment was gel purified.
- the isolated 250 base-pair and 1400 base-pair restriction fragments were ligated to form a fragment of ⁇ 1650 base-pairs.
- the pHis-ATG vector (InVitrogen, Carlsbad, Calif.) was digested with EcoRV and XbaI. The vector was recovered and the 650 base-pair restriction fragment was then ligated into the linearized pHis-ATG. The ligated product was cloned and amplified.
- the pHis-ATG-LMP-1s Expression vector also designated pHIS-A with insert HLMP-1s, was purified by standard methods.
- Rat Calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with glucocorticoid (GC) as described in Example 1. A modification of the Superfect Reagent (Qiagen, Valencia, Calif.) transfection protocol was used to transfect 3 ⁇ g/well of each vector into secondary rat calvarial osteoblast cultures according to Example 25. Mineralized nodules were visualized by Von Kossa staining, as described in Example 3.
- the rat LMP cDNA in clone 10-4 was excised from the vector by double-digesting the clone with NotI and ApaI overnight at 37° C.
- Vector pCMV2 MCS InVitrogen, Carlsbad, Calif.
- Both the linear cDNA fragment from clone 10-4 and pCMV2 were gel purified, extracted and ligated with T4 ligase.
- the ligated DNA was gel purified, extracted and used to transform E. coli JM109 cells for amplification. Positive agar colonies were picked, digested with NotI and ApaI and the restriction digests were examined by gel electrophoresis. Stock cultures were prepared of positive clones.
- a reverse vector was prepared in analogous fashion except that the restriction enzymes used were XbaI and HindIII. Because these restriction enzymes were used, the LMP cDNA fragment from clone 10-4 was inserted into pRc/CMV2 in the reverse (that is, non-translatable) orientation.
- the recombinant vector produced is designated pCMV2/RLMP.
- pCMV10-4 60 nM final concentration is optimal [3 ⁇ g]; for this experiment a range of 0-600 nM/well [0-30 ⁇ g/well] final concentration is preferred) was resuspended in Minimal Eagle Media (MEM) to 450 ⁇ l final volume and vortexed for 10 seconds. Superfect was added (7.5 ⁇ l/ml final solution), the solution was vortexed for 10 seconds and then incubated at room temperature for 10 minutes. Following this incubation, MEM supplemented with 10% FBS (1 ml/well; 6 ml/plate) was added and mixed by pipetting.
- MEM Minimal Eagle Media
- the resulting solution was then promptly pipetted (1 ml/well) onto washed ROB cultures.
- the cultures were incubated for 2 hours at 37° C. in a humidified atmosphere containing 5% CO 2 . Afterward, the cells were gently washed once with sterile PBS and the appropriate normal incubation medium was added.
- results demonstrated significant bone nodule formation in all rat cell cultures which were induced with pCMV10-4.
- pCMV10-4 transfected cells produced 429 nodules/well.
- Positive control cultures, which were exposed to Trm, produced 460 nodules/well.
- negative controls, which received no treatment produced 1 nodule/well.
- no nodules were observed.
- marrow was aspirated from the hind limbs of 4-5 week old normal rats ( ⁇ /+; heterozygous for recessive athymic condition).
- the aspirated marrow cells were washed in alpha MEM, centrifuged, and RBCs were lysed by resuspending the pellet in 0.83% NH 4 Cl in 10 mM Tris (pH 7.4).
- the remaining marrow cells were washed 3 ⁇ with MEM and transfected for 2 hours with 9 ⁇ g of pCMV-LMP-1s (forward or reverse orientation) per 3 ⁇ 10 6 cells.
- the transfected cells were then washed 2 ⁇ with MEM and resuspended at a concentration of 3 ⁇ 10 7 cells/ml.
- the cell suspension (100 ⁇ l) was applied via sterile pipette to a sterile 2 ⁇ 5 mm type I bovine collagen disc (Sulzer Orthopaedics, Wheat Ridge, Colo.).
- the discs were surgically implanted subcutaneously on the skull, chest, abdomen or dorsal spine of 4-5 week old athymic rats (rnu/rnu).
- the animals were sacrificed at 3-4 weeks, at which time the discs or surgical areas were excised and fixed in 70% ethanol.
- the fixed specimens were analyzed by radiography and undecalcified histologic examination was performed on 5 ⁇ m thick sections stained with Goldner Trichrome. Experiments were also performed using devitalized (guanidine extracted) demineralized bone matrix (Osteotech, Shrewsbury, N.J.) in place of collagen discs.
- the restriction and modifying enzymes in examples 26-38 were purchased from Promega (Madison, Wis.) and the bacterial host strain, BL21 (DE3) was from Stratagene (La Jolla, Calif.).
- the TAT-vector was a generous gift from Steven F Dowdy (Howard Hughes Medical Institute, St. Louis, Mo.).
- the chelating affinity resin (Probond) was purchased from Invitrogen (San Diego, Calif.).
- the Sephacryl S-100 (HiPrep 16 ⁇ 60) and other chromatographic columns and AKTA FPLC system were from Amersham-Pharmacia Biotech (Piscataway, N.J.).
- Fluorescent tag, fluorescein isothiocyanate (FITC) was from Pierce (Rockford, Ill.). All other chemicals and reagents, unless otherwise noted, were from Sigma (St. Louis, Mo.) (analytical grade).
- Escherichia coli BL21 (DE3) host cells were maintained on LB agar plates and grown at 37° C. in the presence of ampicillin at 100 mg/mL. The strains were stored in LB medium containing 15% glycerol at ⁇ 80° C. All cloning methods including PCR, restriction digestion, ligations, E. coli transformation and plasmid DNA preparation were performed according to standard protocols.
- PCR Polymerase chain reaction
- forward primer 5′-CCATGGATTCCTTCAAAGTAGTGC-3′
- reverse primer 5′-CAGGGCGGGCGGCTGGTAG-3′
- the PCR product was cloned into the PCRII-TOPO vector (Invitrogen) and the sequence was verified by sequencing both the complimentary strands.
- the desired clone was digested with Ncol and Clal.
- the insert was gel-purified (Fragment A).
- the pcDNA3.1/hLMP-1 clone was digested with Clal and EcoRI and the inserts were gel purified (Fragment B).
- PTAT-HA vector was digested with Ncol and EcoRI and the vector was gel purified (Fragment C).
- the fragments, A, B, and C were ligated to obtain the desired construct ( FIG. 18 ).
- BL21 (DE3) competent cells were transformed with plasmid by standard methods (Novagen) and the correct clones were selected by restriction analysis followed by DNA sequencing.
- PCR product was then cloned into PCR 2.1 vector (invitrogen) and the insert sequence was verified by sequencing.
- the desired clone was digested with NcoI and XhoI, and the insert was recovered from gel (Fragment A).
- the PTAT-HA vector was digested with NcoI and XhoI, and the vector was recovered (Fragment B). Ligation of fragment A and B yielded the desired construct.
- BL21 (DE3) competent cells were transformed with plasmid by standard methods (Novagen) and the correct clones were selected by restriction analysis followed by DNA sequencing.
- TAT-HA vector was digested with XhoI, followed by treatment with T4 DNA Polymerase to create a blunt end. The vector was then digested again with NcoI to recover the fragment for ligations (Fragment C). Ligation of fragments A, B and C yielded the desired construct.
- BL21 (DE3) competent cells were transformed with plasmid by standard methods (Novagen) and the correct clones were selected by restriction analysis followed by DNA sequencing.
- oligonucleotide primers SEQ ID NOS 81-82
- Osx-forward primer 5′-catggcgtcctctctgcttgaggaagaagctcactatggctccagtcccctggccatgctgact gcagccg-3′
- Osx-reverse primer 5′-gatccggctgcagtcagcatggccaggggactggagccatagtgagcttcttcctcaagcagag aggacgc-3′
- mouse Osterix cDNA which was absent in the pcDNA5UTFlag Osx clone
- the pcDNA5UTFlagOsx clone was digested with BamHI and HindIII, and the insert was recovered (Fragment B).
- the TAT-HA vector was digested with XhoI, followed by treatment with T4 DNA Polymerase to create a blunt end.
- IPTG Isopentenyl thiogalactoside
- Size-exclusion chromatography of the proteins was carried out on a Sephacryl S-100 column connected to the AKTA FPLC System (Amersham Biosciences, Piscataway, N.J.). The column was pre-calibrated with known low- and high-molecular weight protein markers from gel filtration calibration kits (Amersham Biosciences, Piscataway, N.J.) in 50 mM sodium phosphate, 150 mM NaCl, pH 7.0 buffer.
- the marker proteins were thyroglobulin ⁇ molecular weight (Mw) 669 kDa ⁇ , ferritin (Mw 440 kDa), catalase (Mw 232 kDa), aldolase (Mw 158 kDa), albumin (Mw 67 kDa), ovalbumin (Mw 43 kDa), chymotrypsinogen A (Mw 25 kDa), and ribonuclease A (Mw 13.7 kDa).
- Bacterial pellets were suspended in 100 ml of ice-cold lysis buffer (20 mM phosphate buffer, pH 7.0 containing 50 mM Tris-HCl, pH 7.5 and 5 M NaCl).
- the uniform cell suspension was sonicated (Sonicator, Model W-385, Heat systems-Ultrasonics, Inc.) 4 ⁇ 15 sec bursts at minimum power-out put settings in ice with 2 min interval between each burst.
- the lysate was centrifuged at 10,000 g (Beckman #17 Rotor, 13,000 RPM) at 4° C.
- the fractions from molecular exclusion chromatography, identified by western blots were pooled, dialyzed against 20 mM phosphate buffer, pH 7.5 containing Urea (8 M), NaCl (50 mM) and imidazole (20 mM) for metal-ion affinity selection.
- the dialyzed protein sample was applied to a 10 ml-Ni ++ -nitrilotriacetic acid (NTA) agarose affinity resin (Probond, Invitrogen) previously equilibrated with 4 ⁇ 10 ml of buffer.
- NTA ml-Ni ++ -nitrilotriacetic acid
- Non-specific and low-affinity bound proteins were removed from the column with 3 ⁇ 10 ml of 20 mM phosphate buffer, pH 6.0 containing urea (8 M), NaCl (50 mM) and imidazole (20 mM). Affinity-bound proteins were eluted using 3 ⁇ 10 ml 20 mM phosphate buffer, pH 4.0 containing urea (8 M), NaCl (50 mM). The eluates were combined and concentrated using a centriprep YM 50 ultrafiltration device by spinning at 2000 ⁇ g. Flow-thru, washes, and eluate were concentrated using a centriprep and analyzed by SDSPAGE and western blotting using rabbit polyclonal antibodies specific to the hemagglutinin fusion-tag.
- Fractions containing desired proteins were pooled (based on western blot) and then concentrated, de-salted and buffer-exchanged using the centriprep devices (Amicon). Protein samples were stored at ⁇ 70° C. Fractions containing unwanted contaminant proteins were discarded. Protein quantitation was performed with protein assay reagent (BioRad) using BSA as the standard. The yield of recombinant protein was routinely about 0.5 to 1 mg of pure protein from every 2-liter culture.
- FITC fluorescein isothiocyanate
- the cells were trypsinized and washed one time with PBS and resuspended in 500 ul of PBS. The percentage of the total cells labeled with FITC-specific fluorescence was determined by Flow Cytometry (Becton Dickinson, Franklin, N.J.).
- MSCs at passage 2 were purchased from Cambrex Bio Sciences. Cells were grown at 37° C. in 5% CO 2 in MSC basal medium supplemented with Singlequots (Cambrex Bio Sciences), split at confluence, and plated at 3 ⁇ 10 4 cells/well in 6-well dishes at passage 4 in these studies. The next day treatments were applied in the presence of 50 uM L-Ascorbic Acid 2-Phosphate and 5 mM ⁇ -glycerol phosphate (Sigma-Aldrich).
- Cell pellets were suspended in buffer A (20 mM HEPES, pH 7.9, 10 mM KCl, 1 mM EGTA, 1 mM EDTA, 0.2% Nonidet P-40, 10% Glycerol, 1 mM PMSF and 1 ug/ml protease inhibitor mix (Sigma)), incubated on ice for 10 min, and centrifuged. Supernatants (cytoplasmic fraction) were collected. Nuclear pellets were suspended in high salt buffer B (buffer A plus 600 mM KCl, 20% glycerol), incubated on ice for 30 min and centrifuged. Supernatants were collected as the nuclear fraction. Samples were aliquoted, the protein concentration determined, and stored at ⁇ 70° C. until further use.
- buffer A 20 mM HEPES, pH 7.9, 10 mM KCl, 1 mM EGTA, 1 mM EDTA, 0.2% Nonidet P-40, 10% Glycerol, 1 mM PMSF
- SDS-PAGE was performed using 10% gels and transferred to nitrocellulose membrane.
- the membrane was blocked with milk protein, incubated with specific antibody, washed with Tris Buffered Saline containing 0.1% Tween 20 (TBST), incubated with anti-rabbit goat IgG-linked to horseradish peroxidase (NEN), and again washed with TBST.
- Chemi-luminescent substrates were applied to the membrane and the signal was detected by exposing the membrane to X-ray film for 30 sec.
- Nuclear proteins were prepared from mesenchymal stem cells as described above. TAT-LMP-1 (50 ug) was incubated for 1 hr at 4° C. with the nuclear proteins (500 ug) with gentle mixing in PBS containing 0.1 M NaCl and 50 mM imidazole. Ni ++ -NTA-affinity beads (Probond, Invitrogen) (a 50 ul of 1:1 slurry in PBS) were added and the mixture was incubated for another 30 min. Non-specific proteins were removed by washing three times with 500 ul of PBS containing 0.1 M NaCl and 50 mM imidazole.
- Affinity bound proteins were eluted with 250 mM imidazole in PBS followed by a final elution with 50 mM EDTA removing the Ni ++ from the resin.
- the imidazole and EDTA eluates were analyzed by SDS-PAGE, staining of blots with colloidal gold stain to visualize total proteins, and western blots using HA-specific antibodies to detect input TAT protein.
- the cloned cDNAs were transferred from pcDNA 3.1 vectors to the TAT-HA vector.
- the desired restriction sites were introduced by oligonucleotides and/or PCR followed by ligation in-frame into the linearized TAT-vector.
- a general cloning strategy followed for the construction of LMP-1 into TAT-HA vector is shown in FIG. 18 .
- Insertion of the desired cDNA in the correct coding frame in to the expression vector was confirmed by restriction digestions and sequencing of sense and anti-sense strands of DNA.
- the positive clones were selected based on the small scale induction of protein and the detection of correct molecular size bands in western blots performed with the HA tag-specific antibody.
- the SDS-PAGE gels and western blots of purified LMP-1, Dlx5, Runx2 and Osterix showed predominantly a single band.
- the molecular size for each protein corresponded to the expected size of the protein plus the fusion-tags (55, 37, 49, 53 kDa, respectively) ( FIG. 26 ).
- the hexahistidine-TAT-HA tags contribute 5 kDa to the actual molecular weight of each protein but it may have different effects on the apparent size/shape of each fusion protein.
- the charged tag extends out and increases the apparent molecular size of the proteins. Premature termination of polypeptides was not observed to any significant degree for each of the expressed recombinant proteins as we did not co-purify significant amounts of truncated forms.
- the labeled proteins were all effectively separated from free FITC by gel filtration, resulting in little or no background of free label.
- Rabbit buffy coat cells were incubated with various doses of TAT-fusion protein (1-25 nM) for different durations. The primary reasons for using buffy coat cells are that they are relatively easy to separate and high number of cells can be readily obtained from the blood of human volunteers.
- FIG. 24 shows that TAT-LMP-1-FITC entry into rabbit buffy coat cells is both time and dose dependent.
- the FITC-labeled Runx2, Osx and Dlx5 also showed time and dose dependent entry into cells (data not shown).
- the limitation of the flow cytometry method is that it does not distinguish intracellular TAT-protein from TAT-protein adsorbed to the cell surface.
- the inventors focused on the cellular entry and the intracellular protein interactions of TAT-LMP-1.
- Mesenchymal stem cells were incubated with various concentrations of TAT-LMP-1 (0.3-300 nM). The cells were harvested after 4 hr and the cytoplasmic and nuclear extracts were prepared as mentioned in methods. Equal aliquots (as determined by protein amounts) of these preparations were subjected to SDS-PAGE. The resolved proteins were blotted onto nitrocellulose and probed with HA-antibody in western blots.
- TAT-LMP-1 a dose dependent increase of TAT-LMP-1 at the expected size (55 kDa) is observed in both cytoplasmic and nuclear fractions when compared to untreated controls ( FIG. 25 ).
- the higher intensity of the signal observed in cytoplasmic fractions may be due to a higher concentration of TAT-protein in the cytoplasm.
- the control lanes showed little or no signal confirming that the observed signal is specific to exogenously added TAT-protein.
- exogenously added TAT-protein is relatively resistant to cellular proteases and is easily detectable with HA-antibodies in both cytoplasmic and nuclear compartments.
- eukaryotic cells One defining feature of eukaryotic cells is their spatial and functional division into the nucleus and the cytoplasm by the nuclear envelope.
- Each of the nuclear osteogenic factors, LMP-1, Dlx5, Runx2 or Osterix, has been postulated to function in a signaling network involving a large number of interacting proteins.
- the aim of this study was to optimize methods to perform the controlled delivery of these signaling molecules either to promote or disrupt protein interaction events in nuclear compartment resulting in the control of cellular differentiation.
- TAT-LMP-1 as molecular bait to detect any MSC nuclear proteins with which it interacts.
- the inventors also observed a large number of proteins binding TAT-LMP-1 with high affinity ( FIG. 26 ). Proteins of molecular size 80 to 90 kDa showed predominant colloidal gold staining suggesting that proteins in this zone are the most likely binding candidates for LMP-1 interaction. Based on these results one of ordinary skill in the art may slightly alter the currently disclosed experimental approach and performed photo-induced biotin transfer experiments to identify target nuclear molecules that interact with TAT-LMP-1.
- the 717 base-pair clone (Example 17) was digested with ClaI and EcoRV (New England Biologicals, city, MA). A small fragment ( ⁇ 250 base pairs) was gel purified. Clone No. 7 (Example 18) was digested with ClaI and XbaI. A 1400 base-pair fragment was gel purified from that digest. The isolated 250 base-pair and 1400 base-pair cDNA fragments were ligated by standard methods to form a fragment of ⁇ 1650 bp. The pHis-A vector (InVitrogen) was digested with EcoRV and XbaI. The linearized vector was recovered and ligated to the chimeric 1650 base-pair cDNA fragment.
- the ligated product was cloned and amplified by standard methods, and the pHis-A-5′ ATG LMP-1s expression vector, also denominated as the vector pHis-A with insert HLMP-1s, was deposited at the ATCC as previously described.
- Rat calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with glucocorticoid (GC) according to Example 1. The cultures were transfected with 3 ⁇ g of recombinant pHis-A vector DNA/well as described in Example 25. Mineralized nodules were visualized by Von Kossa staining according to Example 3.
- GC glucocorticoid
- Conditioned media harvested from cells transfected with RLMP-1 or HLMP-1s at day 4 was approximately as effective in inducing nodule formation as direct overexpression of RLMP-1 in transfected cells.
- Conditioned media from cells transfected with RLMP-1 or HLMP-1 in the reverse orientation had no apparent effect on nodule formation.
- Partial purification of the osteoinductive soluble factor was accomplished by standard 25% and 100% ammonium sulfate cuts followed by DE-52 anion exchange batch chromatography (100 mM or 500 mM NACl). All activity was observed in the high ammonium sulfate, high NaCl fractions. Such localization is consistent with the possibility of a single factor being responsible for conditioning the medium.
- the restriction and modifying enzymes used in examples 41-50 were purchased from Promega (Madison, Wis.).
- the chelating affinity resin (Probond) and the pHisA vector were purchased from Invitrogen (San Diego, Calif.).
- the Sephacryl S-300 (HiPrep 16 ⁇ 60), other chromatographic columns and the AKTA FPLC system were from Amersham-Pharmacia Biotech (Piscataway, N.J.). All other chemicals and reagents, unless otherwise noted, were from Sigma (St. Louis, Mo.) (analytical grade).
- Escherichia coli DH5alpha cells was the host for propagation of plasmids. DH5alpha cells were maintained on LB agar plates and grown at 37° C. in the presence of ampicillin (100 mg/mL). The strains were maintained in LB medium including 15% glycerol at ⁇ 80° C.
- A-549 cells were grown in F12K medium (Gibco, Grand Island, N.Y.) in a humidified 10% CO 2 incubator at 37° C. supplemented with 10% non-heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, Ga.).
- the 1623-bp cDNA for LMP-1 was cloned into the mammalian expression vector pHisA/pcDNA 3.1 following standard methods.
- the over-expressed LMP-1 contains a 6His-fusion tag at the N-terminus to facilitate affinity purification.
- the plasmid construct (10 ug/100 mm plate) was incubated for 2 h with A-549 cells using 60 ul of Superfect (Qiagen, Valencia, Calif.) per plate in 10 ml medium and the cultures were incubated for 2 days. Cells from 50 ⁇ 100 mm plates were harvested with phosphate-buffered saline by scraping with rubber policemen.
- the A-549 cell pellets were resuspended in low salt buffer (20 mM HEPES, pH 7.9, 10 mM KCl, 1 mM EGTA, 1 mM EDTA, 0.2% Nonidet P-40, 10% Glycerol, 1 mM phenylmethylsulfonyl fluoride and 1 ug/ml of protease inhibitor mix (Sigma), incubated on ice for 10 min, and centrifuged (8000 ⁇ g, 2 min, 4° C.). Supernatants (cytoplasmic fraction) were collected for further analysis.
- low salt buffer 20 mM HEPES, pH 7.9, 10 mM KCl, 1 mM EGTA, 1 mM EDTA, 0.2% Nonidet P-40, 10% Glycerol, 1 mM phenylmethylsulfonyl fluoride and 1 ug/ml of protease inhibitor mix (Sigma), incubated on ice for 10 min, and centrif
- the nuclear pellets were suspended in high salt buffer (low salt buffer with 600 mM KCl, 20% glycerol), incubated on ice for 30 min and centrifuged as before. Supernatants were collected as the nuclear fraction. Both cytoplasmic and nuclear fractions were alquoted and stored frozen at ⁇ 20° C. until further use.
- high salt buffer low salt buffer with 600 mM KCl, 20% glycerol
- Size-exclusion chromatography of the cellular proteins was carried out on a Sephacryl S-300 column connected to the AKTA FPLC System (Amersham Biosciences, Piscataway, N.J.). The column was pre-calibrated with known low- and high-molecular weight protein markers from gel filtration calibration kits (Amersham Biosciences, Piscataway, N.J.) in 50 mM sodium phosphate, 150 mM NaCl, pH 7.0 buffer.
- the marker proteins were thyroglobulin (molecular weight (Mw) 669 kDa), ferritin (Mw 440 kDa), catalase (Mw 232 kDa), aldolase (Mw 158 kDa), albumin (Mw 67 kDa), ovalbumin (Mw 43 kDa), chymotrypsinogen A (Mw 25 kDa), and ribonuclease A (Mw 13.7 kDa).
- the cell pellets were suspended in 100 ml of ice-cold lysis buffer (20 mM phosphate buffer, pH 7.0 containing 50 mM Tris-HCl, pH 7.5 and 5 M NaCl).
- the uniform cell suspension was centrifuged at 10,000 g (Beckman #17 Rotor, 13,000 RPM) at 4° C. and the supernatant was applied onto a Sephacryl S-300 column (HiPrep 16 ⁇ 60) using AKTA FPLC system with Unicorn 3.1 software (Amersham Pharmacia Biotech) at a flow rate of 1 ml/min. Fractions (4 ml) were collected immediately after the void volume (V 0 ) (35 ml).
- the proteins were applied onto Ni ++ -affinity column (5 ml resin) previously equilibrated with 4 ⁇ 5 ml of buffer.
- Non-specific and low-affinity proteins were washed off the column with 3 ⁇ 10 ml of 20 mM phosphate buffer, pH 6.0 containing urea (8 M), NaCl (50 mM) and imidazole (20 mM).
- Affinity-bound proteins were eluted using 3 ⁇ 10 ml washes with 20 mM phosphate buffer, pH 4.0 containing urea (8 M), NaCl (50 mM).
- the eluates were combined and concentrated by spinning at 2000 g using a centriprep YM 50 ultrafiltration device.
- Affinity eluted fractions were dialyzed against 20 mM Tris-HCl pH 7.5 (Buffer A) over night at 4° C. using a 10 kDa cut-off membrane for cation-exchange chromatography.
- Fractions (1 ml) were diluted 3-fold (5 ul of sample plus 10 ul of water to reduce the salt concentration) and analysed by SDS-PAGE followed by western blotting using specific primary antibodies and horse radish peroxidase labeled secondary antibodies.
- Fractions containing recombinant protein (based on western blot) were pooled, concentrated and de-salted using the centriprep devices (Amicon). Protein samples were stored at ⁇ 70° C., until further use, at this stage. Fractions containing unwanted contaminant proteins were discarded.
- Protein quantitation was performed with protein assay reagent (BioRad) using BSA as standard. Due to poor dye binding by LMP-1 (abundance of Pro, Gly, Ser and Cys residues), more accurate protein amounts were determined from the overall yield of peptides from trypsin digestion and mass spectrometric analysis. The collective yield of the recombinant LMP-1 protein was about 75-100 ug from 120 ⁇ 100 mm cell culture plates from three batches of 40 plates each).
- SDS-PAGE is performed using 10% gels according to Laemmli et al and the electrophoresed proteins were transferred from the gel to a nitrocellulose membrane at 50 volts (constant) for 2 hrs.
- the membranes were blocked with 25 ml 5% milk protein for 1 hour at room temperature.
- Membranes were incubated with LMP-1 antibody at a dilution of 1:5000 (5 ul/25 ml of Tris-buffered saline containing 0.1% Tween 20) gently shaking for 2 hours at room temperature. Membranes were washed with 25 ml of TBST for 5 min. The washes were repeated two times.
- Membranes were incubated with anti-rabbit goat IgG-linked to horse radish peroxidase (NEF 812, NEN, Boston) diluted 1:5000 in 25 ml TBST for 1 hour. Membranes were washed three times, 5-min each with 25 ml of TBST as before. Chemiluminescent substrate reagent A (2 ml) and reagent B (2 ml) were mixed and applied to the membrane. The damp-dried membrane was exposed to X-ray film for signal detection.
- the dried sample was derivatized with ABEE in the presence of borane-pyridine complex at 80° C. After 1 hr, the reaction mixture was cooled to room temperature. Distilled water (200 ⁇ l) and an equal volume of chloroform were added to the reaction mixture. After vigorous vortexing, the sample was centrifuged (6000 ⁇ g, 1 min). The upper aqueous layer was analyzed by reversed-phase HPLC under the following conditions: column, Wakosil-II 5C18HG (4.6 ⁇ 150 mm); solvent, A 0.02% TFA/CH 3 CN (90/10), B 0.02% TFA/CH 3 CN (50/50); program, 0-45 min (B conc. 0%), 45-55 min (B conc.
- the monosaccharide and amino monosaccharide standards used were N-acetyl glucosamine, N-acetyl galactosamine, glucose, galactose, mannose, xylose, and L-fucose.
- SDS-PAGE gels were stained with 0.25% Coomassie brilliant blue in 45% methanol and 10% acetic acid and destained in 35% methanol with 10% acetic acid.
- the protein bands corresponding to a positive signal on western blots were sliced from the gel, soaked in 50% methanol with 0.1 M NH 4 HCO 3 and mixed vigorously overnight. The wash solution was changed once and incubated for 2 hr. The clear gel bands were then soaked in water for 2 hr followed by soaking in 25 mM NH 4 HCO 3 for 5 min. The wet gel pieces were smashed into fine pieces in Eppendorf tubes (0.5 ml).
- Peptide samples were purified and concentrated using a Zip Tip (Millipore) which has C 18 resin fixed at its end. The resin was rinsed according to the manufacturer's instructions with 10 ⁇ l of 0.1% trifluoroacetic acid (TFA) and 50% acetonitrile (ACN). Peptides were eluted in 10 ⁇ l 1:1 ACN-0.1% TFA. A 0.5 ⁇ l volume of the concentrated peptide-containing sample was mixed with 0.5 ⁇ l of a saturated solution of ⁇ -cyano-4-hydroxycinnamic acid. Each sample (0.5 ul) was spotted on the mass spectrometer sample plate (Tremoulet et al).
- TFA trifluoroacetic acid
- ACN acetonitrile
- the mixture (85%) of LMP-1 peptides were separated by capillary reversed-phase HPLC using the method described before [Hubalek, F., Edmondson].
- the peptide fragments were separated by small bore reverse phase HPLC on a Vydac C 18 column (4.6 ⁇ 250 mm) using a gradient HPLC system (Waters).
- the chromatographic run was performed with an aqueous phase containing 0.1% trifluoroacetic acid and organic phase containing 0.085% trifluoroacetic acid in acetonitrile with a flow rate of 0.5 ml/min.
- the gradient used for separation was 2-60% of acetonitrile for 40 min; the total run time was 60 min.
- the collected peptides were subjected to internal fragment N-terminal sequence analysis by standard Edman degradation (Procise 494 HT protein sequencer, Applied Biosystems, Foster City, Calif.). The eluate absorbing at 210 nm was manually collected for sequence analysis.
- HPLC fractions of the digest were analyzed by MALDITOF/TOF MS/MS using a model 4700 Proteomics Analyzer (Applied Biosystems). For each fraction, an MS spectrum was initially collected. For post source decay analysis, the HPLC-purified peptide was subjected to ion generation by post-source decay (Chaurand P 1999).
- a matrix-assisted laser desorption ionization-post-source decay (MALDI-PSD) time-of-flight spectrum was recorded using alpha-cyano-4-hydroxy cinnamic acid as a matrix; acquisition was at 27.5 kV under continuous extraction conditions; reflector voltage was stepped from 30 to 1.27 kV, and the spectrum was constructed using the FASTTM method from Bruker-Daltonic (Bremen, Germany).
- the MS and MS/MS data were submitted to a MASCOT search engine (www.matrixscience.com) for positive identification.
- the NCBI non-redundant database and the Mammalia taxonomy were used for these and all other searches.
- Monoisotopic peptide masses obtained from mass spectra were searched against the SWISS-PROT, NCBInr and MSDB databases using the MASCOT search program. The following parameters were used in the searches: mammalian, human, MS/MS Ion Search, protein mass of 50 kDa, trypsin digest with two missed cleavages, fragment ion mass tolerance of ⁇ 75 ppm and possible oxidation of methionine.
- the resulting protein hits were scored using a probability based Mowse score. The score is ⁇ 10*Log(P), where P is the probability that the observed match is a random event.
- This study determined the optimal dose of adenoviral delivery of the LMP-1 cDNA (SEQ. ID NO: 2) to promote spine fusion in normal, that is, immune competent, rabbits.
- a replication-deficient human recombinant adenovirus was constructed with the LMP-1 cDNA (SEQ. ID NO: 2) driven by a CMV promoter using the Adeno-QuestTM Kit (Quantum Biotechnologies, Inc., Montreal).
- a commercially available (Quantum Biotechnologies, Inc., Montreal) recombinant adenovirus containing the beta-galactosidase gene was used as a control.
- AdV-LMP-1 adenovirus-delivered LMP-1
- MOI multiplicity of infection
- pfu plaque-forming units
- carrier either rabbit devitalized bone matrix or a collagen sponge
- AdV-BGal AdV-BGal
- transduced cells were the buffy coat from venous blood rather than bone marrow. These cells were transfected with Adeno-LMP or pHIS-LMP plasmid and had equivalent successful results as when bone marrow cells were used. This discovery of using ordinary venous blood cells for gene delivery makes gene therapy more feasible clinically since it avoids painful marrow harvest under general anesthesia and yields two times more cells per mL of starting material.
- Intron/Exon mRNA transcript splice variants are a relatively common regulatory mechanism in signal-transduction and cellular/tissue development. Splice variants of various genes have been shown to alter protein-protein, protein-DNA, protein-RNA, and protein-substrate interactions. Splice variants may also control tissue specificity for gene expression allowing different forms (and therefore functions) to be expressed in various tissues. Splice variants are a common regulatory phenomenon in cells. It is possible that the LMP splice variants may result in effects in other tissues such as nerve regeneration, muscle regeneration, or development of other tissues.
- the forward PCR primer which was synthesized using standard techniques, corresponds to nucleotides 35-54 of SEQ. ID NO: 22. It has the following sequence:
- the reverse PCR primer which is the reverse complement of nucleotides 820-839 in SEQ. ID NO: 22, has the following sequence:
- the forward and reverse PCR primers were used to screen human heart cDNA (ClonTech, Cat No. 7404-1) for sequences similar to HLMP-1 by standard techniques, using a cycling protocol of 94° C. for 30 seconds, 64° C. for 30 seconds, and 72° C. for 1 minute, repeated 30 times and followed by a 10 minute incubation at 72° C.
- the amplification cDNA sequences were gel-purified and submitted to the Emory DNA Sequence Core Facility for sequencing.
- the clones were sequenced using standard techniques and the sequences were examined with PCGENE (intelligenetics; Programs SEQUIN and NALIGN) to determine homology to SEQ. ID NO: 22.
- PCGENE intelligenetics
- Programs SEQUIN and NALIGN Two homologous nucleotide sequences with putative alternative splice sites compared to SEQ. ID NO: 22 were then translated to their respective protein products with Intelligenetic's program TRANSL.
- One of these two novel human cDNA sequences comprises 1456 bp:
- This 423 amino acid protein demonstrates 100% homology to the protein shown in SEQ. ID NO. 10, except for the sequence in the highlighted area (amino acids 94-99), which are due to the nucleotide changes depicted above.
- the second novel human heart cDNA sequence (SEQ. ID NO: 39) comprises 1575 bp:
- This protein demonstrates 100% homology to SEQ. ID NO: 10 until amino acid 94, where the addition of the 17 bp fragment depicted in the nucleotide sequence results in a frame shift. Over amino acids 94-153, the protein is not homologous to SEQ. ID NO: 10. Amino acids 154-457 in SEQ. ID NO: 10 are not present due to the early stop codon depicted in nucleotide sequence.
- Applicants have identified the genomic DNA sequence encoding HLMP-1, including putative regulatory elements associated with HLMP-1 expression.
- the entire genomic sequence is shown in SEQ. ID. NO: 41. This sequence was derived from AC023788 (clone RP11-564G9), Genome Sequencing Center, Washington University School of Medicine, St. Louis, Mo.
- the putative promoter region for HLMP-1 spans nucleotides 2,660-8,733 in SEQ. ID NO: 41.
- This region comprises, among other things, at least ten potential glucocorticoid response elements (“GREs”) (nucleotides 6148-6153, 6226-6231, 6247-6252, 6336-6341, 6510-6515, 6552-6557, 6727-6732, 6752-6757, 7738-7743, and 8255-8260), twelve potential Sma-2 homologues to Mothers against Drosophilla decapentaplegic (“SMAD”) binding element sites (nucleotides 3569-3575, 4552-4558, 4582-4588, 5226-5232, 6228-6234, 6649-6655, 6725-6731, 6930-6936, 7379-7384, 7738-7742, 8073-8079, and 8378-8384), and three T
- the three TATA boxes, all of the GREs, and eight of the SMAD binding elements (“SBEs”) are grouped in the region spanning nucleotides 5,841-8,733 in SEQ. ID NO: 41.
- These regulatory elements can be used, for example, to regulate expression of exogenous nucleotide sequences encoding proteins involved in the process of bone formation. This would permit systemic administration of therapeutic factors or genes relating to bone formation and repair, as well as factors or genes associated with tissue differentiation and development.
- exons corresponding to the nucleotide sequence encoding HLMP-1 have been identified. These exons span the following nucleotides in SEQ. ID NO: 41:
- LIM mineralization protein-1 is an intracellular protein that can direct cellular differentiation in osseous and non-osseous tissues.
- LMP-1 human LMP-1
- HLMP-1 human LMP-1
- BMP-2 BMP-2 gene expression.
- Lumbar intervertebral disc cells were harvested from Sprague-Dawley rats by gentle enzymatic digestion and cultured in monolayer in DMEM/F12 supplemented with 10% FBS. These cells were then split into 6 well plates at approximately 200,000 cells per well and cultured for about 6 days until the cells reached approximately 300,000 cells per well. The culture media was changed to 1% FBS DMEM/F12 and this was considered Day 0.
- Type 5 adenovirus comprising a HLMP-1 cDNA operably linked to a cytomegalovirus (“CMV”) promoter has been previously described, for example, in U.S. Pat. No. 6,300,127.
- the negative control adenovirus was identical except the HLMP-1 cDNA was replaced by LacZ cDNA.
- BMP-2 for a positive control, uninfected cultures were incubated in the continuous presence of BMP-2 at a concentration of 100 nanograms/milliliter.
- FACS Fluorescence Activated Cell Sorter
- AdGFP green fluorescent protein gene
- the cells were treated with adenovirus containing the human LMP-1 cDNA (AdHLMP-1) (at MOIs of 0, 100, 300, 1000, or 3000) or with adenovirus containing the LacZ marker gene (AdLacZ MOI of 1000) (negative control).
- the culture media was changed at day 3 and day 6 after infection.
- Proteoglycan production was estimated by measuring the sulfated glycosaminoglycans (sGAG) present in the culture media (at day 0, 3, and 6) using a di-methyl-methylene blue (“DMMB”) calorimetric assay.
- sGAG sulfated glycosaminoglycans
- FIG. 1 shows the production of sGAG after over-expressing HLMP-1 at different MOIs in rat disc cells in monolayer cultures. The results have been normalized to day 0 untreated cells. Error bars represent the standard error of the mean. As shown in FIG. 1 , the sGAG production observed at day 3 was relatively minor, indicating a lag time between transfection and cellular production of GAG. Treatment with AdLacZ did not significantly change the sGAG production. As also shown in FIG. 1 , the optimal dose of AdhLMP-1 was at a MOI of 1000, resulting in a 260% enhancement of sGAG production over the untreated controls at day 6. Higher or lower doses of AdhLMP-1 lead to a diminished response.
- FIG. 2 is a chart showing rat disc sGAG levels at day 6 after treatment with AdhLMP-1 at different MOIs. As can be seen from FIG. 2 , the optimal dose of AdhLMP-1 was at a MOI of 1000.
- FIG. 3 This figure demonstrates the increase in Aggrecan and BMP-2 mRNA after over-expression of HLMP-1.
- Real-time PCR of mRNA extracted from rat disc cells at day 6 was performed comparing the no-treatment (“NT”) cells with cells treated with AdhLMP-1 at a MOI of 250.
- the data in FIG. 3 are represented as a percentage increase over the untreated sample.
- NT no-treatment
- FIG. 3 a significant increase in Aggrecan and BMP-2 mRNA was noted following AdhLMP-1 treatment.
- the increase in BMP-2 expression suggests that BMP-2 is a down-stream gene that mediates HLMP-1 stimulation of proteoglycan synthesis.
- GAPDH in Table 2 denotes glyceraldehyde phosphate dehydrogenase.
- TaqMan® Ribosomal RNA Control Reagents (Part number 4308329, Applied Biosystems, Foster City, Calif., U.S.A.) were used for the forward primer, reverse primer and probe of 18S ribosomal RNA (rRNA) gene.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- This application claims priority from U.S. application Ser. No. 10/292,951 filed Nov. 13, 2002 which claims priority to the Provisional Application Ser. No. 60/331,321 filed Nov. 14, 2001. The entirety of that provisional application is incorporated herein by reference.
- This application is related to U.S. patent application Ser. No. 09/124,238, filed Jul. 29, 1988, now U.S. Pat. No. 6,300,127, and U.S. patent application Ser. No. 09/959,578, filed Apr. 28, 2000, now U.S. Pat. No. 7,045,614. Each of these applications is incorporated by reference herein in its entirety.
- 1. Field of the Invention
- The field of the invention relates generally to methods for expressing LIM mineralization proteins in a host cell. More specifically, the field of the invention relates to expression and purification of intracellular mediators involved in the osteogenic factor signaling cascade during osteoblast differentiation. The field of invention also relates to methods of improving the nuclear localization of osteogenic factors in suitable cells. Finally, the field of invention relates to transfecting host cells such as intervertebral disc cells with a nucleic acid encoding a LIM mineralization protein.
- 2. Background of the Technology
- Osteoblasts are thought to differentiate from pluripotent mesenchymal stem cells. The maturation of an osteoblast results in the secretion of an extracellular matrix which can mineralize and form bone. The regulation of this complex process is not well understood but is thought to involve a group of signaling glycoproteins known as bone morphogenetic proteins (BMPs). These proteins have been shown to be involved with embryonic dorsal-ventral patterning, limb bud development, and fracture repair in adult animals. B. L. Hogan, Genes & Develop., 10, 1580 (1996).
- BMPs are members of the Transforming growth factor-beta superfamily (TGF-β) proteins that play a role in maturation of osteoblasts and the bone regulation pathways. TGF-β secreted proteins has a spectrum of activities in a variety of cell types at different stages of differentiation. However, differences in physiological activity between these closely related molecules have not been clarified. D. M. Kingsley, Trends Genet., 10, 16 (1994).
- In addition to extracellular signals, such as the BMPs, intracellular signals or regulatory molecules also play a role in the cascade of events leading to formation of new bone. Examples of such regulatory osteogenic molecules include LIM mineralization proteins (LMPs), Runt-Related Transcription Factor (Runx-2), Drosophila distalles (Dlx), and Osterix (Osx).
- It is common knowledge that the differentiation process of osteoblasts requires a complex coordination of all such osteogenic factors including BMPs, other members of the transforming TGF-β superfamily, LMPs, Dlx, Runx-2, Osx are key osteogenic factors that play critical roles in the BMP pathway.
- To better discern the unique physiological role of different factors studies are required to better understand the nature of their interaction. We have performed many studies on the nature of BMP signaling protein pathways. We have recently compared the potency of BMP-6 with that of BMP-2 and BMP-4, for inducing rat calvarial osteoblast differentiation. Boden, et al., Endocrinology, 137, 3401 (1996). We studied this process in first passage (secondary) cultures of fetal rat calvaria that require BMP or glucocorticoid for initiation of differentiation. In this model of membranous bone formation, glucocorticoid (GC) or a BMP will initiate differentiation to mineralized bone nodules capable of secreting osteocalcin, the osteoblast-specific protein. This secondary culture system is distinct from primary rat osteoblast cultures which undergo spontaneous differentiation. In this secondary system, glucocorticoid resulted in a ten-fold induction of BMP-6 mRNA and protein expression which was responsible for the enhancement of osteoblast differentiation. Boden, et al., Endocrinology, 138, 2920 (1997).
- Other investigations have also been performed to assess the relationship between other osteogenic factors and BMPs. Bourque et al elaborated on Runx-2 critical role in the differentiation of cells toward an osteoblastic pathway. Bourque et al, Expression of four growth factors during fracture repair. Int. J. Dev. Biol, 1993:37:573-9. Runx2 is a transcription factor that belongs to the Runx family. Komori, T., et al. 1997. Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:755-764; Fujita et al (2004) “Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling.” J. Cell Biol. 166:85-95.
- Runx2-deficient (Runx2−1−) mice completely lack bone formation owing to the absence of osteoblasts. Runx2 determines the osteoblast lineage from multipotent mesenchymal cells, induces osteoblastic differentiation at the early stage, and inhibits it at the late stage. Further, Runx2 has been shown to induce alkaline phosphatase (ALP) activity, expression of bone matrix protein genes, and mineralization in immature mesenchymal cells and osteoblastic cells in vitro. Chondrocyte differentiation is also disturbed in Runx2−/− mice.
- Overexpression of Runx2 or the dominant-negative (dn) form of Runx2 (dn-Runx2) in chondrocytes accelerates or decelerates chondrocyte maturation, respectively, indicating that Runx2 is a positive regulatory factor in chondrocyte maturation. Further, introduction of dn-Runx2 inhibited cell condensation in insulin-induced chondrogenesis of ATDC5 cells. Thus, Runx2 plays crucial roles in osteoblast and chondrocyte differentiation.
- Dlx proteins have been implicated to play major role in osteogenesis as well. Ryoo, H. M., et al. (1997) “Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression.” Mol. Endocrinol. 11, 1681-1694. It has been shown that the mammalian homologs of
Dlx Dlx - Osx is a novel zinc finger containing transcription factor expressed by osteoblasts and required for endochondral and intra membranous bone formation. Nakashima, K., et al, (2002) “The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.” Cell 108:17-29. Osterix-null mice have normal cartilage development but fail to develop mineralized skeleton. Yasko et al. the Healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. J Bone Joint Surg Am, 1992; 74:659-70.
- Another broad class of intracellular regulatory molecules are the LIM proteins, which are so named because they possess a characteristic structural motif known as the LIM domain. Viggeswarapu M, Boden S D et al. (2001) “Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo.” J Bone & Joint Surg Am. 83:364-376. The LIM domain is a cysteine-rich structural motif composed of two special zinc fingers that are joined by a 2-amino acid spacer. Some proteins have only LIM domains, while others contain a variety of additional functional domains. LIM proteins form a diverse group, which includes transcription factors and cytoskeletal proteins. The primary role of LIM domains appears to be in mediating protein-protein interactions, through the formation of dimers with identical or different LIM domains, or by binding distinct proteins.
- In LIM homeodomain proteins, that is, proteins having both LIM domains and a homeodomain sequence, the LIM domains function as negative regulatory elements. LIM homeodomain proteins are involved in the control of cell lineage determination and the regulation of differentiation, although LIM-only proteins may have similar roles. LIM-only proteins are also implicated in the control of cell proliferation since several genes encoding such proteins are associated with oncogenic chromosome translocations.
- Humans and other mammalian species are prone to diseases or injuries that require the processes of bone repair and/or regeneration. For example, treatment of fractures would be improved by new treatment regimens that could stimulate the natural bone repair mechanisms, thereby reducing the time required for the fractured bone to heal. In another example, individuals afflicted with systemic bone disorders, such as osteoporosis, would benefit from treatment regimens that would result in systemic formation of new bone. Such treatment regimens would reduce the incidence of fractures arising from the loss of bone mass that is a characteristic of this disease.
- For at least these reasons, extracellular factors, such as the BMPs, have been investigated for the purpose of using them to stimulate formation of new bone in vivo. Despite the early successes achieved with BMPs and other extracellular signaling molecules, their use entails a number of disadvantages.
- For example, relatively large doses of purified BMPs are required to enhance the production of new bone, thereby increasing the expense of such treatment methods. Furthermore, extracellular proteins are susceptible to degradation following their introduction into a host animal. In addition, because they are typically immunogenic, the possibility of stimulating an immune response to the administered proteins is ever present.
- Due to such concerns, it would be desirable to have available treatment regimens that use an intracellular signaling molecule that can induce new bone formation. Advances in the field of gene therapy now make it possible to introduce into osteogenic precursor cells, that is, cells involved in bone formation, or peripheral blood leukocytes, nucleotide fragments encoding intracellular signals that form part of the bone formation process. Gene therapy for bone formation offers a number of potential advantages: (1) lower production costs; (2) greater efficacy, compared to extracellular treatment regimens, due to the ability to achieve prolonged expression of the intracellular signal; (3) it would by-pass the possibility that treatment with extracellular signals might be hampered due to the presence of limiting numbers of receptors for those signals; (4) it permits the delivery of transfected potential osteoprogenitor cells directly to the site where localized bone formation is required; and (5) it would permit systemic bone formation, thereby providing a treatment regimen for osteoporosis and other metabolic bone diseases.
- In addition to diseases of the bone, humans and other mammalian species are also subject to intervertebral disc degeneration, which is associated with, among other things, low back pain, disc herniation, and spinal stenosis. Disc degeneration is associated with a progressive loss of proteoglycan matrix. This may cause the disc to be more susceptible to bio-mechanical injury and degeneration. Accordingly, it would be desirable to have a method of stimulating proteoglycan and/or collagen synthesis by the appropriate cells, such as, for example, cells of the nucleus pulpous, cells of the annulus fibrosis, and cells of the intervertebral disc.
- According to a first aspect of the invention, a method of expressing a LIM mineralization protein in a host mammalian cell is provided. According to this aspect of the invention, the method comprises transfecting the cell with an isolated nucleic acid comprising a nucleotide sequence encoding the LIM mineralization protein operably linked to a promoter. The cell can be a cell capable of producing proteoglycan and/or collagen such that the expression of the LIM mineralization protein stimulates proteoglycan and/or collagen synthesis in the cell. The isolated nucleic acid according to this aspect of the invention can be a nucleic acid which can hybridize under standard conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 25; and/or a nucleic acid molecule which can hybridize under highly stringent conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 26. The cell can be a stem cell, an intervertebral disc cell, a cell of the annulus fibrosus, or a cell of the nucleus pulposus.
- According to a second aspect of the invention, a mammalian cell comprising an isolated nucleic acid sequence encoding a LIM mineralization protein is provided. According to this aspect of the invention, purified chimeric nucleotides are also prepared that are expected to exhibit a greater degree of expression relative to those of their parental counterparts. According to this aspect of the invention, the cell can be a stem cell, a cell of the nucleus pulposus, a cell of the annulus fibrosus, an intervertebral disc cell or other types of cell capable of such expression.
- According to a third goal of this invention purified recombinant protein constructs were developed. According to this aspect of the invention, chimeric polypeptide sequences are developed for delivery of the bone specific mammalian transcription factors. According to this aspect of the invention, the developed chimeric polypeptide sequences are capable of nuclear localization in a form accessible to interaction with other nuclear proteins.
- According to a fourth aspect of the invention, a method of treating intervertebral disc injury or disease is provided. According to this aspect of the invention, the method comprises transfecting an isolated nucleic acid into a mammalian cell capable of producing proteoglycan and/or collagen. The isolated nucleic acid comprises a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. The LIM mineralization protein stimulates proteoglycan and/or collagen synthesis in the cell.
- According to a fifth aspect of the invention, an intervertebral disc implant is provided. According to this aspect of the invention, the implant comprises a carrier material and a plurality of mammalian cells comprising an isolated nucleic acid sequence encoding a LIM mineralization protein optionally with a nuclear localization signal. Also according to this aspect of the invention, the carrier material comprises a porous matrix of biocompatible material and the mammalian cells are incorporated into the carrier material.
- According to a sixth aspect of the invention, a system and a method is developed to meet the demands of proteomics for transient transfection-based mammalian expression. According to this aspect of the invention, a method is developed for identifying LMP-1 protein internal sequencing and assessing post-translational glycosylation in a mammalian expression system wherein the method employs carbohydrate analysis of LMP-1 hydrolysates.
- Furthermore, this aspect of the invention introduces a novel purification and detection methods wherein the skilled artisan is now able to purify the recombinant proteins to a level of homogeneity by means of (1) size fractionation of proteins prior to metal affinity chromatography to improve efficiency of affinity resin and (2) identification of tryptic fragments of purified protein.
- According to a seventh aspect of the invention, a composition is prepared that comprises a LIM mineralization protein that is substantially free of any carbohydrate moiety.
- The present invention may be better understood with reference to the accompanying drawings in which:
-
FIG. 1 is a graph showing the production of sulfated glycosaminoglycan (sGAG) after expression of HLMP-1 by rat intervertebral disc cells transfected with different MOIs (SEQ ID NOS 84-86); -
FIG. 2 is a chart showing the dose response of rat intervertebral disc cells six days after infection with different MOI of AdHLMP-1; -
FIG. 3 is a chart showing the expression of Aggrecan and BMP-2 mRNA by AdHLMP-1 transfected rat intervertebral disc cells six days following transfection with an MOI of 250 virions/cell; -
FIG. 4A is a chart showing HLMP-1mRNA expression 12 hours after infection with Ad-hLMP-1 at different MOIs. InFIG. 4A , exogenous LMP-1 expression was induced with different doses (MOI) of the Ad-hLMP-1 virus and quantitated with real-time PCR. The data is normalized to HLMP-1 mRNA levels from Ad-LMP-1MOI 5 for comparison purposes. No HLMP-1 was detected in negative control groups, the no-treatment (“NT”) or Ad-LacZ treatment (“LacZ”). HLMP-1 mRNA levels in a dose dependent fashion to reach a plateau of approximately 8 fold with a MOI of 25 and 50. -
FIG. 4B is a chart showing the production of sGAG in medium from 3 to 6 days after infection. DMMB assay was used to quantitate total sGAG production betweendays 3 to 6 after infection. The data inFIG. 4B is normalized to the control (i.e., no treatment) group. As can be seen fromFIG. 4B , there was a dose dependent increase in sGAG. with the peak of approximately three fold increase above control reached with a MOI of 25 and 50. The negative control, Ad-LacZ at a MOI of 25, lead to no increase in sGAG. InFIG. 4B , each result is expressed as mean with SD for three samples. -
FIG. 5 is a chart showing time course changes of the production of sGAG. As can be seen fromFIG. 5 , onday 3 sGAG production increased significantly at a MOI of 25 and 50. Onday 6 there was a dose dependent increase in sGAG production in response to AdLMP-1. The plateau level of sGAG increase was achieved at a MOI of 25. As can also be seen fromFIG. 5 , treatment with AdLacZ (“LacZ”) did not significantly change the sGAG production. Each result is expressed as mean with SD for six to nine samples. InFIG. 5 , “**” indicates data points for which the P value is <0.01 versus the untreated control. -
FIGS. 6A and 6B are charts showing gene response to LMP-1 over-expression in rat annulus fibrosus cells for aggrecan and BMP-2, respectively. Quantitative real-time PCR was performed onday 3 after infection with Ad-LMP-1 (“LMP-1”) at a MOI of 25. As can be seen fromFIGS. 6A and 6B , the gene expression of aggrecan and BMP-2 increased significantly after infection with Ad-LMP-1 compared to the untreated control (“NT”). Further, treatment with AdLacZ (“LacZ”) at a MOI of 25 did not significantly change the gene expression of either aggrecan or BMP-2 compared to the untreated control. InFIGS. 6A and 6B , each result is expressed as mean with SD for six samples. InFIGS. 6A and 6B , “**” indicates data points for which the P value is P<0.01. -
FIG. 7 is a graph showing the time course of HLMP-1 mRNA levels in rat annulus fibrosus cells after infection with AdLMP-1 at a MOI of 25. The data is expressed as a fold increase above a MOI of 5 of AdLMP-1 after standardization using 18S and replication coefficient of over-expression LMP-1 primer. As can be seen fromFIG. 7 , HLMP-1 mRNA was upregulated significantly as early as 12 hours after infection. Further, there was a marked increase of expression levels betweenday 1 andday 3. Each result inFIG. 7 is expressed as mean with SD for six samples. -
FIG. 8 is a chart showing changes in mRNA levels of BMPs and aggrecan in response to HLMP-1 over-expression. The mRNA levels of BMP-2, BMP-4, BMP-6, BMP-7, and aggrecan were determined with real-time-PCR at different time points after infection with Ad-hLMP-1 at a MOI of 25. As can be seen fromFIG. 8 , BMP-2 mRNA was upregulated significantly as early as 12 hours after infection with AdLMP-1. On the other hand, Aggrecan mRNA was not upregulated until 3 day after infection. Each result is expressed as mean with SD for six samples. InFIG. 8 , “**” indicates data points for which the P value is <0.01 for infection with AdLMP-1 versus an untreated control. -
FIG. 9 is a graph showing the time course of sGAG production enhancement in response to HLMP-1 expression. For the data inFIG. 9 , rat annulus cells were infected with Ad-hLMP-1 at a MOI of 25. The media was changed every three days after infection and assayed for sGAG with the DMMB assay. This data shows that sGAG production reaches a plateau atday 6 and is substantially maintained atday 9. -
FIG. 10 is a chart showing the effect of noggin (a BMP antagonist) on LMP-1 mediated increase in sGAG production. As seen inFIG. 10 , infection of rat annulus cells with Ad-LMP-1 at a MOI of 25 led to a three fold increase in sGAG produced betweenday 3 andday 6. This increase was blocked by the addition of noggin (a BMP antagonist) at concentration of 3200 ng/ml and 800 ng/m. As shown inFIG. 10 , however, noggin did not significantly alter sGAG production in uninfected cells. As can also be seen inFIG. 10 , stimulation with rhBMP-2 at 100 ng/ml led to a 3 fold increase in sGAG production betweenday 3 andday 6 after addition of BMP-2. Noggin at 800 ng/ml also blocked this increase. -
FIG. 11 is a chart showing the effect of LMP-1 on sGAG in media afterday 6 of culture in monolayer. The data points are represented as fold increase above untreated cells. As shown inFIG. 11 , LMP-1 with the CMV promoter when delivered by the AAV vector is also effective in stimulating glycosaminoglycan synthesis by rat disc cells in monolayer. -
FIG. 12 shows Sephacryl S-300 molecular exclusion chromatographic profile obtained for the crude A549 lysate. The clarified lysate was applied to Sephacryl S-300 column (HiPrep 16×60) using the AKTA FPLC/Unicorn 3.1 System in 50 mM phosphate buffer, pH 7.5 and 5 M NaCl. After the void volume eluted from the column, fractions (6 ml) were collected. Fractions containing fusion proteins were detected by western blots with LMP-1-specific antibody and pooled for Ni++-affinity enrichment. Inclusion of 5 M NaCl in buffer avoided non-specific aggregation of recombinant proteins on column resin. -
FIG. 13 is a graph showing SDS-PAGE and detection of purified LMP-1. Purified protein fractions were concentrated, dialyzed and a 5 ug aliquot of recombinant protein was loaded. The purity of pooled fractions from Sephacryl S-300 molecular exclusion chromatography and Ni++-affinity chromatography were determined by coomassie staining of gels after SDS-PAGE (10% acrylamide). Each of the fusion-protein was the expected size as determined from molecular weight markers as marked. -
FIG. 14 is a chromatograph showing the tryptic digest (15%) OF LMP-1 purified and concentrated by a Zip Tip (Millipore) column which has Cl8 resin fixed at its end. The column was rinsed in 10 μl of 0.1% trifluoroacetic acid (TFA) in 50% acetonitrile (ACN). Peptides were eluted in 10 μl 1:1 ACN-0.1% TFA. A 0.5 μl volume of the concentrated peptide-containing sample was mixed with 0.5 μl of a saturated solution of alpha-cyano-4-hydroxycinnamic acid. Each sample (0.5 ul) was spotted on the mass spectrometer sample plate for analysis. -
FIG. 15 is a graph showing post source decay (PSD) MALDI MS analysis of a LMP-1 derived molecular ion (m/Z=1328). HPLC-purified peptide was subjected to ion generation by post-source decay using the FAST™ method as described in the methods. A matrix-assisted laser adsorption ionization-post-source decay (MALDI-PSD) time-of-flight spectrum was recorded using α-cyano-4-hydroxy cinnamic acid as a matrix; acquisition was at 27.5 kV under continuous extraction conditions; reflector voltage was stepped from 30 to 1.27 kV, and the spectrum was constructed. A representative analysis on one of the matching molecular ions obtained from tryptic digest of LMP-1 running at m/z=1328 is shown. Indeed, the product ion spectrum of m/z=1328 confirmed the identity of this ion with the a tryptic fragment of LMP-1. -
FIG. 16 is a chromatograph of a tryptic peptide mixture (85%) of LMP-1 after digestion was separated by capillary reversed-phase HPLC using the method described before [Hubalek, F., Edmondson]. The peptide fragments were separated by small bore reverse phase HPLC on a Vydac C18 column (4.6×250 mm) with a gradient HPLC system (Waters). The chromatographic run was performed with an aqueous phase containing 0.1% trifluoroacetic acid and an organic phase containing 0.085% trifluoroacetic acid in acetonitrile with a flow rate of 0.5 ml/min. The gradient used for separation was 2-60% of acetonitrile during 40 min; the total run time was 60 min. -
FIG. 17 is a chromatograph showing MALDI-TOF MS analysis of HPLC separated tryptic peptide fractions of LMP-1. A representative data obtained for fractions 33 (A), 35 (B), 48 (C) and 51 (D) is shown. These samples contained an exact match of the expected molecular ions for the corresponding peptide species derived from LMP-1. -
FIG. 18 is a depiction of general strategy for construction and cloning of TAT-cDNA for expression in E. coli. The cDNA for signaling factors, LMP-1, Dlx-5, Runx2 or Osterix, were cloned downstream to hexahistidine, TAT-domain and hemaglutinin tags driven by T7 promoter in TAT vector. Collectively the tags add an apparent molecular size of about 5 kDa to each fusion-protein. -
FIG. 19 is a Sephacryl S-100 molecular exclusion chromatographic profiles obtained for the bacterial crude lysates for LMP-1. The clarified bacterial lysate was applied to Sephacryl S-100 column (HiPrep 16×60) using the AKTA FPLC/Unicorn 3.1 System in 50 mM phosphate buffer, pH 7.5 and 5 M NaCl. After the void volume eluted from the column, fractions (4 ml) were collected. Fractions containing fusion proteins were detected by slot blots and western blots with hemagglutinin-specific antibody and pooled for Ni++-affinity enrichment. Inclusion of 5 M NaCl in buffer avoided non-specific aggregation of recombinant proteins on column resin. -
FIG. 20 is a Sephacryl S-100 molecular exclusion chromatographic profiles obtained for the bacterial crude lysates for Dlx5. same method was employed as for LMP-1 inFIG. 19 . -
FIG. 21 is a Sephacryl S-100 molecular exclusion chromatographic profiles obtained for the bacterial crude lysates for Runx2. Same method was employed as forFIG. 19 . -
FIG. 22 is a Sephacryl S-100 molecular exclusion chromatographic profiles obtained for the bacterial crude lysates for Osx. Same method was employed as forFIG. 19 . -
FIG. 23 is a depiction of SDS-PAGE of purified LMP-1, Dlx5, Runx2 and Osterix. Purified protein fractions were concentrated, dialyzed and a 5 ug aliquot of each recombinant protein was loaded. The purity of each preparation was determined by coomassie staining of gels after SDS-PAGE (12% acrylamide). Each of the fusion-protein was the expected size as determined from molecular weight markers as marked. -
FIG. 24 is a time and Dose-dependent accumulation of FITC labeled TAT-LMP-1 into rabbit buffy coat cells. TAT-LMP-1 was labeled with FITC and incubated with rabbit buffy coat cells. Concentrations ranging from 1.0 to 25 nM of FITC-labeled TAT-LMP-1 was incubated for 15, 30 and 60 min at 37° C. with 106 cells. After washes the % of total cells containing FITC was determined by flow cytometry. -
FIG. 25 shows that a TAT-fusion protein was detected in both nuclear and cytoplasmic fractions in MSCs. Equal aliquots of protein (10 ug) were loaded in each lane. The cytoplasmic and nuclear lanes contained samples obtained from cells that were treated with 0.3 to 300 nM TAT-LMP-1. The blots were blocked and probed with rabbit HA-specific antibodies. The signal is detected by HRP-labeled anti-rabbit second antibodies and enhanced chemi-luminescence. -
FIG. 26 shows TAT-LMP-1 associates with specific nuclear proteins. A Metal affinity tag pull-down assay was performed as described in methods. The bound proteins were eluted with 250 mM imidazole followed by removal of Ni++ with 50 mM EDTA. Protein samples (5 ug) were resolved by SDS-PAGE, transblotted to nitrocellulose membrane. The blotted proteins were stained with colloidal gold for total protein (Panel A) or probed with HA-specific primary antibody followed by horse radish peroxidase (HRP)-labeled second antibody (Panel B). The signal was developed with enhanced chemi-luminescence as described in methods. - BMP, Bone Morphogenetic Protein;
- HLMP-1, Human LMP-1, also designated as Human LIMProtein or HLMP;
- HLMP-1s Human LMP-1 Short (truncated) protein,
- HLMPU Human LIM Protein Unique Region;
- LMP LIM mineralization protein,
- LMP-1, LIM mineralization protein-1;
- MEM Minimal essential medium;
- Trm, Triamcinolone;
- β-GlyP; beta-GlyP, Beta-glycerolphosphate;
- RACE, Rapid Amplification of cDNA Ends;
- RLMP, Rat LIM mineralization protein, also designated as RLMP-1; RLMPU,
- Rat LIM Protein Unique Region;
- RNAsin, RNase inhibitor;
- ROB, Rat Osteoblast;
- 10-4, Clone containing cDNA sequence for RLMP (SEQ ID
- NO: 2);
- UTR, Untranslated Region;
- HLMP-2, Human
LMP Splice Variant 2; - HLMP-3, Human
LMP Splice Variant 3; - MOI, multiplicity of infection;
- sGAG, sulfated glycosaminoglycan;
- AdHLMP-1,
Recombinant Type 5 Adenovirus comprising nucleotide sequence encoding HLMP-1; - SDS-PAGE, Sodium dodecyl polyacrylamide gel electrophoresis;
- FPLC, Fast performance liquid chromatography;
- HPLC, High performance liquid chromatography;
- Ni-NTA, Nickel-nitrilotriacetic acid;
- PMSF, phenylmethylsulfonyl fluoride;
- BSA, bovine serum albumin.
- MALDI TOF, Matrix Assisted Laser Desorption Ionization Time of Flight;
- MS, Mass spectrometry;
- PSD, Post source decay;
- IPTG, Isopropyl-βD-thiogalactopyranoside; LB, Luria
- As used herein, the term “isolated/and or purified” refers to in vitro preparation, isolation, and/or purification of a nucleic acid or protein from its natural cellular environment or from association with other components of the cell, so that it is not associated with in vivo substances.
- As used herein, the term “recombinant DNA” means any DNA molecule consisting of segments of DNA from different genomes (the entire DNA or cell or virus) which have been joined end-to-end outside of living cells and have the capacity to transfect suitable host cells and be maintained therein. Moreover, the term “recombinant polypeptide, protein or amino acid sequence” means any such molecule that was expressed from a recombinant DNA consisting of segments of DNA that have been joined end-to-end outside of living cells and have the capacity to be transfected into host cells and be maintained therein.
- As used herein, the term “chimeric” means that a vector comprises DNA from at least two different species or comprises DNA from the same species which is linked or associated in a manner which does not occur in the “native,” or “wild type” of the species.
- As used herein, the term “operably linked” means that the nucleic acids are placed in a functional relationship with another nucleic acid sequence.
- Transfection can occur either ex vivo or in vivo by direct injection of virus or naked DNA, such as, for example, a plasmid. In certain embodiments, the virus is a recombinant adenovirus, preferably AdHLMP-1
- The present invention relates to the transfection of non-osseous cells with nucleic acids encoding LIM mineralization proteins. The present inventors have discovered that transfection of non-osseous and osseous cells such as intervertebral disc cells with nucleic acids encoding LIM mineralization proteins can result in the increased synthesis of proteoglycan, collagen and other intervertebral disc components and tissue. The present invention also provides a method for treating intervertebral disc disease associated with the loss of proteoglycan, collagen, or other intervertebral disc components.
- It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed.
- A LIM gene (10-4/RLMP) has been isolated from stimulated rat calvarial osteoblast cultures (SEQ. ID NO: 1, SEQ. ID NO: 2). See U.S. Pat. No. 6,300,127. This gene has been cloned, sequenced and assayed for its ability to enhance the efficacy of bone mineralization in vitro. The protein RLMP has been found to affect the mineralization of bone matrix as well as the differentiation of cells into the osteoblast lineage. Unlike other known cytokines (e.g., BMPs), RLMP is not a secreted protein, but is instead an intracellular signaling molecule. This feature has the advantage of providing intracellular signaling amplification as well as easier assessment of transfected cells. It is also suitable for more efficient and specific in vivo applications. Suitable clinical applications include enhancement of bone repair in fractures, bone defects, bone grafting, and normal homeostasis in patients presenting with osteoporosis.
- The amino acid sequence of a corresponding human protein, named human LMP-1 (“HLMP-1”), has also been cloned, sequenced and deduced. (SEQ. ID NO: 10). See U.S. Pat. No. 6,300,127. The human protein has been found to demonstrate enhanced efficacy of bone mineralization in vitro and in vivo. The sequence of LMP-1 contains a highly conserved N-terminal PDZ domain and three C-terminal LIM domains. The sequence analysis of LMP-1 predicts two putative N-glycosylation sites. At least one aspect of this invention is to verify whether LMP-1 was expressed in detectable amounts and purify the recombinant LMP-1 for carbohydrate analysis to determine if the LMP-1 expressed in mammalian system undergoes post translational glycosylation.
- Additionally, a truncated (short) version of HLMP-1, termed HLMP-1s, has been characterized. See U.S. Pat. No. 6,300,127. This short version resulted from a point mutation in one source of a cDNA clone, providing a stop codon which truncates the protein. HLMP-1s has been found to be fully functional when expressed in cell culture and in vivo.
- Using PCR analysis of human heart cDNA library, two alternative splice variants (referred to as HLMP-2 and HLMP-3) have been identified that differ from HLMP-1 in a region between
base pairs 325 and 444 in the nucleotide sequence encoding HLMP-1. See U.S. patent application Ser. No. 09/959,578, filed Apr. 28, 2000, now U.S. Pat. No. 7,045,614. The HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. Compared to HLMP-1, the nucleotide sequence encoding HLMP-3 has no deletions, but it does have the same 17 base pairs as HLMP-2, which are inserted at position 444 in the HLMP-1 sequence. - LMP is a pluripotent molecule, which regulates or influences a number of biological processes. The different splice variants of LMP are expected to have different biological functions in mammals. They may play a role in the growth, differentiation, and/or regeneration of various tissues. For example, some form of LMP is expressed not only in bone, but also in muscle, tendons, ligaments, spinal cord, peripheral nerves, and cartilage.
- According to one aspect, the present invention relates to a method of stimulating proteoglycan and/or collagen synthesis in a mammalian cell by providing an isolated nucleic acid comprising a nucleotide sequence encoding LIM mineralization protein operably linked to a promoter; transfecting said isolated nucleic acid sequence into a mammalian cell capable of producing proteoglycan; and expressing said nucleotide sequence encoding LIM mineralization protein, whereby proteoglycan synthesis is stimulated. The mammalian cell may be a non-osseous cell, such as an intervertebral disc cell, a cell of the annulus fibrosus, or a cell of the nucleus pulposus. Transfection may occur either ex vivo or in vivo by direct injection of virus or naked DNA, such as, for example, a plasmid. In certain embodiments, the virus is a recombinant adenovirus, preferably AdHLMP-1.
- Another embodiment of the invention comprises a non-osseous mammalian cell comprising an isolated nucleic acid sequence encoding a LIM mineralization protein. The non-osseous mammalian cell may be a stem cell (e.g., a pluripotent stem cell or a mesenchymal stem cell) or an intervertebral disc cell, preferably a cell of the nucleus pulposus or a cell of the annulus fibrosus.
- In a different aspect, the invention is directed to a method of expressing an isolated nucleotide sequence encoding LIM mineralization protein in a non-osseous mammalian cell, comprising: providing an isolated nucleic acid comprising a nucleotide sequence encoding LIM mineralization protein operably linked to a promoter; transfecting said isolated nucleic acid sequence into a non-osseous mammalian cell; and expressing said nucleotide sequence encoding LIM mineralization protein. The non-osseous mammalian cell may be a stem cell or an intervertebral disc cell (e.g., a cell of the nucleus pulposus or annulus fibrosus). Transfection may occur either ex vivo or in vivo by direct injection of virus or naked DNA, such as, for example, a plasmid. The virus can be a recombinant adenovirus, preferably AdHLMP-1.
- In yet another embodiment, purified chimeric nucleotides are prepared that will exhibit a greater degree of expression relative to those of their parental counterparts. According to this aspect of the invention, bacterially expressed TAT-fusion-cDNAs of osteogenic factors were prepared that have the potential to either replace BMP-2 in inducing bone formation or to serve as enhancers of BMP-2 efficacy.
- According to another aspect of this invention, purified recombinant protein constructs were developed. According to this aspect of the invention, chimeric polypeptide sequences are developed for delivery of the bone specific mammalian transcription factors. According to this aspect of the invention, Osteogenic factors containing TAT domain were obtained and purified. The developed chimeric polypeptide sequences are capable of nuclear localization in a form accessible to interaction with other nuclear proteins.
- In yet another aspect of this invention, the application is directed to a method of treating intervertebral disc disease by reversing, retarding or slowing disc degeneration, comprising providing an isolated nucleic acid comprising a nucleotide sequence encoding LIM mineralization protein operably linked to a promoter; transfecting said isolated nucleic acid sequence into a mammalian cell capable of producing proteoglycan; and stimulating proteoglycan synthesis in said cell by expressing said nucleotide sequence encoding LIM mineralization protein, whereby disc degeneration is reversed, halted or slowed. The disc disease may involve lower back pain, disc herniation, or spinal stenosis. The mammalian cell may be a non-osseous cell, such as a stem cell or an intervertebral disc cell (e.g., a cell of the annulus fibrosus, or a cell of the nucleus pulposus).
- Transfection may occur either ex vivo or in vivo by direct injection of virus or naked DNA, such as, for example, a plasmid. In certain embodiments, the virus is a recombinant adenovirus, preferably AdHLMP-1.
- The present invention relates to novel mammalian LIM proteins, herein designated LIM mineralization proteins, or LMPs. The invention relates more particularly to human LMP, known as HLMP or HLMP-1, or alternative splice variants of human LMP, which are known as HLMP-2 or HLMP-3. The Applicants have discovered that these proteins enhance bone mineralization in mammalian cells grown in vitro. When produced in mammals, LMP also induces bone formation in vivo.
- It is well established that uptake of charged molecules or high molecular weight peptides and proteins into live cells is hampered by the lipophilic nature of the plasma membrane. Protein engineering is currently used for the creation of new fusion proteins with desirable traits, which include penetration of exogenously added recombinant proteins into cytosolic and nuclear compartments of cells. In at least one aspect of this invention, we have prepared hybrid proteins that are expressed and further accumulated in both cytoplasmic and nuclear compartments. Preferably, the hybrid protein is a TAT-tagged osteogenic factor, more preferably a TAT-tagged-LMP-1. This is the first time that a recombinant TAT-LMP-1 has been shown to interact with nuclear proteins. Accordingly, such TAT-fusion proteins can be used as molecular bait to identify the intracellular interacting proteins.
- With respect to clinical use, ex vivo transfection of bone marrow cells, osteogenic precursor cells, peripheral blood cells, and stem cells (e.g., pluripotent stem cells or mesenchymal stem cells) with nucleic acid that encodes a LIM mineralization protein (e.g., LMP or HLMP), followed by reimplantation of the transfected cells in the donor, is suitable for treating a variety of bone-related disorders or injuries. For example, one can use this method to: augment long bone fracture repair; generate bone in segmental defects; provide a bone graft substitute for fractures; facilitate tumor reconstruction or spine fusion; and provide a local treatment (by injection) for weak or osteoporotic bone, such as in osteoporosis of the hip, vertebrae, or wrist. Transfection with LMP or HLMP-encoding nucleic acid is also useful in: the percutaneous injection of transfected marrow cells to accelerate the repair of fractured long bones; treatment of delayed union or non-unions of long bone fractures or pseudoarthrosis of spine fusions; and for inducing new bone formation in avascular necrosis of the hip or knee.
- In addition to ex vivo methods of gene therapy, transfection of a recombinant DNA vector comprising a nucleic acid sequence that encodes LMP or HLMP can be accomplished in vivo. When a DNA fragment that encodes LMP or HLMP is inserted into an appropriate viral vector, for example, an adenovirus vector, the viral construct can be injected directly into a body site were endochondral bone formation is desired. By using a direct, percutaneous injection to introduce the LMP or HLMP sequence stimulation of bone formation can be accomplished without the need for surgical intervention either to obtain bone marrow cells (to transfect ex vivo) or to reimplant them into the patient at the site where new bone is required. Alden, et al., Neurosurgical Focus (1998), have demonstrated the utility of a direct injection method of gene therapy using a cDNA that encodes BMP-2, which was cloned into an adenovirus vector.
- It is also possible to carry out in vivo gene therapy by directly injecting into an appropriate body site, a naked, that is, unencapsulated, recombinant plasmid comprising a nucleic acid sequence that encodes HLMP. In this embodiment of the invention, transfection occurs when the naked plasmid DNA is taken up, or internalized, by the appropriate target cells, which have been described. As in the case of in vivo gene therapy using a viral construct, direct injection of naked plasmid DNA offers the advantage that little or no surgical intervention is required. Direct gene therapy, using naked plasmid DNA that encodes the endothelial cell mitogen VEGF (vascular endothelial growth factor), has been successfully demonstrated in human patients. Baumgartner, et al., Circulation, 97, 12, 1114-1123 (1998).
- For intervertebral disc applications, ex vivo transfection may be accomplished by harvesting cells from an intervertebral disc, transfecting the cells with nucleic acid encoding LMP in vitro, followed by introduction of the cells into an intervertebral disc. The cells may be harvested from or introduced back into the intervertebral disc using any means known to those of skill in the art, such as, for example, any surgical techniques appropriate for use on the spine. In one embodiment, the cells are introduced into the intervertebral disc by injection.
- Also according to the invention, stem cells (e.g., pluripotential stem cells or mesenchymal stem cells) can be transfected with nucleic acid encoding a LIM Mineralization Protein ex vivo and introduced into the intervertebral disc (e.g., by injection).
- The cells transfected ex vivo can also be combined with a carrier to form an intervertebral disc implant. The carrier comprising the transfected cells can then be implanted into the intervertebral disc of a subject. Suitable carrier materials are disclosed in Helm, et al., “Bone Graft Substitutes for the Promotion of Spinal Arthrodesis”, Neurosurg Focus, Vol. 10 (4): April 2001. The carrier preferably comprises a biocompatible porous matrix such as a demineralized bone matrix (DBM), a biocompatible synthetic polymer matrix or a protein matrix. Suitable proteins include extracellular matrix proteins such as collagen. The cells transfected with the LMP ex vivo can be incorporated into the carrier (i.e., into the pores of the porous matrix) prior to implantation.
- Similarly, for intervertebral disc applications where the cells are transfected in vivo, the DNA may be introduced into the intervertebral disc using any suitable method known to those of skill in the art. In one embodiment, the nucleic acid is directly injected into the intervertebral space.
- By using an adenovirus vector to deliver LMP into osteogenic cells, transient expression of LMP is achieved. This occurs because adenovirus does not incorporate into the genome of target cells that are transfected. Transient expression of LMP, that is, expression that occurs during the lifetime of the transfected target cells, is sufficient to achieve the objects of the invention. Stable expression of LMP, however, can occur when a vector that incorporates into the genome of the target cell is used as a delivery vehicle. Nishida et al, the teaching of which is incorporated herewith in its entirety, investigated the efficacy of adenovirus-mediate gene transfer to Nucleus Pulposus cells. Neshida et al., Spine, Vol. 23(22): 2437-2442 (15 Nov. 1998).
- Nishida et al successfully demonstrate adenovirus-mediated gene transfer to the intervertebral disc with persistent expression of the marker gene for at least 12 weeks in vivo in high titters. In addition, the transfected intervertebral discs in Nishida's experiment did not exhibit typical signs of local immune activity. This result indicates that the avascular environment of intervertebral disc limits the access of immunocompetent cells, thereby preventing immune reactivity and prolonging gene expressions. Due to such results the inventors believe that Retrovirus-based vectors, are also suitable for this purpose.
- Stable expression of LMP is particularly useful for treating various systemic bone-related disorders, such as osteoporosis and osteogenesis imperfecta. For this embodiment of the invention, in addition to using a vector that integrates into the genome of the target cell to deliver an LMP-encoding nucleotide sequence into target cells, LMP expression can be placed under the control of a regulatable promoter. For example, a promoter that is turned on by exposure to an exogenous inducing agent, such as tetracycline, is suitable.
- It has been shown that uptake of charged molecules or high molecular weight peptides and proteins into live cells is hampered by the lipophilic nature of the plasma membrane. Protein engineering is currently used for the creation of new fusion proteins with desirable traits, which include penetration of exogenously added recombinant proteins into cytosolic and nuclear compartments of cells.
- Using this approach, one can stimulate formation of new bone on a systemic basis by administering an effective amount of the exogenous inducing agent. Once a sufficient quantity of bone mass is achieved, administration of the exogenous inducing agent can be discontinued. This process may be repeated as needed to replace bone mass lost, for example, as a consequence of osteoporosis. Antibodies specific for HLMP are particularly suitable for use in methods for assaying the osteoinductive, that is, bone-forming, potential of patient cells. In this way one can identify patients at risk for slow or poor healing of bone repair. Also, HLMP-specific antibodies are suitable for use in marker assays to identify risk factors in bone degenerative diseases, such as, for example, osteoporosis.
- Following well known and conventional methods, the genes of the present invention are prepared by ligation of nucleic acid segments that encode LMP to other nucleic acid sequences, such as cloning and/or expression vectors. Methods needed to construct and analyze these recombinant vectors, for example, restriction endonuclease digests, cloning protocols, mutagenesis, organic synthesis of oligonucleotides and DNA sequencing, have been described. For DNA sequencing DNA, the dioxyterminator method is the preferred.
- Many treatises on recombinant DNA methods have been published, including Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Press, (1988), Davis. et al., Basic Methods in Molecular Biology, Elsevier (1986), and Ausubel, et al., Current Protocols in Molecular Biology, Wiley Interscience (1988). These reference manuals are specifically incorporated by reference herein.
- Primer-directed amplification of DNA or cDNA is a common step in the expression of the genes of this invention. It is typically performed by the polymerase chain reaction (PCR). PCR is described in U.S. Pat. No. 4,800,159 to Mullis, et al. and other published sources. The basic principle of PCR is the exponential replication of a DNA sequence by successive cycles of primer extension. The extension products of one primer, when hybridized to another primer, becomes a template for the synthesis of another nucleic acid molecule. The primer-template complexes act as substrate for DNA polymerase, which in performing its replication function, extends the primers. The conventional enzyme for PCR applications is the thermostable DNA polymerase isolated from Thermus aquaticus, or Taq DNA polymerase.
- Numerous variations of the basic PCR method exist, and a particular procedure of choice in any given step needed to construct the recombinant vectors of this invention is readily performed by a skilled artisan. For example, to measure cellular expression of 10-4/RLMP, RNA is extracted and reverse transcribed under standard and well known procedures. The resulting cDNA is then analyzed for the appropriate mRNA sequence by PCR.
- The gene encoding the LIM mineralization protein is expressed in an expression vector in a recombinant expression system. Of course, the constructed sequence need not be the same as the original, or its complimentary sequence, but instead may be any sequence determined by the degeneracy of the DNA code that nonetheless expresses an LMP having bone forming activity. Conservative amino acid substitutions, or other modifications, such as the occurrence of an amino-terminal methionine residue, may also be employed.
- A ribosome binding site active in the host expression system of choice is ligated to the 5′ end of the chimeric LMP coding sequence, forming a synthetic gene. The synthetic gene can be inserted into any one of a large variety of vectors for expression by ligating to an appropriately linearized plasmid. A regulatable promoter, for example, the E. coli lac promoter, is also suitable for the expression of the chimeric coding sequences. Other suitable regulatable promoters include trp, tac, recA, T7 and lambda promoters.
- DNA encoding LMP is transfected into recipient cells by one of several standard published procedures, for example, calcium phosphate precipitation, DEAE-Dextran, electroporation or protoplast fusion, to form stable transformants. Calcium phosphate precipitation is preferred, particularly when performed as follows.
- DNAs are co precipitated with calcium phosphate according to the method of Graham and Van Der, Virology, 52, 456 (1973), before transfer into cells. An aliquot of 40-50 μg of DNA, with salmon sperm or calf thymus DNA as a carrier, is used for 0.5×106 cells plated on a 100 mm dish. The DNA is mixed with 0.5 ml of 2× Hepes solution (280 mM NaCl, 50 mM Hepes and 1.5 mM Na2HPO4, pH 7.0), to which an equal volume of 2×CaCl2 (250 mM CaCl2 and 10 mM Hepes, pH 7.0) is added. A white granular precipitate, appearing after 30-40 minutes, is evenly distributed dropwise on the cells, which are allowed to incubate for 4-16 hours at 37° C. The medium is removed and the cells shocked with 15% glycerol in PBS for 3 minutes. After removing the glycerol, the cells are fed with Dulbecco's Minimal Essential Medium (DMEM) containing 10% fetal bovine serum.
- DNA can also be transfected using: the DEAE-Dextran methods of Kimura, et al., Virology, 49:394 (1972) and Sompayrac et al., Proc. Natl. Acad. Sci. USA, 78, 7575 (1981); the electroporation method of Potter, Proc. Natl. Acad. Sci. USA, 81, 7161 (1984); and the protoplast fusion method of Sandri-Goddin et al., Molec. Cell. Biol., 1, 743 (1981).
- Phosphoramidite chemistry in solid phase is the preferred method for the organic synthesis of oligodeoxynucleotides and polydeoxynucleotides. In addition, many other organic synthesis methods are available. Those methods are readily adapted by those skilled in the art to the particular sequences of the invention.
- The present invention also includes nucleic acid molecules that hybridize under standard conditions to any of the nucleic acid sequences encoding the LIM mineralization proteins of the invention. “Standard hybridization conditions” will vary with the size of the probe, the background and the concentration of the nucleic acid reagents, as well as the type of hybridization, for example, in situ, Southern blot, or hybrization of DNA-RNA hybrids (Northern blot). The determination of “standard hybridization conditions” is within the level of skill in the art. For example, see U.S. Pat. No. 5,580,775 to Fremeau, et al., herein incorporated by reference for this purpose. See also, Southern, J. Mol. Biol., 98:503 (1975), Alwine, et al., Meth. Enzymol., 68:220 (1979), and Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Press, 7.19-7.50 (1989).
- One preferred set of standard hybrization conditions involves a blot that is prehybridized at 42° C. for 2 hours in 50% formamide, 5×SSPE (150 nM NaCl, 10 mM Na H2PO4 [pH 7.4], 1 mM EDTA [pH 8.0])
l 5×Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water), 10% dextran sulphate, 1% SDS and 100 μg/ml salmon sperm DNA. A 32P-labeled cDNA probe is added, and hybridization is continued for 14 hours. Afterward, the blot is washed twice with 2×SSPE, 0.1% SDS for 20 minutes at 22° C., followed by a 1 hour wash at 65° C. in 0.1×SSPE, 0.1% SDS. The blot is then dried and exposed to x-ray film for 5 days in the presence of an intensifying screen. - Under “highly stringent conditions,” a probe will hybridize to its target sequence if those two sequences are substantially identical. As in the case of standard hybridization conditions, one of skill in the art can, given the level of skill in the art and the nature of the particular experiment, determine the conditions under which only susbstantially identical sequences will hybridize.
- According to one aspect of the present invention, an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a LIM mineralization protein is provided. The nucleic acid molecule according to the invention can be a molecule which hybridizes under standard conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 25 and/or which hybridizes under highly stringent conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 26. More specifically, the isolated nucleic acid molecule according to the invention can encode HLMP-1, HLMP-1s, RLMP, HLMP-2, or HLMP-3.
- In still another embodiment, the invention relates to the identification of such proteins based on anti-LMP antibodies. In this embodiment, protein samples are prepared for Western blot analysis by lysing cells and separating the proteins by SDS-PAGE. The proteins are transferred to nitrocellulose by electrobloffing as described by Ausubel, et al., Current Protocols in Molecular Biology, John Wiley and Sons (1987). After blocking the filter with instant nonfat dry milk (1 gm in 100 ml PBS), anti-LMP antibody is added to the filter and incubated for 1 hour at room temperature. The filter is washed thoroughly with phosphate buffered saline (PBS) and incubated with horseradish peroxidase (HRPO)-antibody conjugate for 1 hour at room temperature. The filter is again washed thoroughly with PBS and the antigen bands are identified by adding diaminobenzidine (DAB).
- Monospecific antibodies are the reagent of choice in the present invention, and are specifically used to analyze patient cells for specific characteristics associated with the expression of LMP. “Monospecific antibody” as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for LMP. “Homogeneous binding” as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with LMP, as described above. Monospecific antibodies to LMP are purified from mammalian antisera containing antibodies reactive against LMP or are prepared as monoclonal antibodies reactive with LMP using the technique of Kohler and Milstein. Kohler et al., Nature, 256, 495-497 (1975). The LMP specific antibodies are raised by immunizing animals such as, for example, mice, rats, guinea pigs, rabbits, goats or horses, with an appropriate concentration of LMP either with or without an immune adjuvant.
- In this process, pre-immune serum is collected prior to the first immunization. Each animal receives between about 0.1 mg and about 1.0 mg of LMP associated with an acceptable immune adjuvant, if desired. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA adjuvants. The initial immunization consists of LMP in, preferably, Freund's complete adjuvant injected at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are generally given an equal amount of the antigen in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about −20° C.
- Monoclonal antibodies (mAb) reactive with LMP are prepared by immunizing inbred mice, preferably Balb/c mice, with LMP. The mice are immunized by the IP or SC route with about 0.1 mg to about 1.0 mg, preferably about 1.0 mg, of LMP in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on
day 0 and are rested for about 3-30 weeks. Immunized mice are given one or more booster immunizations of about 0.1 to about 10 mg of LMP in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes from antibody-positive mice, preferably splenic lymphocytes, are obtained by removing the spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1; MPC-11; S-194 andSp 2/0, withSp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1,000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin in supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on aboutdays 14, 18, and 21, and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using LMP as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, “Soft Agar Techniques Tissue Culture Methods and Applications”, Kruse and Paterson (eds.), Academic Press (1973). See, also, Harlow, et al., Antibodies: A Laboratory Manual, Cold Spring Laboratory (1988). - Monoclonal antibodies may also be produced in vivo by injection of pristane-primed Balb/c mice, approximately 0.5 ml per mouse, with about 2×106 to about 6×106 hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.
- In vitro production in anti-LMP mAb is carried out by growing the hydridoma cell line in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.
- Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays, which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of the LMP in body fluids or tissue and cell extracts.
- It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be utilized to produce antibodies specific for polypeptide fragments of LMP, full-length nascent LMP polypeptide, or variants or alleles thereof.
- In another embodiment, the invention is directed to alternative splice variants of HLMP-1. PCR analysis of human heart cDNA revealed mRNA for two HLMP alternative splice variants, named HLMP-2 and HLMP-3, that differ from HLMP-1 in a region between
base pairs 325 and 444 in the HLMP-1 sequence. The HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. These changes preserve the reading frame, resulting in a 423 amino acid protein, which compared to HLMP-1, has a net loss of 34 amino acids (40 amino acids deletedplus 6 inserted amino acids). HLMP-2 contains the c-terminal LIM domains that are present in HLMP-1. - Compared to HLMP-1, HLMP-3 has no deletions, but it does have the same 17 base pair insertion at position 444. This insertion shifts the reading frame, causing a stop codon at base pairs 459-461. As a result, HLMP-3 encodes a protein of 153 amino acids. This protein lacks the c-terminal LIM domains that are present in HLMP-1 and HLMP-2. The predicted size of the proteins encoded by HLMP-2 and HLMP-3 was confirmed by western blot analysis.
- PCR analysis of the tissue distribution of the three splice variants revealed that they are differentially expressed, with specific isoforms predominating in different tissues. HLMP-1 is apparently the predominant form expressed in leukocytes, spleen, lung, placenta, and fetal liver. HLMP-2 appears to be the predominant isoform in skeletal muscle, bone marrow, and heart tissue. HLMP-3, however, was not the predominant isoform in any tissue examined.
- Over-expression of HLMP-3 in secondary rat osteoblast cultures induced bone nodule formation (287±56) similar to the effect seen for glucicorticoid (272±7) and HLMP-1 (232±200). Since HLMP-3 lacks the C-terminal LIM domains, there regions are not required for osteoinductive activity.
- Over-expression of HLMP-2, however, did not induce nodule formation (11±3). These data suggest that the amino acids encoded by the deleted 119 base pairs are necessary for osteoinduction. The data also suggest that the distribution of HLMP splice variants may be important for tissue-specific function. Surprisingly, we have shown that HLMP-2 inhibits steroid-induced osteoblast formation in secondary rat osteoblast cultures. Therefore, HLMP-2 may have therapeutic utility in clinical situations where bone formation is not desirable.
- On Jul. 22, 1997, a sample of 10-4/RLMP in a vector designated pCMV2/RLMP (which is vector pRc/CMV2 with insert 10-4 clone/RLMP) was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852. The culture accession number for that deposit is 209153. On Mar. 19, 1998, a sample of the vector pHis-A with insert HLPM-1s was deposited at the American Type Culture Collection (“ATCC”). The culture accession number for that deposit is 209698. On Apr. 14, 2000, samples of plasmids pHAhLMP-2 (vector pHisA with cDNA insert derived from human heart muscle cDNA with HLMP-2) and pHAhLMP-3 (vector pHisA with cDNA insert derived from human heart muscle cDNA with HLMP-3) were deposited with the ATCC, 10801 University Blvd., Manassas, Va., 20110-2209, USA, under the conditions of the Budapest treaty. The accession numbers for these deposits are PTA-1698 and PTA-1699, respectively. These deposits, as required by the Budapest Treaty, will be maintained in the ATCC for at least 30 years and will be made available to the public upon the grant of a patent disclosing them. It should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by government action.
- According to another embodiment of the instant invention, inventors have enhance the bioavailability of osteogenic factors within a cell. Work by Becker-Hapak et al. has shown that the TAT protein of HIV-1 can enter a wide variety of cells efficiently when added exogenously. Becker-Hapak, M., et al. (2001) TAT-mediated protein transduction into mammalian cells. Methods. 24, 247-256. TAT protein added to medium at concentrations of 1 nM can induce biological responses in the nucleus of the target cell, although the mechanisms by which the molecule is taken up and distributed within the cell are unknown. In addition, a cellular entry was demonstrated by chemically cross-linking TAT-peptides to a number of heterologous proteins otherwise impermeable to living cells. See Fawell S, et al. (1994) TAT-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A. 91:664-668.
- Of the different peptide constructs employed, it was found that the most successful was a peptide corresponding to TAT residues 37-72 and 47-59 in HIV TAT protein. See Pepinsky R B, et al. (1994) Specific inhibition of a human papillomavirus E2 trans-activator by intracellular delivery of its repressor. DNA Cell Biol. 13:1011-1019. The ability of the TAT protein to cross the plasma membrane has since been shown to reside primarily in a highly basic region composed of the 9-amino acid residues 49-57 (RKKRRQRRR) (SEQ ID No. 87). see Vogel, B. E., et al. (1993) A novel integrin specificity exemplified by binding of the R vs
â 5 integrin to the basic domain of the HIV TAT protein and vitronectin, J. Cell Biol. 121, 461-468; and Wender, P. A. et al. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. Natl. Acad. Sci. U.S.A. 97, 13003-13008. Unlike the previously described TAT-fusion proteins reported in the art, the inventors of this invention chose regulatory factors that are known to reside in the nuclear compartment and participate in transcriptional induction of bone-specific genes. - In one embodiment of the instant invention, the inventors have developed an efficient systems for delivery of osteogenic factors into the cells. Accordingly, a purified recombinant protein cargo delivered by the TAT-peptide tag was delivered for nuclear localization in such form accessible to interaction with other nuclear proteins. In this aspect of the invention, the inventors applied techniques to deliver signaling molecules as bait to eventually identify and characterize their interacting partners to determine the mode of action of each of these factors.
- Transcription factors, in general, are expressed in response to specific extra and/or intracellular signals. These proteins are transiently expressed in low amounts in cells. For extensive studies on their interacting proteins in vitro, it is necessary to isolate them in large quantities. At least one objective of the present embodiment was to engineer, express and purify such factors in large quantities that can be used to develop further tools (antibodies, protein-interaction pull-down assays, protein delivery vehicles etc.) to facilitate our understanding of their mode of action in vivo.
- Enrichment of desired recombinant proteins based on their molecular size prior to metal-affinity chromatography greatly improved the ease and purity of recombinant proteins. Using these strategies, the inventors were the first to obtain milligram quantities of pure LMP-1, Dlx5, Runx2 and Osterix suitable for chemical labeling studies.
- Labeling of the purified fusion-proteins with FITC allowed us to monitor their entry into cells in a time and concentration dependent manner. Incubation of TAT-proteins for 30 min attained maximum cellular entry when doses of 25 nM and above were added. The inventors have also the first to demonstrate that the presence of the cationic peptide allows the TAT-tagged protein to accumulate both in the cytoplasmic and nuclear fractions in a dose dependent fashion.
- Taken collectively, this aspect of the invention provides a quick purification protocol for the purification of HIV derived TAT-domain fused signaling molecules. Accordingly, the purified proteins were able to enter cells in a time and dose-dependent manner. In a more preferred embodiment of this aspect of the invention, inventors confirmed the presence of newly accumulated TAT-protein in cytoplasmic and nuclear compartments. One of ordinary skill in the art in possession of this aspect of the invention can determine the down stream interacting proteins by pull-down assays and binding assays in vitro using conventional methods in the art.
- Another aspect of the invention includes the proteins encoded by the nucleic acid sequences. Specifically, according to this aspect of the invention, purified recombinant protein cargo of bone-specific mammalian transcription factors are prepared for delivery into the nucleus. More specifically, protein cargos comprise osteogenic proteins which are delivered by the TAT-peptide tag capable of nuclear localization.
- In another embodiment, this invention is directed to cell expression systems and methods of use thereof to meet the demands of proteomics for large scale production of LMP proteins. According to this aspect of the invention, a method is developed to remedy the main drawback of the expression of heterologous proteins in non-mammalian hosts (e.g. bacteria, yeast, baculovirus). Inventors are thus the first to introduce a method for purifying and manufacturing LMP-1 protein by identifying LMP-1 protein internal sequencing and assessing post-translational glycosylation.
- Recombinant expression of protein factors has become a powerful tool for a variety of applications ranging from basic research to human therapy. Cultured mammalian cells have become the dominant system for the production of recombinant mammalian proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification.
- However, the expression of heterologous proteins in non-mammalian hosts (e.g. bacteria, yeast, baculovirus) results in recombinant proteins that often display poor functional and structural properties due to a lack of proper folding and/or post-translational modifications. High-level mammalian recombinant protein production mostly relies on the establishment of stably expressing cell lines. Such procedures are not only labor-intensive and time consuming, but also precludes the expression of proteins whose biological activities interfere with cell growth.
- In this embodiment of the invention, the inventors show that LMP-1 protein is expressed upon plasmid-mediated transformation of mammalian cells by purifying and characterizing the identity of the protein. The inventors have purified the recombinant proteins to a suitable level of homogeneity using a novel purification and detection methods with following features: (1) size fractionation of proteins prior to metal affinity chromatography to improve efficiency of affinity resin and (2) identification of tryptic fragments of purified protein.
- The appeal of this approach is the short time span of a few days between DNA delivery and protein harvest. The improvements described in this invention are readily amenable to scale-up procedures.
- In yet another embodiment of this invention, inventors determined whether the expressed protein undergoes any post-translational modification. According to this aspect of the invention inventors assess the presence of carbohydrate on LMP-1 polypeptide in any suitable cell expression system which includes prokaryotic (e.g bacteria, blue green algae) and non-mammalian eukaryotic cells (e.g. insect cells, plant cells) as well as mammalian cells (e.g. A-549 cells). The inventions have further characterized the structural and functional role of the carbohydrate moiety in LMP-1 purified in normal human cells.
- A549 cells, derived from a human lung adenocarcinoma, are not fully representative of normal human respiratory epithelium but have been a quick and useful in vitro model for protein expression studies. Allen and White, Am. J. Physiol., 274 (Lung Cell. Mol. Physiol. 18): L159-L164, (1998). Kazzaz et al, J. Biol. Chem., 271:15182-15186 (1996). Wong et al. J. Clin. Invest., 99: 2423-2428 (1997). The A-549 cell system has all the eukaryotic protein processing capabilities. It is generally accepted that A-549 cells can fold, modify, traffic and assemble newly synthesized polypeptides to produce highly authentic, soluble end products. The present invention provides that a full length LMP-1 is indeed expressed in A549 cells and milligram quantities of protein can be obtained from mammalian cell cultures.
- According to this aspect of the invention, the inventors were able to determine that the protein did not contain carbohydrate as chemical analysis showed little or no N-acetyl glucosamine or N-acetyl galactosamine. These observations suggest to those of ordinary skill in the art that prokaryotic cell systems (e.g. bacteria) as well as non-mammalian eukaryotic cells (e.g. insect and plant cells) are suitable candidates to provide expression systems for determination of the LMP-1 mode of action and further its mass production.
- In the final aspect of this invention, compositions of matter comprising LIM mineralization protein that are substantially free of carbohydrate moieties and are manufactured in accord to the instantly described method. Such compositions can further contain physiologically acceptable carrier system for in vivo administration. In assessing the nucleic acids, proteins, or antibodies of the invention, enzyme assays, protein purification, and other conventional biochemical methods are employed. DNA and RNA are analyzed by Southern blotting and Northern blotting techniques, respectively. Typically, the samples analyzed are size fractionated by gel electrophoresis. The DNA or RNA in the gels are then transferred to nitrocellulose or nylon membranes. The blots, which are replicas of sample patterns in the gels, were then hybridized with probes. Typically, the probes are radio-labeled, preferably with 32P, although one could label the probes with other signal-generating molecules known to those in the art. Specific bands of interest can then be visualized by detection systems, such as autoradiography.
- For purposes of illustrating preferred embodiments of the present invention, the following, non-limiting examples are included. These results demonstrate the feasibility of inducing or enhancing the formation of bone using the LIM mineralization proteins of the invention, and the isolated nucleic acid molecules encoding those proteins.
- Rat calvarial cells, also known as rat osteoblasts (“ROB”), were obtained from 20-day pre-parturition rats as previously described. Boden. et al., Endocrinology, 137, 8, 3401-3407 (1996). Primary cultures were grown to confluence (7 days), trypsinized, and passed into 6-well plates (1×105 cells/35 mm well) as first subculture cells. The subculture cells, which were confluent at
day 0, were grown for an additional 7 days. Beginning onday 0, media were changed and treatments (Trm and/or BMPs) were applied, under a laminar flow hood, every 3 or 4 days. The standard culture protocol was as follows: days 1-7, MEM, 10% FBS, 50 μg/ml ascorbic acid, ±stimulus; days 8-14, BGJb medium, 10% FBS, 5 mM βGlyP (as a source of inorganic phosphate to permit mineralization). Endpoint analysis of bone nodule formation and osteocalcin secretion was performed at day 14. The dose of BMP was chosen as 50 ng/ml based on pilot experiments in this system that demonstrated a mid-range effect on the dose-response curve for all BMPs studied. - To explore the potential functional role of LMP-1 during membranous bone formation, we synthesized an antisense oligonucleotide to block LMP-1 mRNA translation and treated secondary osteoblast cultures that were undergoing differentiation initiated by glucocorticoid. Inhibition of RLMP expression was accomplished with a highly specific antisense oligonucleotide (having no significant homologies to known rat sequences) corresponding to a 25 bp sequence spanning the putative translational start site (SEQ. ID NO: 42). Control cultures either did not receive oligonucleotide or they received sense oligonucleotide. Experiments were performed in the presence (preincubation) and absence of lipofectamine. Briefly, 22 μg of sense or antisense RLMP oligonucleotide was incubated in MEM for 45 minutes at room temperature. Following that incubation, either more MEM or pre-incubated lipofectamine/MEM (7% v/v; incubated 45 minutes at room temperature) was added to achieve an oligonucleotide concentration of 0.2 μM. The resulting mixture was incubated for 15 minutes at room temperature. Oligonucleotide mixtures were then mixed with the appropriate medium, that is, MEM/Ascorbate/±Trm, to achieve a final oligonucleotide concentration of 0.1 μM.
- Cells were incubated with the appropriate medium (±stimulus) in the presence or absence of the appropriate oligonucleotides. Cultures originally incubated with lipofectamine were re-fed after 4 hours of incubation (37° C.; 5% CO2) with media containing neither lipofectamine nor oligonucleotide. All cultures, especially cultures receiving oligonucleotide, were re-fed every 24 hours to maintain oligonucleotide levels.
- LMP-1 antisense oligonucleotide inhibited mineralized nodule formation and osteocalcin secretion in a dose-dependent manner, similar to the effect of BMP-6 oligonucleotide. The LMP-1 antisense block in osteoblast differentiation could not be rescued by addition of exogenous BMP-6, while the BMP-6 antisense oligonucleotide inhibition was reversed with addition of BMP-6. This experiment further confirmed the upstream position of LMP-1 relative to BMP-6 in the osteoblast differentiation pathway. LMP-1 antisense oligonucleotide also inhibited spontaneous osteoblast differentiation in primary rat osteoblast cultures.
- Cultures of ROBs prepared according to Examples 1 and 2 were fixed overnight in 70% ethanol and stained with von Kossa silver stain. A semi-automated computerized video image analysis system was used to quantitate nodule count and nodule area in each well. Boden. et al., Endocrinology, 137, 8, 3401-3407 (1996). These values were then divided to calculate the area per nodule values. This automated process was validated against a manual counting technique and demonstrated a correlation coefficient of 0.92 (p<0.000001). All data are expressed as the mean ±standard error of the mean (S.E.M.) calculated from 5 or 6 wells at each condition. Each experiment was confirmed at least twice using cells from different calvarial preparations.
- OSTEOCALCIN LEVELS IN THE CULTURE MEDIA WERE MEASURED USING A COMPETITIVE radioimmunoassay with a monospecific polygonal antibody (Pab) raised in our laboratory against the C-terminal nonapeptide of rat osteocalcin as described in Nanes. et al., Endocrinology, 127:588 (1990). Briefly, 1 μg of nonapeptide was iodinated with 1 mCi 125I—Na by the lactoperoxidase method. Tubes containing 200 gl of assay buffer (0.02 M sodium phosphate, 1 mM EDTA, 0.001% thimerosal, 0.025% BSA) received media taken from cell cultures or osteocalcin standards (0-12,000 fmole) at 100 gl/tube in assay buffer. The Pab (1:40,000; 100 μl) was then added, followed by the iodinated peptide (12,000 cpm; 100 μl). Samples tested for non-specific binding were prepared similarly but contained no antibody.
- Bound and free PAbs were separated by the addition of 700 μl goat antirabbit IgG, followed by incubation for 18 hours at 4° C. After samples were centrifuged at 1200 rpm for 45 minutes, the supernatants were decanted and the precipitates counted in a gamma counter. Osteocalcin values were reported in fmole/100 μl, which was then converted to pmole/ml medium (3-day production) by dividing those values by 100. Values were expressed as the mean ±S.E.M. of triplicate determinations for 5-6 wells for each condition. Each experiment was confirmed at least two times using cells from different calvarial preparations.
- There was little apparent effect of either the sense or antisense oligonucleotides on the overall production of bone nodules in the non-stimulated cell culture system. When ROBs were stimulated with Trm, however, the antisense oligonucleotide to RLMP inhibited mineralization of nodules by >95%.
- The addition of exogenous BMP-6 to the oligonucleotide-treated cultures did not rescue the mineralization of RLMP-antisense-treated nodules. Osteocalcin has long been synonymous with bone mineralization, and osteocalcin levels have been correlated with nodule production and mineralization. The RLMP-antisense oligonucleotide significantly decreases osteocalcin production, but the nodule count in antisense-treated cultures does not change significantly. In this case, the addition of exogenous BMP-6 only rescued the production of osteocalcin in RLMP-antisense-treated cultures by 10-15%. This suggests that the action of RLMP is downstream of, and more specific than, BMP-6.
- Cellular RNA from duplicate wells of ROBs (prepared according to Examples 1 and 2 in 6-well culture dishes) was harvested using 4M guanidine isothiocyanate (GIT) solution to yield statistical triplicates. Briefly, culture supernatant was aspirated from the wells, which were then overlayed with 0.6 ml of GIT solution per duplicate well harvest. After adding the GIT solution, the plates were swirled for 5-10 seconds (being as consistent as possible). Samples were saved at −70° C. for up to 7 days before further processing.
- RNA was purified by a slight modification of standard methods according to Sambrook, et al. Molecular Cloning: a Laboratory Manual, Chapter 7.19, 2nd Edition, Cold Spring Harbor Press (1989). Briefly, thawed samples received 60 μl 2.0 M sodium acetate (pH 4.0), 550 μl phenol (water saturated) and 150 μl chloroform:isoamyl alcohol (49:1). After vortexing, the samples were centrifuged (10000×g; 20 minutes; 4° C.), the aqueous phase transferred to a fresh tube, 600 μl isopropanol was added and the RNA precipitated overnight at −20° C.
- Following the overnight incubation, the samples were centrifuged (10000×g; 20 minutes) and the supernatant was aspirated gently. The pellets were resuspended in 400 μl DEPC-treated water, extracted once with phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and precipitated overnight at −20° C. after addition of 40 μl sodium acetate (3.0 M; pH 5.2) and 1.0 ml absolute ethanol. To recover the cellular RNA, the samples were centrifuged (10000×g; 20 min), washed once with 70% ethanol, air dried for 5-10 minutes and resuspended in 20 μl of DEPC-treated water. RNA concentrations were calculated from optical densities that were determined with a spectrophotometer.
- Heated total RNA (5 μg in 10.5 μl total volume DEPC-H2O at 65° C. for 5 minutes) was added to tubes containing 4
μl 5×MMLV-RT buffer, 2 μl dNTPs, 2 μl dT17 primer (10 pmol/ml), 0.5 μl RNAsin (40 U/ml) and 1 μl MMLV-RT (200 units/μl). The samples were incubated at 37° C. for 1 hour, then at 95° C. for 5 minutes to inactivate the MMLV-RT. The samples were diluted by addition of 80 μl of water. - Reverse-transcribed samples (5μ) were subjected to polymerase-chain reaction using standard methodologies (50 μl total volume). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer, 25 mM MgCl2, dNTPs, forward and reverse primers for glyceraldehyde 3-phosphate dehydrogenase (GAP, a housekeeping gene) and/or BMP-6, 32P-dCTP, and Taq polymerase. Unless otherwise noted, primers were standardized to run consistently at 22 cycles (94° C., 30″; 58° C., 30″; 72° C., 20″).
- RT-PCR products received 5 μl/tube loading dye, were mixed, heated at 65° C. for 10 min and centrifuged. Ten μl of each reaction was subjected to PAGE (12% polyacrylamide:bis; 15 V/well; constant current) under standard conditions. Gels were then incubated in gel preserving buffer (10% v/v glycerol, 7% v/v acetic acid, 40% v/v methanol, 43% deionized water) for 30 minutes, dried (80° C.) in vacuo for 1-2 hours and developed with an electronically-enhanced phosphoresence imaging system for 6-24 hours. Visualized bands were analyzed. Counts per band were plotted graphically.
- RNA was extracted from cells stimulated with glucocorticoid (Trm, 1 nM). Heated, DNase-treated total RNA (5 μg in 10.5 μl total volume in DEPC-H2O at 65° C. for 5 minutes) was reverse transcribed as described in Example 7, but H-T11 M (SEQ. ID. NO: 4) was used as the MMLV-RT primer. The resulting cDNAs were PCR-amplified as described above, but with various commercial primer sets (for example, H-T11G (SEQ. ID NO: 4) and H-AP-10 (SEQ. ID NO: 5); GenHunter Corp, Nashville, Tenn.). Radio-labeled PCR products were fractionated by gel electrophoresis on a DNA sequencing gel. After electrophoresis, the resulting gels were dried in vacuo and autoradiographs were exposed overnight. Bands representing differentially-expressed cDNAs were excised from the gel and reamplified by PCR using the method of Conner. et al., Proc. Natl. Acad. Sci. USA, 88, 278 (1983). The products of PCR reamplification were cloned into the vector PCR-11 (TA cloning kit; InVitrogen, Carlsbad, Calif.).
- A UMR 106 library (2.5×1010 pfu/ml) was plated at 5×104 pfu/ml onto agar plates (LB bottom agar) and the plates were incubated overnight at 37° C. Filter membranes were overlaid onto plates for two minutes. Once removed, the filters were denatured, rinsed, dried and UV cross-linked. The filters were then incubated in pre-hybridization buffer (2×PIPES [pH 6.5], 5% formamide, 1% SDS and 100 μg/ml denatured salmon sperm DNA) for 2 h at 42°
C. A 260 base-pair radio-labeled probe (SEQ. ID NO: 3; 32P labeled by random priming) was added to the entire hybridization mix/filters, followed by hybridization for 18 hours at 42° C. The membranes were washed once at room temperature (10 min, 1×SSC, 0.1% SDS) and three times at 55° C. (15 min, 0.1×SSC, 0.1% SDS). - After they were washed, the membranes were analyzed by autoradiography as described above. Positive clones were plaque purified. The procedure was repeated with a second filter for four minutes to minimize spurious positives. Plaque-purified clones were rescued as lambda SK(−) phagemids. Cloned cDNAs were sequenced as described below.
- Cloned cDNA inserts were sequenced by standard methods. Ausubel, et al., Current Protocols in Molecular Biology, Wiley Interscience (1988). Briefly, appropriate concentrations of termination mixture, template and reaction mixture were subjected to an appropriate cycling protocol (95° C., 30 sec; 68° C., 30 sec; 72° C., 60 sec; x25). Stop mixture was added to terminate the sequencing reactions. After heating at 92° C. for 3 minutes, the samples were loaded onto a
denaturing 6% polyacrylamide sequencing gel (29:1 acrylamide:bisacrylamide). Samples were electrophoresed for about 4 hours at 60 volts, constant current. After electrophoresis, the gels were dried in vacuo and autoradiographed. - The autoradiographs were analyzed manually. The resulting sequences were screened against the databases maintained by the National Center for Biotechnology Information (NIH, Bethesda, Md.; hftp://www.ncbi.nlm.nih.gov-/) using the BLASTN program set with default parameters. Based on the sequence data, new sequencing primers were prepared and the process was repeated until the entire gene had been sequenced. All sequences were confirmed a minimum of three times in both orientations.
- Nucleotide and amino acid sequences were also analyzed using the PCGENE software package (version 16.0). Percent homology values for nucleotide sequences were calculated by the program NALIGN, using the following parameters: weight of non-matching nucleotides, 10; weight of non-matching gaps, 10; maximum number of nucleotides considered, 50; and minimum number of nucleotides considered, 50.
- For amino acid sequences, percent homology values were calculated using PALIGN. A value of 10 was selected for both the open gap cost and the unit gap cost.
- The differential display PCR amplification products described in Example 9 contained a major band of approximately 260 base pairs. This sequence was used to screen a rat osteosarcoma (UMR 106) cDNA library. Positive clones were subjected to nested primer analysis to obtain the primer sequences necessary for amplifying the full length cDNA. (SEQ. ID NOs: 11, 12, 29, 30 and 31). One of those positive clones selected for further study was designated clone 10-4.
- Sequence analysis of the full-length cDNA in clone 10-4, determined by nested primer analysis, showed that clone 10-4 contained the original 260 base-pair fragment identified by differential display PCR.
- Clone 10-4 (1696 base pairs; SEQ ID NO: 2) contains an open reading frame of 1371 base pairs encoding a protein having 457 amino acids (SEQ. ID NO: 1). The termination codon, TGA, occurs at nucleotides 1444-1446. The polyadenylation signal at nucleotides 1675-1680, and adjacent poly(A)+ tail, was present in the 3′ noncoding region. There were two potential N-glycosylation sites, Asn-Lys-Thr and Asn-Arg-Thr, at amino acid positions 113-116 and 257-259 in SEQ. ID NO: 1, respectively. Two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites, Ser and Thr, were found at amino acid positions 191 and 349, respectively. There were five potential protein kinase C phosphorylation sites, Ser or Thr, at
amino acid positions 3, 115, 166, 219, 442. One potential ATP/GTP binding site motif A (P-loop), Gly-Gly-Ser-Asn-Asn-Gly-Lys-Thr, was determined at amino acid positions 272-279 of SEQ ID NO: 1. - In addition, two highly conserved putative LIM domains were found at amino acid positions 341-391 and 400-451. The putative LIM domains in this newly identified rat cDNA clone showed considerable homology with the LIM domains of other known LIM proteins. However, the overall homology with other rat LIM proteins was less than 25%. RLMP (also designated 10-4) has 78.5% amino acid homology to the human enigma protein (see U.S. Pat. No. 5,504,192), but only 24.5% and 22.7% amino acid homology to its closest rat homologs, CLP-36 and RIT-18, respectively.
- Thirty μg of total RNA from ROBs, prepared according to Examples 1 and 2, was size fractionated by formaldehyde gel electrophoresis in 1% agarose flatbed gels and osmotically transblotted to nylon membranes. The blot was probed with a 600 base pair EcoRI fragment of full-length 10-4 cDNA labeled with 32P-dCTP by random priming.
- Northern blot analysis showed a 1.7 kb mRNA species that hybridized with the RLMP probe. RLMP mRNA was up-regulated approximately 3.7-fold in ROBs after 24 hours exposure to BMP-6. No up-regulation of RMLP expression was seen in BMP-2 or BMP-4-stimulated ROBs at 24 hours.
- For each reported nodule/osteocalcin result, data from 5-6 wells from a representative experiment were used to calculate the mean. +−.S.E.M. Graphs may be shown with data normalized to the maximum value for each parameter to allow simultaneous graphing of nodule counts, mineralized areas and osteocalcin.
- For each reported RT-PCR, RNase protection assay or Western blot analysis, data from triplicate samples of representative experiments, were used to determine the mean. +−.S.E.M. Graphs may be shown normalized to either
day 0 or negative controls and expressed as fold-increase above control values. - Statistical significance was evaluated using a one-way analysis of variance with post-hoc multiple comparison corrections of Bonferroni as appropriate. D. V. Huntsberger, “The Analysis of Variance”, Elements of Statistical Variance, P. Billingsley (ed.), Allyn & Bacon Inc., Boston, Mass., 298-330 (1977) and SigmaStat, Jandel Scientific, Corte Madera, Calif. Alpha levels for significance were defined as p<0.05.
- Polyclonal antibodies were prepared according to the methods of England, et al., Biochem. Biophys. Acta, 623, 171 (1980) and Timmer, et al., J. Biol. Chem., 268, 24863 (1993).
- HeLa cells were transfected with pCMV2/RLMP. Protein was harvested from the transfected cells according to the method of Hair, et al., Leukemia Research, 20, 1 (1996). Western Blot Analysis of native RLMP was performed as described by Towbin, et al., Proc. Natl. Acad. Sci. USA, 76:4350 (1979).
- Based on the sequence of the rat LMP-1 cDNA, forward and reverse PCR primers (SEQ. ID NOS: 15 and 16) were synthesized and a unique 223 base-pair sequence was PCR amplified from the rat LMP-1 cDNA. A similar PCR product was isolated from human MG63 osteosarcoma cell cDNA with the same PCR primers.
- RNA was harvested from MG63 osteosarcoma cells grown in T-75 flasks. Culture supernatant was removed by aspiration and the flasks were overlayed with 3.0 ml of GIT solution per duplicate, swirled for 5-10 seconds, and the resulting solution was transferred to 1.5 ml eppendorf tubes (6 tubes with 0.6 ml/tube). RNA was purified by a slight modification of standard methods, for example, see Sambrook, et al., Molecular Cloning: A Laboratory Manual,
Chapter 7, page 19, Cold Spring Harbor Laboratory Press (1989) and Boden, et al., Endocrinology, 138, 2820-2828 (1997). Briefly, the 0.6 ml samples received 60 μl 2.0 M sodium acetate (pH 4.0), 550 μl water saturated phenol and 150 μl chloroform:isoamyl alcohol (49:1). After addition of those reagents, the samples were vortexed, centrifuged (10000×g; 20 min; 4 C) and the aqueous phase transferred to a fresh tube. Isopropanol (600, μl) was added and the RNA was precipitated overnight at −20° C. The samples were centrifuged (10000×g; 20 minutes) and the supernatant was aspirated gently. The pellets were resuspended in 400 μl of DEPC-treated water, extracted once with phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and precipitated overnight at −20° C. in 40 μl sodium acetate (3.0 M; pH 5.2) and 1.0 ml absolute ethanol. After precipitation, the samples were centrifuged (10000×g; 20 min), washed once with 70% ethanol, air dried for 5-10 minutes and resuspended in 20 μl of DEPC-treated water. RNA concentrations were derived from optical densities. - Total RNA (5 μg in 10.5 μl total volume in DEPC-H2O) was heated at 65° C. for 5 minutes, and then added to tubes containing 4
μl 5×MMLV-RT buffer, 2 μl dNTPS, 2 μl dT17 primer (10 μmol/ml), 0.5 μl RNA sin (40 U/ml) and 1 μl MMLV-RT (200 units/μl). The reactions were incubated at 37° C. for 1 hour. Afterward, the MMLV-RT was inactivated by heating at 95° C. for 5 minutes. The samples were diluted by addition of 80 μl water. - Transcribed samples (5 μl) were subjected to polymerase-chain reaction using standard methodologies (50 μl total volume). Boden, et al., Endocrinology, 138, 2820-2828 (1997); Ausubel, et al., “Quantitation of Rare DNAs by the Polymerase Chain Reaction”, Current Protocols in Molecular Biology, Chapter 15.31-1, Wiley & Sons, Trenton, N.J. (1990). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer (25 mM MgCl2, dNTPs, forward and reverse primers (for RLMPU; SEQ. ID NOS: 15 and 16), 32P-dCTP, and DNA polymerase. Primers were designed to run consistently at 22 cycles for radioactive band detection and 33 cycles for amplification of PCR product for use as a screening probe (94° C., 30 sec, 58° C., 30 sec; 72° C., 20 sec).
- Sequencing of the agarose gel-purified MG63 osteosarcoma-derived PCR product gave a sequence more than 95% homologous to the RLMPU PCR product. That sequence is designated HLMP unique region (HLMPU; SEQ. ID NO: 6).
- Screening was performed with PCR using specific primers (SEQ. ID NOS:16 and 17) as described in Example 7. A 717 base-pair MG63 PCR product was agarose gel purified and sequenced with the given primers (SEQ. ID NOs: 12, 15, 16, 17, 18, 27 and 28). Sequences were confirmed a minimum of two times in both directions. The MG63 sequences were aligned against each other and then against the full-length rat LMP cDNA sequence to obtain a partial human LMP cDNA sequence (SEQ. ID NO: 7).
- Based on Northern blot experiments, it was determined that LMP-1 is expressed at different levels by several different tissues, including human heart muscle. A human heart cDNA library was therefore examined. The library was plated at 5×104 pfu/ml onto agar plates (LB bottom agar) and plates were grown overnight at 37° C. Filter membranes were overlaid onto the plates for two minutes. Afterward, the filters were denatured, rinsed, dried, UV cross-linked and incubated in pre-hybridization buffer (2×PIPES [pH 6.5]; 5% formamide, 1% SDS, 100 g/ml denatured salmon sperm DNA) for 2 h at 42° C. A radio-labeled, LMP-unique, 223 base-pair probe (32P, random primer labeling; SEQ ID NO: 6) was added and hybridized for 18 h at 42° C. Following hybridization, the membranes were washed once at room temperature (10 min, 1×SSC, 0.1% SDS) and three times at 55° C. (15 min, 0.1×SSC, 0.1% SDS). Double-positive plaque-purified heart library clones, identified by autoradiography, were rescued as lambda phagemids according to the manufacturers' protocols (Stratagene, La Jolla, Calif.).
- Restriction digests of positive clones yielded cDNA inserts of varying sizes. Inserts greater than 600 base-pairs in length were selected for initial screening by sequencing. Those inserts were sequenced by standard methods as described in Example 11.
- One clone,
number 7, was also subjected to automated sequence analysis using primers corresponding to SEQ. ID NOS: 11-14, 16 and 27. The sequences obtained by these methods were routinely 97-100% homologous. Clone 7 (Partial Human LMP-1 cDNA from a heart library; SEQ. ID NO: 8) contained a sequence that was more than 87% homologous to the rat LMP cDNA sequence in the translated region. - Overlapping regions of the MG63 human osteosarcoma cell cDNA sequence and the human
heart cDNA clone 7 sequence were used to align those two sequences and derive a complete human cDNA sequence of 1644 base-pairs. NALIGN, a program in the PCGENE software package, was used to align the two sequences. The overlapping regions of the two sequences constituted approximately 360 base-pairs having complete homology except for a single nucleotide substitution at nucleotide 672 in the MG63 cDNA (SEQ. ID NO: 7) withclone 7 having an “A” instead of a “G” at the corresponding nucleotide 516 (SEQ. ID NO: 8). - The two aligned sequences were joined using SEQIN, another subprogram of PCGENE, using the “G” substitution of the MG63 osteosarcoma cDNA clone. The resulting sequence is shown in SEQ. ID NO: 9. Alignment of the novel human-derived sequence with the rat LMP-1 cDNA was accomplished with NALIGN. The full-length human LMP-1 cDNA sequence (SEQ. ID NO: 9) is 87.3% homologous to the translated portion of rat LMP-1 cDNA sequence.
- The putative amino acid sequence of human LMP-1 was determined with the PCGENE subprogram TRANSL. The open reading frame in SEQ. ID NO: 9 encodes a protein comprising 457 amino acids (SEQ. ID NO: 10). Using the PCGENE subprogram PALIGN, the human LMP-1 amino acid sequence was found to be 94.1% homologous to the rat LMP-1 amino acid sequence.
-
MG63 5′ cDNA was amplified by nested RT-PCR of MG63 total RNA using a 5′ rapid amplification of cDNA ends (5′ RACE) protocol. This method included first strand cDNA synthesis using a lock-docking oligo (dT) primer with two degenerate nucleotide positions at the 3′ end (Chenchik. et al., CLONTECHniques, X:5 (1995); Borson, et al., PC Methods Applic., 2, 144 (1993)). Second-strand synthesis is performed according to the method of Gubler, et al., Gene, 2, 263 (1983), with a cocktail of Escherichiacoli DNA polymerase 1, RNase H, and E. coli DNA ligase. After creation of blunt ends with T4 DNA polymerase, double-stranded cDNA was ligated to the fragment (5′-CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGT-3′) (SEQ. ID NO: 19). Prior to RACE, the adaptor-ligated cDNA was diluted to a concentration suitable for Marathon RACE reactions (1:50). Adaptor-ligated double-stranded cDNA was then ready to be specifically cloned. - First-round PCR was performed with the adaptor-specific oligonucleotide, 5′-CCATCCTAATACGACTCACTATAGGGC-3′ (AP1) (SEQ. ID NO: 20) as sense primer and a Gene Specific Primer (GSP) from the unique region described in Example 16 (HLMPU). The second round of PCR was performed using a nested primers GSP1-HLMPU (antisense/reverse primer) (SEQ. ID NO: 23) and GSP2-HLMPUF (SEQ. ID NO: 24) (see Example 16; sense/forward primer). PCR was performed using a commercial kit (Advantage cDNA PCR core kit; CloneTech Laboratories Inc., Palo Alto, Calif.) that utilizes an antibody-mediated, but otherwise standard, hot-start protocol. PCR conditions for MG63 cDNA included an initial hot-start denaturation (94° C., 60 sec) followed by: 94° C., 30 sec; 60° C., 30 sec; 68° C., 4 min; 30 cycles. The firstround PCR product was approximately 750 base-pairs in length whereas the nested PCR product was approximately 230 base-pairs. The first-round PCR product was cloned into linearized pCR 2.1 vector (3.9 Kb). The inserts were sequenced in both directions using M13 Forward and Reverse primers (SEQ. ID NO: 11; SEQ. ID NO: 12).
- Overlapping MG63 human
osteosarcoma cell cDNA 5′-UTR sequence (SEQ. ID NO: 21), MG63 717 base-pair sequence (Example 17; SEQ. ID NO: 8) and humanheart cDNA clone 7 sequence (Example 18) were aligned to derive a novel human cDNA sequence of 1704 base-pairs (SEQ. ID NO: 22). The alignment was accomplished with NALIGN, (both PCGENE and Omiga 1.0; Intelligenetics). Over-lapping sequences constituted nearly the entire 717 base-pair region (Example 17) with 100% homology. Joining of the aligned sequences was accomplished with SEQIN. - The construction of pHIS-5ATG LMP-1s expression vector was carried out with the sequences described in Examples 17 and 18. The 717 base-pair clone (Example 17; SEQ. ID NO: 7) was digested with ClaI and EcoRV. A small fragment (˜250 base-pairs) was gel purified. Clone 7 (Example 18; SEQ. ID NO: 8) was digested with ClaI and XbaI and a 1400 base-pair fragment was gel purified. The isolated 250 base-pair and 1400 base-pair restriction fragments were ligated to form a fragment of ˜1650 base-pairs.
- Due to the single nucleotide substitution in Clone 7 (relative to the 717 base-pair PCR sequence and the original rat sequence) a stop codon at translated base-pair 672 resulted. Because of this stop codon, a truncated (short) protein was encoded, hence the name LMP-1s. This was the construct used in the expression vector (SEQ. ID NO: 32). The full length cDNA sequence with 5′ UTR (SEQ. ID NO: 33) was created by alignment of SEQ. ID NO: 32 with the 5′ RACE sequence (SEQ. ID NO: 21). The amino acid sequence of LMP-1s (SEQ. ID NO: 34) was then deduced as a 223 amino acid protein and confirmed by Western blot (as in Example 15) to run at the predicted molecular weight of ˜23.7 kD.
- The pHis-ATG vector (InVitrogen, Carlsbad, Calif.) was digested with EcoRV and XbaI. The vector was recovered and the 650 base-pair restriction fragment was then ligated into the linearized pHis-ATG. The ligated product was cloned and amplified. The pHis-ATG-LMP-1s Expression vector, also designated pHIS-A with insert HLMP-1s, was purified by standard methods.
- Rat Calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with glucocorticoid (GC) as described in Example 1. A modification of the Superfect Reagent (Qiagen, Valencia, Calif.) transfection protocol was used to transfect 3 μg/well of each vector into secondary rat calvarial osteoblast cultures according to Example 25. Mineralized nodules were visualized by Von Kossa staining, as described in Example 3.
- Human LMP-1s gene product over expression alone induced bone nodule formation (203 nodules/well) in vitro. Levels of nodules were approximately 50% of those induced by the GC positive control (412 nodules/well). Other positive controls included the pHisA-LMP-Rat expression vector (˜152 nodules/well) and the pCMV2/LMP-Rat-Fwd Expression vector (˜206 nodules/well), whereas the negative controls included the pCMV2/LMP-Rat-Rev. expression vector (˜2 nodules/well) and untreated (NT) plates (˜4 nodules/well). These data demonstrate that the human cDNA was at least as osteoinductive as the rat cDNA. The effect was less than that observed with GC stimulation, most likely due to sub-optimal doses of Expression vector.
- The rat LMP cDNA in clone 10-4 (see Example 12) was excised from the vector by double-digesting the clone with NotI and ApaI overnight at 37° C. Vector pCMV2 MCS (InVitrogen, Carlsbad, Calif.) was digested with the same restriction enzymes. Both the linear cDNA fragment from clone 10-4 and pCMV2 were gel purified, extracted and ligated with T4 ligase. The ligated DNA was gel purified, extracted and used to transform E. coli JM109 cells for amplification. Positive agar colonies were picked, digested with NotI and ApaI and the restriction digests were examined by gel electrophoresis. Stock cultures were prepared of positive clones.
- A reverse vector was prepared in analogous fashion except that the restriction enzymes used were XbaI and HindIII. Because these restriction enzymes were used, the LMP cDNA fragment from clone 10-4 was inserted into pRc/CMV2 in the reverse (that is, non-translatable) orientation. The recombinant vector produced is designated pCMV2/RLMP.
- An appropriate volume of pCMV10-4 (60 nM final concentration is optimal [3 μg]; for this experiment a range of 0-600 nM/well [0-30 μg/well] final concentration is preferred) was resuspended in Minimal Eagle Media (MEM) to 450 μl final volume and vortexed for 10 seconds. Superfect was added (7.5 μl/ml final solution), the solution was vortexed for 10 seconds and then incubated at room temperature for 10 minutes. Following this incubation, MEM supplemented with 10% FBS (1 ml/well; 6 ml/plate) was added and mixed by pipetting.
- The resulting solution was then promptly pipetted (1 ml/well) onto washed ROB cultures. The cultures were incubated for 2 hours at 37° C. in a humidified atmosphere containing 5% CO2. Afterward, the cells were gently washed once with sterile PBS and the appropriate normal incubation medium was added.
- Results demonstrated significant bone nodule formation in all rat cell cultures which were induced with pCMV10-4. For example, pCMV10-4 transfected cells produced 429 nodules/well. Positive control cultures, which were exposed to Trm, produced 460 nodules/well. In contrast, negative controls, which received no treatment, produced 1 nodule/well. Similarly, when cultures were transfected with pCMV10-4 (reverse), no nodules were observed.
- For demonstrating de novo bone formation in vivo, marrow was aspirated from the hind limbs of 4-5 week old normal rats (μ/+; heterozygous for recessive athymic condition). The aspirated marrow cells were washed in alpha MEM, centrifuged, and RBCs were lysed by resuspending the pellet in 0.83% NH4Cl in 10 mM Tris (pH 7.4). The remaining marrow cells were washed 3× with MEM and transfected for 2 hours with 9 μg of pCMV-LMP-1s (forward or reverse orientation) per 3×106 cells. The transfected cells were then washed 2× with MEM and resuspended at a concentration of 3×107 cells/ml.
- The cell suspension (100 μl) was applied via sterile pipette to a sterile 2×5 mm type I bovine collagen disc (Sulzer Orthopaedics, Wheat Ridge, Colo.). The discs were surgically implanted subcutaneously on the skull, chest, abdomen or dorsal spine of 4-5 week old athymic rats (rnu/rnu). The animals were sacrificed at 3-4 weeks, at which time the discs or surgical areas were excised and fixed in 70% ethanol. The fixed specimens were analyzed by radiography and undecalcified histologic examination was performed on 5 μm thick sections stained with Goldner Trichrome. Experiments were also performed using devitalized (guanidine extracted) demineralized bone matrix (Osteotech, Shrewsbury, N.J.) in place of collagen discs.
- Radiography revealed a high level of mineralized bone formation that conformed to the form of the original collagen disc containing LMP-1s transfected marrow cells. No mineralized bone formation was observed in the negative control (cells transfected with a reverse-oriented version of the LMP-1s cDNA that did not code for a translated protein), and absorption of the carrier appeared to be well underway.
- Histology revealed new bone trabeculae lined with osteoblasts in the LMP-1s transfected implants. No bone was seen along with partial resorption of the carrier in the negative controls.
- Radiography of a further experiment in which 18 sets (9 negative control pCMV-LMP-REV & 0.9 experimental pCMV-LMP-1s) of implants were added to sites alternating between lumbar and thoracic spine in athymic rats demonstrated 0/9 negative control implants exhibiting bone formation (spine fusion) between vertebrae. All nine of the pCMV-LMP-1s treated implants exhibited solid bone fusions between vertebrae.
- The restriction and modifying enzymes in examples 26-38 were purchased from Promega (Madison, Wis.) and the bacterial host strain, BL21 (DE3) was from Stratagene (La Jolla, Calif.). The TAT-vector was a generous gift from Steven F Dowdy (Howard Hughes Medical Institute, St. Louis, Mo.). The chelating affinity resin (Probond) was purchased from Invitrogen (San Diego, Calif.). The Sephacryl S-100 (HiPrep 16×60) and other chromatographic columns and AKTA FPLC system were from Amersham-Pharmacia Biotech (Piscataway, N.J.). Fluorescent tag, fluorescein isothiocyanate (FITC) was from Pierce (Rockford, Ill.). All other chemicals and reagents, unless otherwise noted, were from Sigma (St. Louis, Mo.) (analytical grade).
- Escherichia coli BL21 (DE3) host cells were maintained on LB agar plates and grown at 37° C. in the presence of ampicillin at 100 mg/mL. The strains were stored in LB medium containing 15% glycerol at −80° C. All cloning methods including PCR, restriction digestion, ligations, E. coli transformation and plasmid DNA preparation were performed according to standard protocols.
- For human LMP-1 the Polymerase chain reaction (PCR) was performed with forward primer: 5′-CCATGGATTCCTTCAAAGTAGTGC-3′ (SEQ ID NO: 75), reverse primer: 5′-CAGGGCGGGCGGCTGGTAG-3′ (SEQ ID NO: 76) using the template cDNA plasmid under the conditions: 95° C. 2 min, (95° C. 30 Sec, 66° C. 30 Sec, 72° C. 1 min)×25, 72° C. 10 min. The PCR product was cloned into the PCRII-TOPO vector (Invitrogen) and the sequence was verified by sequencing both the complimentary strands. The desired clone was digested with Ncol and Clal. The insert was gel-purified (Fragment A). The pcDNA3.1/hLMP-1 clone was digested with Clal and EcoRI and the inserts were gel purified (Fragment B). Similarly, PTAT-HA vector was digested with Ncol and EcoRI and the vector was gel purified (Fragment C). The fragments, A, B, and C were ligated to obtain the desired construct (
FIG. 18 ). BL21 (DE3) competent cells were transformed with plasmid by standard methods (Novagen) and the correct clones were selected by restriction analysis followed by DNA sequencing. - For mouse Dlx5 the PCR was performed with forward primer: 5′-CCATGGCAGGAGTGTTTGACAGAAGAGT-3′ (SEQ ID NO: 77)
- and reverse primer:
-
5′-TAATAAAGCGTCCCGGAGGCC-3′ (SEQ ID NO: 78) - using the template cDNA plasmid under the conditions: 95° C. for 1 min (94° C. 30 sec, 66° C. 30 sec, 72° C. for 2 min)×35 cycles, 72° C. 10 min. The PCR product was then cloned into PCR 2.1 vector (invitrogen) and the insert sequence was verified by sequencing. The desired clone was digested with NcoI and XhoI, and the insert was recovered from gel (Fragment A). Similarly the PTAT-HA vector was digested with NcoI and XhoI, and the vector was recovered (Fragment B). Ligation of fragment A and B yielded the desired construct. BL21 (DE3) competent cells were transformed with plasmid by standard methods (Novagen) and the correct clones were selected by restriction analysis followed by DNA sequencing.
- Two oligonucleotide primers (SEQ ID NOS 79-80) (Runx2-forward primer: 5′-catggcgtcaaacagcctcttcagcgcagtgacaccgtgtcagcaaagcttcttttgg-3′ Runx2-reverse primer: 5′ gatcccaaaagaagctttgctgacacggtgtcactgcgctgaagaggctgtttgacgc-3′) corresponding to the 5′ sequence of mouse Runx2 cDNA were designed and annealed together with a NcoI site at the ATG translation start site and a BamH1 site at the 3′ end matching that site in the Runx2 cDNA sequence (Fragment A). The pAV-CMV-CBFAIII-iresGFP clone (Dr. Mirek Kozlowski, Emory University) was digested with BamHI and EcoRV and the insert was recovered (Fragment B).
- TAT-HA vector was digested with XhoI, followed by treatment with T4 DNA Polymerase to create a blunt end. The vector was then digested again with NcoI to recover the fragment for ligations (Fragment C). Ligation of fragments A, B and C yielded the desired construct. BL21 (DE3) competent cells were transformed with plasmid by standard methods (Novagen) and the correct clones were selected by restriction analysis followed by DNA sequencing.
- Two oligonucleotide primers (SEQ ID NOS 81-82) (Osx-forward primer: 5′-catggcgtcctctctgcttgaggaagaagctcactatggctccagtcccctggccatgctgact gcagccg-3′
- Osx-reverse primer: 5′-gatccggctgcagtcagcatggccaggggactggagccatagtgagcttcttcctcaagcagag aggacgc-3′
- corresponding to the 5′sequence of mouse Osterix cDNA (which was absent in the pcDNA5UTFlag Osx clone) were designed and annealed together with a NcoI site at the ATG translation start site and a BamHI site at the 3′ end, which matched that site in the osterix cDNA clone (Fragment A). The pcDNA5UTFlagOsx clone was digested with BamHI and HindIII, and the insert was recovered (Fragment B). The TAT-HA vector was digested with XhoI, followed by treatment with T4 DNA Polymerase to create a blunt end. The vector was then digested again with NcoI to recover the vector (Fragment C). Ligation of fragment A, B and C yielded the desired construct. BL21 (DE3) competent cells were transformed with plasmid by standard methods (Novagen) and the correct clones were selected by restriction analysis followed by DNA sequencing.
- A single colony of BL21 (DE3) host grown on LB plate (100 ug/ml ampicillin) was inoculated into 10 ml LB broth containing 100 mg/mL Amp and incubated at 37° C. on a rotary shaker shaking at 250 RPM overnight. The culture was used to inoculate 2×500 ml LB broth containing 100 ug/ml Amp in a 2-liter flask (two) and grown at 37° C. until O.D600 reached 0.80. Isopentenyl thiogalactoside (IPTG) was added to 200 uM and the culture continued to grow for another 6 hrs at 37° C. Cells were harvested in 250-ml centrifuge tubes, spun at 3000×g at 4° C. (
Beckman Rotor # 10, 6500 RPM) for 15 min and the pellets were store at −70° C. - Size-exclusion chromatography of the proteins was carried out on a Sephacryl S-100 column connected to the AKTA FPLC System (Amersham Biosciences, Piscataway, N.J.). The column was pre-calibrated with known low- and high-molecular weight protein markers from gel filtration calibration kits (Amersham Biosciences, Piscataway, N.J.) in 50 mM sodium phosphate, 150 mM NaCl, pH 7.0 buffer. The marker proteins were thyroglobulin {molecular weight (Mw) 669 kDa}, ferritin (Mw 440 kDa), catalase (Mw 232 kDa), aldolase (Mw 158 kDa), albumin (Mw 67 kDa), ovalbumin (Mw 43 kDa), chymotrypsinogen A (
Mw 25 kDa), and ribonuclease A (Mw 13.7 kDa). - Bacterial pellets were suspended in 100 ml of ice-cold lysis buffer (20 mM phosphate buffer, pH 7.0 containing 50 mM Tris-HCl, pH 7.5 and 5 M NaCl). The uniform cell suspension was sonicated (Sonicator, Model W-385, Heat systems-Ultrasonics, Inc.) 4×15 sec bursts at minimum power-out put settings in ice with 2 min interval between each burst. The lysate was centrifuged at 10,000 g (
Beckman # 17 Rotor, 13,000 RPM) at 4° C. and the supernatant was applied onto a Sephacryl S-100 column (HiPrep 16×60) using AKTA FPLC system with Unicorn 3.1 software (Amersham Pharmacia Biotech) at a flow rate of 1 ml/min. Fractions (2-4 ml) were collected immediately after the void volume (V0) (35 ml). Aliquots from each fraction were assayed by slot blotting, SDS-PAGE and western blotting. The strategy for employing slot blotting was to detect the desired fractions quickly (in less than 6 hrs) on large number of fractions so that any protein degradation is minimized by reducing the processing time. Once the positive fractions were identified by slot blots, we employed western blotting to confirm the molecular size of the desired protein. - The fractions from molecular exclusion chromatography, identified by western blots were pooled, dialyzed against 20 mM phosphate buffer, pH 7.5 containing Urea (8 M), NaCl (50 mM) and imidazole (20 mM) for metal-ion affinity selection. The dialyzed protein sample was applied to a 10 ml-Ni++-nitrilotriacetic acid (NTA) agarose affinity resin (Probond, Invitrogen) previously equilibrated with 4×10 ml of buffer. Non-specific and low-affinity bound proteins were removed from the column with 3×10 ml of 20 mM phosphate buffer, pH 6.0 containing urea (8 M), NaCl (50 mM) and imidazole (20 mM). Affinity-bound proteins were eluted using 3×10
ml 20 mM phosphate buffer, pH 4.0 containing urea (8 M), NaCl (50 mM). The eluates were combined and concentrated using acentriprep YM 50 ultrafiltration device by spinning at 2000×g. Flow-thru, washes, and eluate were concentrated using a centriprep and analyzed by SDSPAGE and western blotting using rabbit polyclonal antibodies specific to the hemagglutinin fusion-tag. - Fractions containing desired proteins were pooled (based on western blot) and then concentrated, de-salted and buffer-exchanged using the centriprep devices (Amicon). Protein samples were stored at −70° C. Fractions containing unwanted contaminant proteins were discarded. Protein quantitation was performed with protein assay reagent (BioRad) using BSA as the standard. The yield of recombinant protein was routinely about 0.5 to 1 mg of pure protein from every 2-liter culture.
- Labeling of purified proteins was performed following the standard protocol. Staros, J. V. (1988). Membrane-impermeant crosslinking reagents. Probes of the structure and dynamics of membrane proteins. Acc. Chem. Res. 21:435-441. Briefly, fluorescein isothiocyanate (FITC) was prepared fresh (1 mg/ml) in conjugation buffer (50 mM borate buffer, pH 8.0 containing 0.5 N NaCl). 20 ul of FITC solution was mixed with 100 ul of purified recombinant protein (0.1 mg/100 ul of conjugation buffer) and incubated for 1 h at 37° C. in the dark. Excess or hydrolyzed FITC was removed by gel filtration in a 5-ml desalting column. Labeled protein was buffer exchanged and/or concentrated to the original volume using a centricon device.
- Rabbit peripheral blood (3 ml) was obtained by venipuncture and the buffy coat cells were isolated by centrifugation at 1200×g for 10 min. Minamide A, Boden S D, et al. (2003) Mechanism of bone formation with gene transfer of the cDNA encoding for the intracellular protein LMP-1. J Bone & Joint Surg Am. 85A:1030-1039. Buffy coat cells were counted and 1 million cells were incubated with various concentrations of TAT-fusion proteins. Various concentrations (1.0, 2.5, 5.0, 10.0, and 25.0 nM) of the FITC labeled proteins were incubated for 15, 30 and 60 minutes with 1 million rabbit buffy coat cells. After the incubation, the cells were trypsinized and washed one time with PBS and resuspended in 500 ul of PBS. The percentage of the total cells labeled with FITC-specific fluorescence was determined by Flow Cytometry (Becton Dickinson, Franklin, N.J.).
- MSCs at
passage 2 were purchased from Cambrex Bio Sciences. Cells were grown at 37° C. in 5% CO2 in MSC basal medium supplemented with Singlequots (Cambrex Bio Sciences), split at confluence, and plated at 3×104 cells/well in 6-well dishes atpassage 4 in these studies. The next day treatments were applied in the presence of 50 uM L-Ascorbic Acid 2-Phosphate and 5 mM β-glycerol phosphate (Sigma-Aldrich). - Preparation of Nuclear and Cytoplasmic Protein Fractions.
- Cell pellets were suspended in buffer A (20 mM HEPES, pH 7.9, 10 mM KCl, 1 mM EGTA, 1 mM EDTA, 0.2% Nonidet P-40, 10% Glycerol, 1 mM PMSF and 1 ug/ml protease inhibitor mix (Sigma)), incubated on ice for 10 min, and centrifuged. Supernatants (cytoplasmic fraction) were collected. Nuclear pellets were suspended in high salt buffer B (buffer A plus 600 mM KCl, 20% glycerol), incubated on ice for 30 min and centrifuged. Supernatants were collected as the nuclear fraction. Samples were aliquoted, the protein concentration determined, and stored at −70° C. until further use.
- SDS-PAGE was performed using 10% gels and transferred to nitrocellulose membrane. The membrane was blocked with milk protein, incubated with specific antibody, washed with Tris Buffered Saline containing 0.1% Tween 20 (TBST), incubated with anti-rabbit goat IgG-linked to horseradish peroxidase (NEN), and again washed with TBST. Chemi-luminescent substrates were applied to the membrane and the signal was detected by exposing the membrane to X-ray film for 30 sec.
- Nuclear proteins were prepared from mesenchymal stem cells as described above. TAT-LMP-1 (50 ug) was incubated for 1 hr at 4° C. with the nuclear proteins (500 ug) with gentle mixing in PBS containing 0.1 M NaCl and 50 mM imidazole. Ni++-NTA-affinity beads (Probond, Invitrogen) (a 50 ul of 1:1 slurry in PBS) were added and the mixture was incubated for another 30 min. Non-specific proteins were removed by washing three times with 500 ul of PBS containing 0.1 M NaCl and 50 mM imidazole. Affinity bound proteins were eluted with 250 mM imidazole in PBS followed by a final elution with 50 mM EDTA removing the Ni++ from the resin. The imidazole and EDTA eluates were analyzed by SDS-PAGE, staining of blots with colloidal gold stain to visualize total proteins, and western blots using HA-specific antibodies to detect input TAT protein.
- Construction of the expression plasmid with cDNAs for LMP-1, Dlx-5, Runx2, and Osterix.
- The cloned cDNAs were transferred from pcDNA 3.1 vectors to the TAT-HA vector. In each case, the desired restriction sites were introduced by oligonucleotides and/or PCR followed by ligation in-frame into the linearized TAT-vector. A general cloning strategy followed for the construction of LMP-1 into TAT-HA vector is shown in
FIG. 18 . - Insertion of the desired cDNA in the correct coding frame in to the expression vector was confirmed by restriction digestions and sequencing of sense and anti-sense strands of DNA. The positive clones were selected based on the small scale induction of protein and the detection of correct molecular size bands in western blots performed with the HA tag-specific antibody.
- Bacterial Growth and Expression of Recombinant Proteins.
- Under the growth conditions used, none of the recombinant proteins were toxic to bacterial cells. No inclusion bodies which are frequently found with high level expression of proteins was encountered. The bacterial pellets that were stored frozen at −70° C., gave consistently better yield (up to approximately 15%) of soluble protein after cell lysis by ultrasonication than un-frozen pellets. The yields of purified protein for LMP-1, Dlx5, Runx2 and Osx, were 1.0, 0.5, 1.5 and 1.5 mg/L, respectively. All the expressed mammalian genes showed yields that were lower than expected and thus the procedure may warrant use of mammalian-‘optimized codon hosts’ for future purifications.
- As the conditions of protein expression can have a profound effect on the stability of mammalian proteins in bacteria, optimization of expression conditions and strategies will probably further increase the successful expression and purification of mammalian proteins from bacteria. However, the recovered proteins in our current method were highly homogeneous and were sufficiently suitable for all the cell entry and pull down studies.
- Purification of Recombinant Proteins.
- The presence of hexahistidine tag in the recombinant protein allows use of Ni++-affinity resins for purification of the desired protein. However, when the bacterial lysate was applied to Ni++-affinity resins directly, the abundance of non-specific bacterial proteins competing with the desired protein for binding did not permit the effective use of the metal affinity resin. In addition, the high concentration of proteins in these samples (over 10 mg/ml) promoted non-specific aggregation and poor performance of the resin. To circumvent this problem, we chose to first perform molecular exclusion chromatography to select desired protein fractions based on molecular size. Addition of this step eliminated about 60-80% of the unwanted proteins before employing Ni++-affinity selection of the desired protein.
- Although all the chromatographic runs were performed at room temperature for short durations, the integrity of purified proteins was not affected. Fractionation of proteins by gel filtration prior to metal-affinity purification reduced the protein load on Ni++-nitrilotriacetic acid (NTA) agarose columns and resulted in greatly improved purity of the proteins eluted from the affinity column. High salt concentrations in the buffers reduced or eliminated non-specific ionic interactions among the proteins, thereby enhancing the efficiency of purification. In addition, the high concentration of NaCl (5.0 N) prevented any weak ionic interaction of proteins with the Sephacryl-100 resin and prevented possible aggregation of proteins on column material. Aliquots (50 ul) of the protein fractions eluting from the column were taken for slot blot assay with antibodies specific for HA-tag epitope to detect the desired recombinant protein.
- The use of slot blots, at this stage, improved efficiency and simplified detection of the desired protein in a large number of fractions from multiple chromatographic runs. Based on these slot blots, a fewer number of fractions that contained the desired protein were then subjected to SDS-PAGE and western blot analysis to confirm the expected molecular size for each protein. The indicated (
FIG. 19-22 ) fractions were pooled, concentrated and dialyzed for Ni++-affinity purification. Ni++-affinity selection was very effective and yielded highly homogeneous preparations for each protein (FIG. 26 ). The optimized two-step purification procedure was quick and, thus, minimizes the chance of oxidation of cysteine residues in the purified protein. - The SDS-PAGE gels and western blots of purified LMP-1, Dlx5, Runx2 and Osterix showed predominantly a single band. The molecular size for each protein corresponded to the expected size of the protein plus the fusion-tags (55, 37, 49, 53 kDa, respectively) (
FIG. 26 ). The hexahistidine-TAT-HA tags contribute 5 kDa to the actual molecular weight of each protein but it may have different effects on the apparent size/shape of each fusion protein. The charged tag extends out and increases the apparent molecular size of the proteins. Premature termination of polypeptides was not observed to any significant degree for each of the expressed recombinant proteins as we did not co-purify significant amounts of truncated forms. - FITC labeling and Flow Cytometry.
- In pilot labeling experiments different ratios (protein: FITC) were used for each recombinant protein as the optimum labeling ratio is unique to each protein. The labeling index was determined for each ratio by calculating the FITC-to-protein molar ratio for optimal labeling by measuring the maximal absorbance of all four proteins (LMP-1, Dlx5, Runx2 and Osx) at wavelengths of 280 and 495 nm, respectively. The specific activity of incorporation was normalized for each protein based on these readings. The optimum labeling indices were 35% for the 10:1 FITC:protein ratio.
- The labeled proteins were all effectively separated from free FITC by gel filtration, resulting in little or no background of free label. Rabbit buffy coat cells were incubated with various doses of TAT-fusion protein (1-25 nM) for different durations. The primary reasons for using buffy coat cells are that they are relatively easy to separate and high number of cells can be readily obtained from the blood of human volunteers. To determine the efficacy of TAT-mediated cellular entry of recombinant proteins the rabbit buffy coat cells were extensively washed to remove the excess TAT-protein and analyzed by flow cytometry. This design allows one of ordinary skill in the art to monitor the dose dependent response for each FITC labeled protein. The highest dose tested (25 nM) showed maximum entry (78%) after 30 min incubation.
- At doses lower than 5 nM, we observed protein entry into less than 1.0% of the cells after 30 min incubation.
FIG. 24 shows that TAT-LMP-1-FITC entry into rabbit buffy coat cells is both time and dose dependent. The FITC-labeled Runx2, Osx and Dlx5 also showed time and dose dependent entry into cells (data not shown). The limitation of the flow cytometry method is that it does not distinguish intracellular TAT-protein from TAT-protein adsorbed to the cell surface. - To address this issue, one must ractionate both cytoplasmic and nuclear extracts and determined the presence of TAT-protein in each extract by western blots using HA-specific antibodies.
- Detection of Tat-Proteins in Nuclear and Cytoplasmic Fractions.
- According to this aspect of the invention, the inventors focused on the cellular entry and the intracellular protein interactions of TAT-LMP-1. Mesenchymal stem cells were incubated with various concentrations of TAT-LMP-1 (0.3-300 nM). The cells were harvested after 4 hr and the cytoplasmic and nuclear extracts were prepared as mentioned in methods. Equal aliquots (as determined by protein amounts) of these preparations were subjected to SDS-PAGE. The resolved proteins were blotted onto nitrocellulose and probed with HA-antibody in western blots.
- One of ordinary skill in the art can appreciate that a dose dependent increase of TAT-LMP-1 at the expected size (55 kDa) is observed in both cytoplasmic and nuclear fractions when compared to untreated controls (
FIG. 25 ). The higher intensity of the signal observed in cytoplasmic fractions may be due to a higher concentration of TAT-protein in the cytoplasm. The control lanes showed little or no signal confirming that the observed signal is specific to exogenously added TAT-protein. This data also suggested that exogenously added TAT-protein is relatively resistant to cellular proteases and is easily detectable with HA-antibodies in both cytoplasmic and nuclear compartments. - In these western blots, inventors chose HA-antibodies so that they could distinguish the exogenously added protein from the cellular endogenous proteins. The TAT-protein accumulated in both the compartments suggesting that the TAT-domain is capable of transducing through all cellular membranes as suggested in the literature. Inventors were then determined that significant amounts of the excess TAT-protein was present in cell culture supernants.
- Detection of Nuclear Proteins in MSCs that Associate with TAT-LMP-1
- One defining feature of eukaryotic cells is their spatial and functional division into the nucleus and the cytoplasm by the nuclear envelope. Each of the nuclear osteogenic factors, LMP-1, Dlx5, Runx2 or Osterix, has been postulated to function in a signaling network involving a large number of interacting proteins. The aim of this study was to optimize methods to perform the controlled delivery of these signaling molecules either to promote or disrupt protein interaction events in nuclear compartment resulting in the control of cellular differentiation.
- As a pilot study, one of ordinary skill in the art would appreciate that the inventors used TAT-LMP-1 as molecular bait to detect any MSC nuclear proteins with which it interacts. The inventors also observed a large number of proteins binding TAT-LMP-1 with high affinity (
FIG. 26 ). Proteins ofmolecular size 80 to 90 kDa showed predominant colloidal gold staining suggesting that proteins in this zone are the most likely binding candidates for LMP-1 interaction. Based on these results one of ordinary skill in the art may slightly alter the currently disclosed experimental approach and performed photo-induced biotin transfer experiments to identify target nuclear molecules that interact with TAT-LMP-1. - The 717 base-pair clone (Example 17) was digested with ClaI and EcoRV (New England Biologicals, city, MA). A small fragment (˜250 base pairs) was gel purified. Clone No. 7 (Example 18) was digested with ClaI and XbaI. A 1400 base-pair fragment was gel purified from that digest. The isolated 250 base-pair and 1400 base-pair cDNA fragments were ligated by standard methods to form a fragment of −1650 bp. The pHis-A vector (InVitrogen) was digested with EcoRV and XbaI. The linearized vector was recovered and ligated to the chimeric 1650 base-pair cDNA fragment. The ligated product was cloned and amplified by standard methods, and the pHis-A-5′ ATG LMP-1s expression vector, also denominated as the vector pHis-A with insert HLMP-1s, was deposited at the ATCC as previously described.
- Rat calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with glucocorticoid (GC) according to Example 1. The cultures were transfected with 3 μg of recombinant pHis-A vector DNA/well as described in Example 25. Mineralized nodules were visualized by Von Kossa staining according to Example 3.
- Human LMP-1s gene product overexpression alone (i.e., without GC stimulation) induced significant bone nodule formation (˜203 nodules/well) in vitro. This is approximately 50% of the amount of nodules produced by cells exposed to the GC positive control (˜412 nodules/well). Similar results were obtained with cultures transfected with pHisA-LMP-Rat Expression vector (˜152 nodules/well) and pCMV2/LMP-Rat-Fwd (˜206 nodules/well). In contrast, the negative control pCMV2/LMP-Rat-Rev yielded (˜2 nodules/well), while approximately 4 nodules/well were seen in the untreated plates. These data demonstrate that the human LMP-1 cDNA was at least as osteoinductive as the rat LMP-1 cDNA in this model system. The effect in this experiment was less than that observed with GC stimulation; but in some the effect was comparable.
- Overexpression of RLMP-1 or HLMP-1s in rat calvarial osteoblast cultures as described in Example 24 resulted in significantly greater nodule formation than was observed in the negative control. To study the mechanism of action of LIM mineralization protein conditioned medium was harvested at different time points, concentrated to 10×, sterile filtered, diluted to its original concentration in medium containing fresh serum, and applied for four days to untransfected cells.
- Conditioned media harvested from cells transfected with RLMP-1 or HLMP-1s at
day 4 was approximately as effective in inducing nodule formation as direct overexpression of RLMP-1 in transfected cells. Conditioned media from cells transfected with RLMP-1 or HLMP-1 in the reverse orientation had no apparent effect on nodule formation. Nor did conditioned media harvested from LMP-1 transfected cultures beforeday 4 induce nodule formation. These data suggest that expression of LMP-1 caused the synthesis and/or secretion of a soluble factor, which did not appear in culture medium in effective amounts until 4 days post transfection. - Since overexpression of rLMP-1 resulted in the secretion of an osteoinductive factor into the medium, Western blot analysis was used to determine if LMP-1 protein was present in the medium. The presence of RLMP-1 protein was assessed using antibody specific for LMP-1 (QDPDEE) and detected by conventional means. LMP-1 protein was found only in the cell layer of the culture and not detected in the medium.
- Partial purification of the osteoinductive soluble factor was accomplished by standard 25% and 100% ammonium sulfate cuts followed by DE-52 anion exchange batch chromatography (100 mM or 500 mM NACl). All activity was observed in the high ammonium sulfate, high NaCl fractions. Such localization is consistent with the possibility of a single factor being responsible for conditioning the medium.
- The restriction and modifying enzymes used in examples 41-50 were purchased from Promega (Madison, Wis.). The chelating affinity resin (Probond) and the pHisA vector were purchased from Invitrogen (San Diego, Calif.). The Sephacryl S-300 (HiPrep 16×60), other chromatographic columns and the AKTA FPLC system were from Amersham-Pharmacia Biotech (Piscataway, N.J.). All other chemicals and reagents, unless otherwise noted, were from Sigma (St. Louis, Mo.) (analytical grade). Escherichia coli DH5alpha cells was the host for propagation of plasmids. DH5alpha cells were maintained on LB agar plates and grown at 37° C. in the presence of ampicillin (100 mg/mL). The strains were maintained in LB medium including 15% glycerol at −80° C.
- A-549 cells were grown in F12K medium (Gibco, Grand Island, N.Y.) in a humidified 10% CO2 incubator at 37° C. supplemented with 10% non-heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, Ga.). The 1623-bp cDNA for LMP-1 was cloned into the mammalian expression vector pHisA/pcDNA 3.1 following standard methods. The over-expressed LMP-1 contains a 6His-fusion tag at the N-terminus to facilitate affinity purification. The plasmid construct (10 ug/100 mm plate) was incubated for 2 h with A-549 cells using 60 ul of Superfect (Qiagen, Valencia, Calif.) per plate in 10 ml medium and the cultures were incubated for 2 days. Cells from 50×100 mm plates were harvested with phosphate-buffered saline by scraping with rubber policemen.
- The A-549 cell pellets were resuspended in low salt buffer (20 mM HEPES, pH 7.9, 10 mM KCl, 1 mM EGTA, 1 mM EDTA, 0.2% Nonidet P-40, 10% Glycerol, 1 mM phenylmethylsulfonyl fluoride and 1 ug/ml of protease inhibitor mix (Sigma), incubated on ice for 10 min, and centrifuged (8000×g, 2 min, 4° C.). Supernatants (cytoplasmic fraction) were collected for further analysis. The nuclear pellets were suspended in high salt buffer (low salt buffer with 600 mM KCl, 20% glycerol), incubated on ice for 30 min and centrifuged as before. Supernatants were collected as the nuclear fraction. Both cytoplasmic and nuclear fractions were alquoted and stored frozen at −20° C. until further use.
- Size-exclusion chromatography of the cellular proteins was carried out on a Sephacryl S-300 column connected to the AKTA FPLC System (Amersham Biosciences, Piscataway, N.J.). The column was pre-calibrated with known low- and high-molecular weight protein markers from gel filtration calibration kits (Amersham Biosciences, Piscataway, N.J.) in 50 mM sodium phosphate, 150 mM NaCl, pH 7.0 buffer. The marker proteins were thyroglobulin (molecular weight (Mw) 669 kDa), ferritin (Mw 440 kDa), catalase (Mw 232 kDa), aldolase (Mw 158 kDa), albumin (Mw 67 kDa), ovalbumin (Mw 43 kDa), chymotrypsinogen A (
Mw 25 kDa), and ribonuclease A (Mw 13.7 kDa). - The cell pellets were suspended in 100 ml of ice-cold lysis buffer (20 mM phosphate buffer, pH 7.0 containing 50 mM Tris-HCl, pH 7.5 and 5 M NaCl). The uniform cell suspension was centrifuged at 10,000 g (
Beckman # 17 Rotor, 13,000 RPM) at 4° C. and the supernatant was applied onto a Sephacryl S-300 column (HiPrep 16×60) using AKTA FPLC system with Unicorn 3.1 software (Amersham Pharmacia Biotech) at a flow rate of 1 ml/min. Fractions (4 ml) were collected immediately after the void volume (V0) (35 ml). - The proteins were applied onto Ni++-affinity column (5 ml resin) previously equilibrated with 4×5 ml of buffer. Non-specific and low-affinity proteins were washed off the column with 3×10 ml of 20 mM phosphate buffer, pH 6.0 containing urea (8 M), NaCl (50 mM) and imidazole (20 mM). Affinity-bound proteins were eluted using 3×10 ml washes with 20 mM phosphate buffer, pH 4.0 containing urea (8 M), NaCl (50 mM). The eluates were combined and concentrated by spinning at 2000 g using a
centriprep YM 50 ultrafiltration device. Flow-thru, washes and eluate were concentrated using a centriprep device and analysed by SDS-PAGE and western blotting. LMP-1 antibodies raised in rabbit for the peptide epitope from the osteogenic region of LMP-1: ADPPRYTFAPSVSLNKTARPFGAPPP (the unique central region of LMP-1) (SEQ ID NO: 43) were used for western blotting. Affinity eluted fractions were dialyzed against 20 mM Tris-HCl pH 7.5 (Buffer A) over night at 4° C. using a 10 kDa cut-off membrane for cation-exchange chromatography. - A HiTrap SP Sepharose (FF) cation exchange column, 1 ml (Pharmacia) was equilibrated in buffer A. Protein sample was syringe filtered using a 0.2 u membrane and applied onto the column in buffer A. The bound proteins were eluted using the AKTA-FPLC system (Amersham-Pharmacia Biotech) by generating a linear gradient of NaCl from 0 to 1.0 M over 20 min at a flow rate of 1 ml/min. Finally the column was washed with 20% ethanol and stored until further use at 4° C. Fractions (1 ml) were diluted 3-fold (5 ul of sample plus 10 ul of water to reduce the salt concentration) and analysed by SDS-PAGE followed by western blotting using specific primary antibodies and horse radish peroxidase labeled secondary antibodies. Fractions containing recombinant protein (based on western blot) were pooled, concentrated and de-salted using the centriprep devices (Amicon). Protein samples were stored at −70° C., until further use, at this stage. Fractions containing unwanted contaminant proteins were discarded.
- Protein quantitation was performed with protein assay reagent (BioRad) using BSA as standard. Due to poor dye binding by LMP-1 (abundance of Pro, Gly, Ser and Cys residues), more accurate protein amounts were determined from the overall yield of peptides from trypsin digestion and mass spectrometric analysis. The collective yield of the recombinant LMP-1 protein was about 75-100 ug from 120×100 mm cell culture plates from three batches of 40 plates each).
- SDS-PAGE is performed using 10% gels according to Laemmli et al and the electrophoresed proteins were transferred from the gel to a nitrocellulose membrane at 50 volts (constant) for 2 hrs. The membranes were blocked with 25
ml 5% milk protein for 1 hour at room temperature. Membranes were incubated with LMP-1 antibody at a dilution of 1:5000 (5 ul/25 ml of Tris-buffered saline containing 0.1% Tween 20) gently shaking for 2 hours at room temperature. Membranes were washed with 25 ml of TBST for 5 min. The washes were repeated two times. Membranes were incubated with anti-rabbit goat IgG-linked to horse radish peroxidase (NEF 812, NEN, Boston) diluted 1:5000 in 25 ml TBST for 1 hour. Membranes were washed three times, 5-min each with 25 ml of TBST as before. Chemiluminescent substrate reagent A (2 ml) and reagent B (2 ml) were mixed and applied to the membrane. The damp-dried membrane was exposed to X-ray film for signal detection. - Sugar compositions were determined as described previously (Yasuno, S., Murata) (Sangadala et al 2001). Briefly, the purified protein (100 μg) was dissolved in 20 μl distilled water in a test tube to which 4 M TFA (20 μl, for neutral sugars) or 8 M HCl (20 μl, for amino sugars) was added. The test tube was incubated at 100° C. in a hot block bath. After 4 hr (neutral sugars) or 6 hr (amino sugars), the tube was cooled to room temperature and the acid was removed by using a centrifugal concentrator at 35° C. The dried sample was derivatized with ABEE in the presence of borane-pyridine complex at 80° C. After 1 hr, the reaction mixture was cooled to room temperature. Distilled water (200 μl) and an equal volume of chloroform were added to the reaction mixture. After vigorous vortexing, the sample was centrifuged (6000×g, 1 min). The upper aqueous layer was analyzed by reversed-phase HPLC under the following conditions: column, Wakosil-II 5C18HG (4.6×150 mm); solvent, A 0.02% TFA/CH3CN (90/10), B 0.02% TFA/CH3CN (50/50); program, 0-45 min (B conc. 0%), 45-55 min (B conc. 100%), 55-70 min (B conc. 0%); flow rate, 1 ml/min; temp., 45° C.; detection, absorbance at 305 nm. The monosaccharide and amino monosaccharide standards used were N-acetyl glucosamine, N-acetyl galactosamine, glucose, galactose, mannose, xylose, and L-fucose.
- SDS-PAGE gels were stained with 0.25% Coomassie brilliant blue in 45% methanol and 10% acetic acid and destained in 35% methanol with 10% acetic acid. The protein bands corresponding to a positive signal on western blots were sliced from the gel, soaked in 50% methanol with 0.1 M NH4HCO3 and mixed vigorously overnight. The wash solution was changed once and incubated for 2 hr. The clear gel bands were then soaked in water for 2 hr followed by soaking in 25 mM NH4HCO3 for 5 min. The wet gel pieces were smashed into fine pieces in Eppendorf tubes (0.5 ml). Trypsin (Promega) digestion was performed in 25 mM NH4HCO3 (pH 8.0) overnight at 37° C. Following digestion, peptides were extracted twice with acetonitrile and aliquots were lyophilyzed. (Bernardo et al, Wilkins et al, Winters et al).
- Peptide samples were purified and concentrated using a Zip Tip (Millipore) which has C18 resin fixed at its end. The resin was rinsed according to the manufacturer's instructions with 10 μl of 0.1% trifluoroacetic acid (TFA) and 50% acetonitrile (ACN). Peptides were eluted in 10 μl 1:1 ACN-0.1% TFA. A 0.5 μl volume of the concentrated peptide-containing sample was mixed with 0.5 μl of a saturated solution of α-cyano-4-hydroxycinnamic acid. Each sample (0.5 ul) was spotted on the mass spectrometer sample plate (Tremoulet et al).
- After trypsin digestion, the mixture (85%) of LMP-1 peptides were separated by capillary reversed-phase HPLC using the method described before [Hubalek, F., Edmondson]. The peptide fragments were separated by small bore reverse phase HPLC on a Vydac C18 column (4.6×250 mm) using a gradient HPLC system (Waters). The chromatographic run was performed with an aqueous phase containing 0.1% trifluoroacetic acid and organic phase containing 0.085% trifluoroacetic acid in acetonitrile with a flow rate of 0.5 ml/min. The gradient used for separation was 2-60% of acetonitrile for 40 min; the total run time was 60 min. The collected peptides were subjected to internal fragment N-terminal sequence analysis by standard Edman degradation (Procise 494 HT protein sequencer, Applied Biosystems, Foster City, Calif.). The eluate absorbing at 210 nm was manually collected for sequence analysis.
- In order to increase sequence coverage of LMP-1, aliquots of HPLC fractions of the digest also were analyzed by MALDITOF/TOF MS/MS using a model 4700 Proteomics Analyzer (Applied Biosystems). For each fraction, an MS spectrum was initially collected. For post source decay analysis, the HPLC-purified peptide was subjected to ion generation by post-source decay (Chaurand P 1999). A matrix-assisted laser desorption ionization-post-source decay (MALDI-PSD) time-of-flight spectrum was recorded using alpha-cyano-4-hydroxy cinnamic acid as a matrix; acquisition was at 27.5 kV under continuous extraction conditions; reflector voltage was stepped from 30 to 1.27 kV, and the spectrum was constructed using the FAST™ method from Bruker-Daltonic (Bremen, Germany). Using the manufacturer's GPS Explorer 2.0 software, the MS and MS/MS data were submitted to a MASCOT search engine (www.matrixscience.com) for positive identification. The NCBI non-redundant database and the Mammalia taxonomy were used for these and all other searches.
- Monoisotopic peptide masses obtained from mass spectra were searched against the SWISS-PROT, NCBInr and MSDB databases using the MASCOT search program. The following parameters were used in the searches: mammalian, human, MS/MS Ion Search, protein mass of 50 kDa, trypsin digest with two missed cleavages, fragment ion mass tolerance of ±75 ppm and possible oxidation of methionine. The resulting protein hits were scored using a probability based Mowse score. The score is −10*Log(P), where P is the probability that the observed match is a random event.
- This study determined the optimal dose of adenoviral delivery of the LMP-1 cDNA (SEQ. ID NO: 2) to promote spine fusion in normal, that is, immune competent, rabbits.
- A replication-deficient human recombinant adenovirus was constructed with the LMP-1 cDNA (SEQ. ID NO: 2) driven by a CMV promoter using the Adeno-Quest™ Kit (Quantum Biotechnologies, Inc., Montreal). A commercially available (Quantum Biotechnologies, Inc., Montreal) recombinant adenovirus containing the beta-galactosidase gene was used as a control.
- Initially, an in vitro dose response experiment was performed to determine the optimal concentration of adenovirus-delivered LMP-1 (“AdV-LMP-1”) to induce bone differentiation in rat calvarial osteoblast cultures using a 60-minute transduction with a multiplicity of infection (“MOI”) of 0.025, 0.25, 2.5, or plaque-forming units (pfu) of virus per cell. Positive control cultures were differentiated by a 7-day exposure to 109 M glucocorticoid (“GC”). Negative control cultures were left untreated. On day 14, the number of mineralized bone nodules was counted after von Kossa staining of the cultures, and the level of osteocalcin secreted into the medium (pmol/mL) was measured by radioimmunoassay (mean ±SEM).
- The results of this experiment are shown in Table 1. Essentially no spontaneous nodules formed in the untreated negative control cultures. The data show that a MOI equal to 0.25 pfu/cell is most effective for osteoinducing bone nodules, achieving a level comparable to the positive control (GC). Lower and higher doses of adenovirus were less effective.
-
TABLE 1 Neg Adv-LMP-Dose (MOI) Outcome Ctrl. GC 0.025 0.25 2.5 25 Bone 0.5 ± 188 ± 79.8 ± 145.1 ± 26.4 ± 87.6 ± Nodules 0.2 35 13 13 15 2 Osteoclacin 1.0 ± 57.8 ± 28.6 ± 22.8 ± 18.3 ± 26.0 ± 0.1 9 11 1 3 2 - In vivo experiments were then performed to determine if the optimal in vitro dose was capable of promoting intertransverse process spine fusions in skeletally mature New Zealand white rabbits. Nine rabbits were anesthetized and 3 cc of bone marrow was aspirated from the distal femur through the intercondylar notch using an 18 gauge needle. The buffy coat was then isolated, a 10-minute transduction with AdV-LMP-1 was performed, and the cells were returned to the operating room for implantation. Single level posterolateral lumbar spine arthrodesis was performed with decortication of transverse processes and insertion of carrier (either rabbit devitalized bone matrix or a collagen sponge) containing 8-15 million autologous nucleated buffy coat cells transduced with either AdV-LMP-1 (MOI=0.4) or AdV-BGal (MOI=0.4). Rabbits were euthanized after 5 weeks and spine fusions were assessed by manual palpation, plain x-rays, CT scans, and undecalcified histology.
- The spine fusion sites that received AdV-LMP-1 induced solid, continuous spine fusion masses in all nine rabbits. In contrast, the sites receiving AdV-BGal, or a lower dose of AdV-LMP-1 (MOI=0.04) made little or no bone and resulted in spine fusion at a rate comparable to the carrier alone (<40%). These results were consistent as evaluated by manual palpation, CT scan, and histology. Plain radiographs, however, sometimes overestimated the amount of bone that was present, especially in the control sites. LMP-1 cDNA delivery and bone induction was successful with both of the carrier materials tested. There was no evidence of systemic or local immune response to the adenovirus vector.
- These data demonstrate consistent bone induction in a previously validated rabbit spine fusion model which is quite challenging. Furthermore, the protocol of using autogenous bone marrow cells with intraoperative ex vivo gene transduction (10 minutes) is a more clinically feasible procedure than other methods that call for overnight transduction or cell expansion for weeks in culture. In addition, the most effective dose of recombinant adenovirus (MOI=0.25) was substantially lower than doses reported in other gene therapy applications (MOI 40-500). We believe this is due to the fact that LMP-1 is an intracellular signaling molecule and may have powerful signal amplification cascades. Moreover, the observation that the same concentration of AdV-LMP-1 that induced bone in cell culture was effective in vivo was also surprising given the usual required increase in dose of other growth factors when translating from cell culture to animal experiments. Taken together, these observations indicate that local gene therapy using adenovirus to deliver the LMP-1 cDNA is possible and the low dose required will likely minimize the negative effects of immune response to the adenovirus vector.
- In four rabbits we performed spine fusion surgery as above (Example 38) except the transduced cells were the buffy coat from venous blood rather than bone marrow. These cells were transfected with Adeno-LMP or pHIS-LMP plasmid and had equivalent successful results as when bone marrow cells were used. This discovery of using ordinary venous blood cells for gene delivery makes gene therapy more feasible clinically since it avoids painful marrow harvest under general anesthesia and yields two times more cells per mL of starting material.
- Intron/Exon mRNA transcript splice variants are a relatively common regulatory mechanism in signal-transduction and cellular/tissue development. Splice variants of various genes have been shown to alter protein-protein, protein-DNA, protein-RNA, and protein-substrate interactions. Splice variants may also control tissue specificity for gene expression allowing different forms (and therefore functions) to be expressed in various tissues. Splice variants are a common regulatory phenomenon in cells. It is possible that the LMP splice variants may result in effects in other tissues such as nerve regeneration, muscle regeneration, or development of other tissues.
- To screen a human heart cDNA library for splice variants of the HLMP-1 sequence, a pair of PCR primer corresponding to sections of SEQ. ID NO: 22 was prepared. The forward PCR primer, which was synthesized using standard techniques, corresponds to nucleotides 35-54 of SEQ. ID NO: 22. It has the following sequence:
-
5′ GAGCCGGCATCATGGATTCC 3′(SEQ. ID NO: 35) - The reverse PCR primer, which is the reverse complement of nucleotides 820-839 in SEQ. ID NO: 22, has the following sequence:
-
5′ GCTGCCTGCACAATGGAGGT 3′(SEQ. ID NO: 36) - The forward and reverse PCR primers were used to screen human heart cDNA (ClonTech, Cat No. 7404-1) for sequences similar to HLMP-1 by standard techniques, using a cycling protocol of 94° C. for 30 seconds, 64° C. for 30 seconds, and 72° C. for 1 minute, repeated 30 times and followed by a 10 minute incubation at 72° C. The amplification cDNA sequences were gel-purified and submitted to the Emory DNA Sequence Core Facility for sequencing. The clones were sequenced using standard techniques and the sequences were examined with PCGENE (intelligenetics; Programs SEQUIN and NALIGN) to determine homology to SEQ. ID NO: 22. Two homologous nucleotide sequences with putative alternative splice sites compared to SEQ. ID NO: 22 were then translated to their respective protein products with Intelligenetic's program TRANSL.
- One of these two novel human cDNA sequences (SEQ. ID No: 37) comprises 1456 bp:
-
CGACGCAGAG CAGCGCCCTG GCCGGGCCAA GCAGGAGCCG GCATCATGGA TTCCTTCAAG 3 GTAGTGCTGG AGGGGCCAGC ACCTTGGGGC TTCCGGCTGC AAGGGGGCAA GGACTTCAAT 60 GTGCCCCTCT CCATTTCCCG GCTCACTCCT GGGGGCAAAG CGGCGCAGGC CGGAGTGGCC 120 GTGGGTGACT GGGTGCTGAG CATCGATGGC GAGAATGCGG GTAGCCTCAC ACACATCGAA 180 GCTCAGAACA AGATCCGGGC CTGCGGGGAG CGCCTCAGCC TGGGCCTCAG CAGGGCCCAG 240 CCGGTTCAGA GCAAACCGCA GAAGGTGCAG ACCCCTGACA AACAGCCGCT CCGACCGCTG 300 x x GTCCCAGATG CCAGCAAGCA GCGGCTGATG GAGAACACAG AGGACTGGCG GCCGCGGCCG 360 GGGACAGGCC AGTCGCGTTC CTTCCGCATC CTTGCCCACC TCACAGGCAC CGAGTTCATG 420 CAAGACCCGG ATGAGGAGCA CCTGAAGAAA TCAAGCCAGG TGCCCAGGAC AGAAGCCCCA 480 GCCCCAGCCT CATCTACACC CCAGGAGCCC TGGCCTGGCC CTACCGCCCC CAGCCCTACC 540 AGCCGCCCGC CCTGGGCTGT GGACCCTGCG TTTGCCGAGC GCTATGCCCC GGACAAAACG 600 AGCACAGTGC TGACCCGGCA CAGCCAGCCG GCCACGCCCA CGCCGCTGCA GAGCCGCACC 660 TCCATTGTGC AGGCAGCTGC CGGAGGGGTG CCAGGAGGGG GCAGCAACAA CGGCAAGACT 720 CCCGTGTGTC ACCAGTGCCA CAAGGTCATC CGGGGCCGCT ACCTGGTGGC GTTGGGCCAC 780 GCGTACCACC CGGAGGAGTT TGTGTGTAGC CAGTGTGGGA AGGTCCTGGA AGAGGGTGGC 840 TTCTTTGAGG AGAAGGGCGC CATCTTCTGC CCACCATGCT ATGACGTGCG CTATGCACCC 900 AGCTGTGCCA AGTGCAAGAA GAAGATTACA GGCGAGATCA TGCACGCCCT GAAGATGACC 960 TGGCACGTGC ACTGCTTTAC CTGTGCTGCC TGCAAGACGC CCATCCGGAA CAGGGCCTTC 1020 TACATGGAGG AGGGCGTGCC CTATTGCGAG CGAGACTATG AGAAGATGTT TGGCACGAAA 1080 TGCCATGGCT GTGACTTCAA GATCGACGCT GGGGACCGCT TCCTGGAGGC CCTGGGCTTC 1140 AGCTGGCATG ACACCTGCTT CGTCTGTGCG ATATGTCAGA TCAACCTGGA AGGAAAGACC 1200 TTCTACTCCA AGAAGGACAG GCCTCTCTGC AAGAGCCATG CCTTCTCTCA TGTGTGAGCC 1260 CCTTCTGCCC ACAGCTGCCG CGGTGGCCCC TAGCCTGAGG GGCCTGGAGT CGTGGCCCTG 1320 CATTTCTGGG TAGGGCTGGC AATGGTTGCC TTAACCCTGG CTCCTGGCCC GACCCTGGGC 1380 TCCCGGGCCC TGCCCA 1440 1456 - Reading frame shifts caused by the deletion of a 119 bp fragment (between X) and the addition of a 17 bp fragment (underlined) results in a truncated gene product having the following derived amino acid sequence (SEQ. ID NO: 38):
-
4 Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe 1 5 10 15 Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg 20 25 30 Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp 35 40 45 Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile 50 55 60 Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly 65 70 75 80 Leu Ser Arq Ala Gln Pro Val Gln Asn Lys Pro Gln Lys Val Gln Thr 85 90 95 Pro Asp Lys Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser Lys Gln 100 105 110 Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly Thr Gly 115 120 125 Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr Glu Phe 130 135 140 Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln Val Pro 145 150 155 160 Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu Pro Trp 165 170 175 Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp Ala Val 180 185 190 Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser Thr Val 195 200 205 Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln Ser Arg 210 215 220 Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly Gly Ser 225 230 235 240 Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Gln Val Ile Arg 245 250 255 Ala Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu Glu Phe 260 265 270 Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe Phe Glu 275 280 285 Glu Lys Gly Ala Ile Phe Cys Pro Pro Cys Tyr Asp Val Arg Tyr Ala 290 295 300 Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile Met His 305 310 315 320 Ala Leu Lys Met Thr Trp His Val Leu Cys Phe Thr Cys Ala Ala Cys 325 330 335 Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly Val Pro 340 345 350 Tyr Cys Glu Arg Asp Tyr Giu Lys Met Phe Gly Thr Lys Cys Gln Trp 355 360 365 Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala Leu Gly 370 375 380 Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln Ile Asn 385 390 395 400 Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Arg Pro Leu Cys Lys 405 410 415 Ser His Ala Phe Ser His Val 420 - This 423 amino acid protein demonstrates 100% homology to the protein shown in SEQ. ID NO. 10, except for the sequence in the highlighted area (amino acids 94-99), which are due to the nucleotide changes depicted above.
- The second novel human heart cDNA sequence (SEQ. ID NO: 39) comprises 1575 bp:
-
CGACGCAGAG CAGCGCCCTG GCCGGGCCAA GCAGGAGCCG GCATCATGGA TTCCTTCAAG 5 GTAGTGCTGG AGGGGCCAGC ACCTTGGGGC TTCCGGCTGC AAGGGGGCAA GGACTTCAAT 60 GTGCCCCTCT CCATTTCCCG GCTCACTCCT GGGGGCAAAG CGGCGCAGGC CGGAGTGGCC 120 GTGGGTGACT GGGTGCTGAG CATCGATGGC GAGAATGCGG GTAGCCTCAC ACACATCGAA 180 GCTCAGAACA AGATCCGGGC CTGCGGGGAG CGCCTCAGCC TGGGCCTCAG CAGGGCCCAG 240 CCGGTTCAGA GCAAACCGCA GAAGGCCTCC GCCCCCGCCG CGGACCCTCC GCGGTACACC 300 TTTGCACCCA GCGTCTCCCT CAACAAGACG GCCCGGCCCT TTGGGGCGCC CCCGCCCGCT 360 GACAGCGCCC CGCAACAGAA TGGGTGCAGA CCCCTGACAA ACAGCCGCTC CGACCGCTGG 420 TCCCAGATGC CAGCAAGCAG CGGCTGATGG AGAACACAGA GGACTGGCGG CCGCGGCCGG 480 GGACAGGCCA GTCGCGTTCC TTCCGCATCC TTGCCCACCT CACAGGCACC GAGTTCATGC 540 AAGACCCGGA TGAGGAGCAC CTGAAGAAAT CAAGCCAGGT GCCCAGGACA GAAGCCCCAG 600 CCCCAGCCTC ATCTACACCC CAGGAGCCCT GGCCTGGCCC TACCGCCCCC AGCCCTACCA 660 GCCGCCCGCC CTGGGCTGTG GACCCTGCGT TTGCCGAGCG CTATGCCCCG GACAAAACGA 720 GCACAGTGCT GACCCGGCAC AGCCAGCCGG CCACGCCCAC GCCGCTGCAG AGCCGCACCT 780 CCATTGTGCA GGCAGCTGCC GGAGGGGTGC CAGGAGGGGG CAGCAACAAC GGCAAGACTC 840 CCGTGTGTCA CCAGTGCCAC AAGGTCATCC GGGGCCGCTA CCTGGTGGCG TTGGGCCACG 900 CGTACCACCC GGAGGAGTTT GTGTGTAGCC AGTGTGGGAA GGTCCTGGAA GAGGGTGGCT 960 TCTTTGAGGA GAAGGGCGCC ATCTTCTGCC CACCATOCTA TGACGTGCGC TATGCACCCA 1020 GCTGTGCCAA GTGCAAGAAG AAGATTACAG GCGAGATCAT GCACGCCCTG AAGATGACCT 1080 GGCACGTGCA CTGCTTTACC TGTGCTGCCT GCAAGACGCC CATCCGGAAC AGGGCCTTCT 1140 ACATGGAGGA GGGCGTGCCC TATTGCGAGC GAGACTATGA GAAGATGTTT GGCACGAAAT 1200 GCCATGGCTG TGACTTCAAG ATCGACGCTG GGGACCGCTT CCTGGAGGCC CTGGGCTTCA 1260 GCTGGCATGA CACCTGCTTC GTCTGTGCGA TATGTCAGAT CAACCTGGAA GGAAAGACCT 1320 TCTACTCCAA GAAGGACAGG CCTCTCTGCA AGAGCCATGC CTTCTCTCAT GTGTGAGCCC 1380 CTTCTGCCCA CAGCTGCCGC GGTGGCCCCT AGCCTGAGGG GCCTGGAGTC GTGGCCCTGC 1440 ATTTCTGGGT AGGGCTGGCA ATGGTTGCCT TAACCCTGGC TCCTGGCCCG AGCCTGGGCT 1500 CCCGGGCCCT GCCCA 1560 1575
Reading frame shifts caused by the addition of a 17 bp fragment (bolded, italicized and underlined) results in an early translation stop codon at position 565-567 (underlined). The derived amino acid sequence (SEQ. ID NO: 40) consists of 153 amino acids: -
6 Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe 1 5 10 15 Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg 20 25 30 Leu Thr Pro Gly Gly Lys Ala Ala Gln AlaGly Val Ala Val Gly Asp 35 40 45 Trp Val Leu Ser Ile Asp Gly GluAsn Ala Gly Ser Leu Thr His Ile 50 55 60 Glu Ala Gln Asn Lys IleArg Ala Cys Gly Glu Arg Leu Ser Leu Gly 65 70 75 80 Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala 85 90 95 Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu 100105 110 Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala 115 120 125 Pro Gln Gln Asn Gly Cys Arg Pro Leu Thr Asn Ser Arg Ser Asp Arg 130 135 140 Trp Ser Gln Met Pro Ala Ser Ser Gly 145 150 - This protein demonstrates 100% homology to SEQ. ID NO: 10 until amino acid 94, where the addition of the 17 bp fragment depicted in the nucleotide sequence results in a frame shift. Over amino acids 94-153, the protein is not homologous to SEQ. ID NO: 10. Amino acids 154-457 in SEQ. ID NO: 10 are not present due to the early stop codon depicted in nucleotide sequence.
- Applicants have identified the genomic DNA sequence encoding HLMP-1, including putative regulatory elements associated with HLMP-1 expression. The entire genomic sequence is shown in SEQ. ID. NO: 41. This sequence was derived from AC023788 (clone RP11-564G9), Genome Sequencing Center, Washington University School of Medicine, St. Louis, Mo.
- The putative promoter region for HLMP-1 spans nucleotides 2,660-8,733 in SEQ. ID NO: 41. This region comprises, among other things, at least ten potential glucocorticoid response elements (“GREs”) (nucleotides 6148-6153, 6226-6231, 6247-6252, 6336-6341, 6510-6515, 6552-6557, 6727-6732, 6752-6757, 7738-7743, and 8255-8260), twelve potential Sma-2 homologues to Mothers against Drosophilla decapentaplegic (“SMAD”) binding element sites (nucleotides 3569-3575, 4552-4558, 4582-4588, 5226-5232, 6228-6234, 6649-6655, 6725-6731, 6930-6936, 7379-7384, 7738-7742, 8073-8079, and 8378-8384), and three TATA boxes (nucleotides 5910-5913, 6932-6935, and 7380-7383). The three TATA boxes, all of the GREs, and eight of the SMAD binding elements (“SBEs”) are grouped in the region spanning nucleotides 5,841-8,733 in SEQ. ID NO: 41. These regulatory elements can be used, for example, to regulate expression of exogenous nucleotide sequences encoding proteins involved in the process of bone formation. This would permit systemic administration of therapeutic factors or genes relating to bone formation and repair, as well as factors or genes associated with tissue differentiation and development.
- In addition to the putative regulatory elements, 13 exons corresponding to the nucleotide sequence encoding HLMP-1 have been identified. These exons span the following nucleotides in SEQ. ID NO: 41:
- 7
Exon 1 8733-8767Exon 2 9790-9895Exon 3 13635-13787Exon 4 13877-13907Exon 5 14387-14502Exon 6 15161-15297Exon 7 15401-15437Exon 8 16483-16545Exon 9 16689-16923Exon 10 18068-18248Exon 11 22117-22240Exon 12 22323-22440 Exon 13 22575-22911 - In HLMP-2 there is another exon (Exon 5A), which spans nucleotides 14887-14904.
- LIM mineralization protein-1 (LMP-1) is an intracellular protein that can direct cellular differentiation in osseous and non-osseous tissues. This example demonstrates that expressing human LMP-1 (“HLMP-1”) in intervertebral disc cells increases proteoglycan synthesis and promotes a more chondrocytic phenotype. In addition, the effect of HLMP-1 expression on cellular gene expression was demonstrated by measuring Aggrecan and BMP-2 gene expression. Lumbar intervertebral disc cells were harvested from Sprague-Dawley rats by gentle enzymatic digestion and cultured in monolayer in DMEM/F12 supplemented with 10% FBS. These cells were then split into 6 well plates at approximately 200,000 cells per well and cultured for about 6 days until the cells reached approximately 300,000 cells per well. The culture media was changed to 1% FBS DMEM/F12 and this was considered
Day 0. - Replication
deficient Type 5 adenovirus comprising a HLMP-1 cDNA operably linked to a cytomegalovirus (“CMV”) promoter has been previously described, for example, in U.S. Pat. No. 6,300,127. The negative control adenovirus was identical except the HLMP-1 cDNA was replaced by LacZ cDNA. For a positive control, uninfected cultures were incubated in the continuous presence of BMP-2 at a concentration of 100 nanograms/milliliter. - On
Day 0, the cultures were infected with adenovirus for 30 minutes at 37° C. in 300 microliters of media containing 1% FBS. Fluorescence Activated Cell Sorter (“FACS”) analysis of cells treated with adenovirus containing the green fluorescent protein (“GFP”) gene (“AdGFP”) was performed to determine the optimal dose range for expression of transgene. The cells were treated with adenovirus containing the human LMP-1 cDNA (AdHLMP-1) (at MOIs of 0, 100, 300, 1000, or 3000) or with adenovirus containing the LacZ marker gene (AdLacZ MOI of 1000) (negative control). The culture media was changed atday 3 andday 6 after infection. - Proteoglycan production was estimated by measuring the sulfated glycosaminoglycans (sGAG) present in the culture media (at
day - For quantification of Aggrecan and BMP-2 mRNA, cells were harvested at
day 6 and the mRNA extracted by the Trizol technique. The mRNA was converted to cDNA using reverse-transcriptase and used for real-time PCR, which allowed the relative abundance of Aggrecan and BMP-2 message to be determined. Real time primers were designed and tested for Aggrecan and BMP-2 in previous experiments. The Cybergreen technique was used. Standardization curves were used to quantitate mRNA abundance. - For transfected cells, cell morphology was documented with a light microscope. Cells became more rounded with AdHLMP-1 (MOI 1000) treatment, but not with AdLacZ treatment. AdLacZ infection did not significantly change cell morphology.
- FACS analysis of rat disc cells infected with ADGFP at MOI of 1000 showed the highest percentage cells infected (45%).
- There was a dose dependent increase between sGAG production and AdhLMP-1 MOI. These data are seen in
FIG. 1 , which shows the production of sGAG after over-expressing HLMP-1 at different MOIs in rat disc cells in monolayer cultures. The results have been normalized today 0 untreated cells. Error bars represent the standard error of the mean. As shown inFIG. 1 , the sGAG production observed atday 3 was relatively minor, indicating a lag time between transfection and cellular production of GAG. Treatment with AdLacZ did not significantly change the sGAG production. As also shown inFIG. 1 , the optimal dose of AdhLMP-1 was at a MOI of 1000, resulting in a 260% enhancement of sGAG production over the untreated controls atday 6. Higher or lower doses of AdhLMP-1 lead to a diminished response. - The effect of AdhLMP-1 dosage (MOI) on sGAG production is further illustrated in
FIG. 2 .FIG. 2 is a chart showing rat disc sGAG levels atday 6 after treatment with AdhLMP-1 at different MOIs. As can be seen fromFIG. 2 , the optimal dose of AdhLMP-1 was at a MOI of 1000. - Aggrecan and BMP-2 mRNA production is seen in
FIG. 3 . This figure demonstrates the increase in Aggrecan and BMP-2 mRNA after over-expression of HLMP-1. Real-time PCR of mRNA extracted from rat disc cells atday 6 was performed comparing the no-treatment (“NT”) cells with cells treated with AdhLMP-1 at a MOI of 250. The data inFIG. 3 are represented as a percentage increase over the untreated sample. As illustrated inFIG. 3 , a significant increase in Aggrecan and BMP-2 mRNA was noted following AdhLMP-1 treatment. The increase in BMP-2 expression suggests that BMP-2 is a down-stream gene that mediates HLMP-1 stimulation of proteoglycan synthesis. - These data demonstrate that transfection with AdhLMP-1 is effective in increasing proteoglycan synthesis of intervertebral disc cells. The dose of virus leading to the highest transgene expression (MOI 1000) also leads to the highest induction of sGAG, suggesting a correlation between HLMP-1 expression and sGAG induction. These data indicate that HLMP-1 gene therapy is a method of increasing proteoglycan synthesis in the intervertebral disc, and that HLMP-1 is a agent for treating disc disease.
-
TABLE 2 Primer Sequences for RT-PCR & Real-time PCR of SYBR Green Primer Sequence Primer Sequence AAGGATGGCTTCCACCAGTGC Aggrecan (forward) (SEQ ID NO: 83) Aggrecan (reverse) TGCGTAAAAGACCTCACCCTCC (SEQ ID NO: 46) BMP-2 (forward) CACAAGTCAGTGGGAGAGC (SEQ ID NO: 47) BMP-2 (reverse) GCTTCCGCTGTTTGTGTTTG (SEQ ID NO: 48) GAPDH (forward) ACCACAGTCCATGCCATCAC (SEQ ID NO: 49) GAPDH (reverse) TCCACCACCCTGTTGCTGTA (SEQ ID NO: 50) -
-
TABLE 3 Primer and Probe sequences for Real-time PCR of TaqMan ® Primer Sequence Overexpression AATACGACTCACTATAGGGCTCGA LMP-1 (forward) (SEQ ID NO: 51) Overexpression GGAAGCCCCAAGGTGCT LMP-1 (reverse) (SEQ ID NO: 52) Overexpression -FAM-AGCCGGCATCATGGATTCCTTCAA LMP-1 (probe) -TA-MRA (SEQ ID NO: 53) - TaqMan® Ribosomal RNA Control Reagents (Part number 4308329, Applied Biosystems, Foster City, Calif., U.S.A.) were used for the forward primer, reverse primer and probe of 18S ribosomal RNA (rRNA) gene.
- All publications cited in the specification, both patent publications and non-patent publications, are indicative of the level of skill of those skilled in the art to which this invention pertains. All these publications are herein fully incorporated by reference to the same extent as if each individual publication were specifically and individually indicated as being incorporated by reference.
- Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the following claims.
Claims (63)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/602,120 US7781574B2 (en) | 2001-11-14 | 2006-11-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
PCT/US2007/084897 WO2008064094A2 (en) | 2006-11-20 | 2007-11-16 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
US12/783,866 US20100279940A1 (en) | 2001-11-14 | 2010-05-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33132101P | 2001-11-14 | 2001-11-14 | |
US10/292,951 US7923250B2 (en) | 1997-07-30 | 2002-11-13 | Methods of expressing LIM mineralization protein in non-osseous cells |
US45655103P | 2003-03-24 | 2003-03-24 | |
US10/806,915 US7892532B2 (en) | 1999-04-30 | 2004-03-23 | Intracellular delivery of osteoinductive proteins and peptides |
US11/602,120 US7781574B2 (en) | 2001-11-14 | 2006-11-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/292,951 Continuation-In-Part US7923250B2 (en) | 1997-07-30 | 2002-11-13 | Methods of expressing LIM mineralization protein in non-osseous cells |
US10/806,915 Continuation-In-Part US7892532B2 (en) | 1999-04-30 | 2004-03-23 | Intracellular delivery of osteoinductive proteins and peptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/783,866 Division US20100279940A1 (en) | 2001-11-14 | 2010-05-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
US20080118526A1 true US20080118526A1 (en) | 2008-05-22 |
US20100119538A9 US20100119538A9 (en) | 2010-05-13 |
US7781574B2 US7781574B2 (en) | 2010-08-24 |
Family
ID=39430511
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/602,120 Active 2026-02-27 US7781574B2 (en) | 2001-11-14 | 2006-11-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
US12/783,866 Abandoned US20100279940A1 (en) | 2001-11-14 | 2010-05-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/783,866 Abandoned US20100279940A1 (en) | 2001-11-14 | 2010-05-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
US (2) | US7781574B2 (en) |
WO (1) | WO2008064094A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916691B2 (en) | 1998-07-29 | 2014-12-23 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein |
US20090110637A1 (en) * | 2007-10-26 | 2009-04-30 | Warsaw Orthopedic, Inc. | LMP and Regulation of Tissue Growth |
CA2827392A1 (en) | 2011-02-24 | 2012-08-30 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
CN102895652B (en) * | 2011-07-27 | 2014-07-09 | 东北师范大学 | Method for promoting osteoblast differentiation by using Runx2 and Osterix and application thereof |
US20140248372A1 (en) | 2011-09-19 | 2014-09-04 | Emory University | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto |
US20150148292A1 (en) | 2012-07-09 | 2015-05-28 | Emory University | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5504192A (en) * | 1993-12-13 | 1996-04-02 | The Regents Of The University Of California | Human insulin receptor endocytic code binding protein |
US5580775A (en) * | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
US6300127B1 (en) * | 1997-07-30 | 2001-10-09 | Emory University | Bone mineralization proteins, DNA, vectors, expression systems |
US20040197867A1 (en) * | 1999-04-30 | 2004-10-07 | Titus Frances Louisa | Intracellular delivery of osteoinductive proteins and peptides |
US7045614B1 (en) * | 1999-04-30 | 2006-05-16 | Emory University | LIM mineralization protein splice variants |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
WO2005111058A1 (en) * | 2004-04-13 | 2005-11-24 | Medtronic Sofamor Danek, Inc | Intracellular delivery of osteoinductive proteins and peptides |
WO2006102417A2 (en) * | 2005-03-22 | 2006-09-28 | Warsaw Orthopedic, Inc. | Mechanisms of osteoinduction by lim mineralization protein-1 (lmp-1) |
WO2006104306A1 (en) * | 2005-03-30 | 2006-10-05 | Jung Moon Kim | Non-activated polypeptides having a function of tissue regeneration and method for preparing the same |
-
2006
- 2006-11-20 US US11/602,120 patent/US7781574B2/en active Active
-
2007
- 2007-11-16 WO PCT/US2007/084897 patent/WO2008064094A2/en active Application Filing
-
2010
- 2010-05-20 US US12/783,866 patent/US20100279940A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5580775A (en) * | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
US5504192A (en) * | 1993-12-13 | 1996-04-02 | The Regents Of The University Of California | Human insulin receptor endocytic code binding protein |
US6300127B1 (en) * | 1997-07-30 | 2001-10-09 | Emory University | Bone mineralization proteins, DNA, vectors, expression systems |
US20040197867A1 (en) * | 1999-04-30 | 2004-10-07 | Titus Frances Louisa | Intracellular delivery of osteoinductive proteins and peptides |
US7045614B1 (en) * | 1999-04-30 | 2006-05-16 | Emory University | LIM mineralization protein splice variants |
Also Published As
Publication number | Publication date |
---|---|
US20100279940A1 (en) | 2010-11-04 |
US7781574B2 (en) | 2010-08-24 |
WO2008064094A2 (en) | 2008-05-29 |
WO2008064094A3 (en) | 2008-12-31 |
US20100119538A9 (en) | 2010-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7517866B2 (en) | LIM mineralization protein splice variants | |
US6444803B1 (en) | Bone mineralization proteins, DNA, vectors, expression systems | |
US7923250B2 (en) | Methods of expressing LIM mineralization protein in non-osseous cells | |
AU2010212481A1 (en) | Methods of inducing the expression of bone morphogenetic proteins (BMPs) and transforming growth factor-beta proteins (TGF-betas) in cells | |
US20100279940A1 (en) | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof | |
US8916691B2 (en) | Methods of expressing LIM mineralization protein | |
US20070134218A1 (en) | Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells | |
AU2004271093A1 (en) | Methods of inducing the expression of bone morphogenetic proteins (BMPs) and transforming growth factor-beta proteins (TGF-betas) in cells | |
AU2002343697A1 (en) | Method of expressing lim mineralization protein in non-osseous cells | |
ZA200403714B (en) | Methods of expressing LIM mineralization protein in non-osseous cells. | |
WO2008156500A2 (en) | Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EMORY UNIVERSITY, GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BODEN, SCOTT D.;SANGADALA, SREEDHARA;REEL/FRAME:018821/0334 Effective date: 20070105 Owner name: EMORY UNIVERSITY,GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BODEN, SCOTT D.;SANGADALA, SREEDHARA;REEL/FRAME:018821/0334 Effective date: 20070105 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |